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1 ABSTRACT 
Herbal medicines are widely used, but despite their ‘natural’ origin they can cause adverse effects. 
Herb hepatotoxicity accounts for 2-12% of drug-induced liver injury and has led to regulatory action 
including market withdrawal. Information is limited on the risks and mechanisms of liver injury from 
herbs and little is known about the toxicity mechanisms involved. The first aim of this study was to 
use pharmacovigilance data from national spontaneous reporting systems to explore herb-
hepatotoxicity associations.  The second aim was to identify a common pharmacophore among the 
phytoconstituents of herbs in such hepatotoxicity. 
Data from the United States Food and Drug Administration (FDA) adverse event reporting system 
(AERS) collected between 2004 and 2011 were analysed retrospectively for herb-hepatotoxicity 
associations using disproportionality analysis. Signals of hepatotoxicity association, at various levels 
of adverse reaction specificity (based on MedDRA preferred-term grouping), were derived for 
several herbs (identified by trade name(s), common name(s) and botanical name).  Chemical 
constituents in identified hepatotoxic herbs were examined for a common pharmacophore and 
validated against a set of known hepatotoxic and non-hepatotoxic compounds. 
There were 54,820 cases with reported herbal exposure between 2004 and 2011. Of these, a 
substantial proportion (6.3%), involving 47 different herbs, was associated with hepatotoxicity. 
Significant herb-liver injury associations (p<0.05) were found for 15 herbs including kava, valerian, 
black cohosh, senna, hoodia, ginseng, ginkgo and soy. Analysis of specific adverse reaction groupings 
revealed new information:  HILI with immune features was significantly associated with kava, 
evening primrose, valerian, ginseng, ginkgo, senna, and Ma Huang. It must be noted that reports in 
the AERS are of variable quality and few make reference to botanical names. Pharmacophore 
analysis revealed several chemical structural patterns common across phytochemical constituents 
from different herb sources. A three-point pharmacophore hypothesis with 1 hydrogen bond 
acceptor, 1 hydrogen bond donor and 1 hydrophobic group gained a high survival score, high 
selectivity and high specificity relative to the other hypotheses. This hypothesis may be a clue to a 
common toxicity pathway shared by these herbs leading to liver injury.  
This study has shown that pharmacovigilance data can assist with identifying associations between 
herbal-medicine exposure and liver injury including for herbal-medicines not previously associated 
with hepatic adverse reactions.  In addition, further investigation of the population-level associations 
at the molecular level reveals possible shared structural patterns, which may be involved in a shared 
hepatotoxicity pathway. Further research is required to investigate whether a causal relationship 
exists between the implicated herbs and liver injury and to identify the toxicity mechanisms. 
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1 CHAPTER 1: LITERATURE REVIEW 
1.1 Introduction 
Herbal products are widely used globally and their use can be traced back as far as ancient Egypt, 
Iraq, China and India [1-3]. Two thirds of the  world’s current 6.1 billion people rely on herbs for 
treatment [2]. The use of herbal remedies has increased dramatically in recent years, although 
evidence supporting their therapeutic effectiveness is often lacking. Between 1990 and 1997, the 
use of herbal medicines in the United States(US) increased by 380%; during the same period, out-of-
pocket expenditure increased from $1.8 billion to $5.1 billion for these medicines [4]. In 2000, herbal 
remedies represented a $180 billion dollar industry. Herbal medicines are a big and relatively 
mainstream business in Europe. In 2003, European countries spent almost $5 billion on over the 
counter herbal remedies [5]. Some European countries such as Germany and France, have taken the 
lead in over the counter sales of herbal remedies (Figure 1.1) [5]. Also in 2003, German health 
insurance paid $283 million as reimbursement for prescribed ginkgo, St John’s Wort, mistletoe, saw 
palmetto and other herbs and French health insurance paid $91 million in partial reimbursement in 
2002 [5].  
 
Figure 1.1 Sales of over-the-counter herbal medicines, 2003 (million $) 
Herbal preparations are used in a wide range of minor ailments and major chronic disease. For 
example, conditions range from insomnia, anxiety, obesity, asthma, constipation, gingivitis and 
eczema to immunodeficiency syndrome [6]. Herbal products may be a crude or commercial 
preparation. Crude preparations may involve the use of plant roots, leaves, seeds or teas and are 
common in developing countries. It is also common to combine herbs as mixtures. For example, Dai-
saiko-to is a traditional Chinese remedy that is a mixture of seven herbs and is used to prevent 
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hepatic inflammation. In herbal mixtures such as Dai-saiko-to, the ‘king herb’ is believed to be the 
primary active component and other components act synergistically with it, modifying the toxicity or 
improving immune function [1]. Crude herbal preparations vary in content and concentration of 
pharmacologic actives and may contain contaminants. Commercial herbal preparations in the form 
of tablets or capsules are more commonly used in developed countries. These preparations undergo 
more processing than crude ones. Even with standardization, the commercial herbal products vary 
from batch to batch and from manufacturer to manufacturer in the content of pharmacological 
actives and contaminants [1]. 
The use of herbal remedies has been increasing, therefore  raising further concerns for the safety of 
these products [7]. For example, herbals may cause significant interactions with other medicines like 
the well-known example of St John’s Wort, which activates liver enzyme CYP3A4 and considerably 
reduces half-life of drugs metabolized by this route such as warfarin and carbamazepine [8]. Herbal 
remedies have limited scientific data about their safety and this was evident when Kava, Piper 
methysticum, was discovered to be associated with hepatotoxicity, resulting in health warnings to 
consumers in several European markets [8]. The development of new diseases, complications and 
lack of satisfactory treatments have promoted the increased use of herbals [6].  In addition, herbal 
medicines are widely believed by consumers to be natural and therefore of low risk. The safe and 
harmless view of natural therapies is further consolidated by the special attention that ecological 
movements in Western countries give to herbal remedies [6]. Moreover, herbals have been 
traditionally used for a very long time and this may seem to be ‘proof’ of their safety [4]. It is 
interesting to note that a number of conventional drugs were originally derived from plant sources.  
For example, digitalis is derived from foxglove and scopolamine is from angels trumpets [7]. These 
plant derived substances however, are regulated as medicines and the public understands that they 
must only be taken as directed. Although herbal remedies are “natural” and perceived to be safe, 
they can cause side effects, be toxic above certain doses and may interact significantly with other 
medicines.  
1.2 Definition of herbal medicines 
Herbal medicines are considered to be a subset of ‘complementary and alternative medicine’ (CAM). 
The National Centre for Complementary and Alternative Medicine (NCCAM) defines CAM as [9]: 
“A group of diverse medical and health care systems, practices, and products that are not 
generally considered part of conventional medicine” 
There are five categories of complementary and alternative medicine according to NCCAM and these 
are whole medical systems such as Ayurveda or homeopathy, mind-body medicine such as 
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meditation, hypnosis, yoga or acupuncture, biologically based practices such as herbal preparations 
or dietary supplements, manipulative and body-based practices such as acupressure, chiropractic or 
massage, and energy medicine such as therapeutic touch[9]. It is important to keep in mind that 
definitions in this area have considerable overlap, they are constantly changing and boundaries 
between terms may not be clear-cut.  
The terms ‘herbal preparation’, ‘herbal remedy’, ‘herbal medicine’ and ‘herbal product’ all refer to 
‘herbal drugs’, which is defined by the British Pharmacopoeia [10] as:  
“Herbal drugs are mainly whole, fragmented, or broken plants, parts of plants, algae, 
fungi or lichen, in an unprocessed state, usually in dried form but sometimes fresh. Certain 
exudates that have not been subjected to a specific treatment are also considered to be 
herbal drugs. Herbal drugs are precisely defined by the botanical scientific name according 
to the binominal system (genus, species, variety and author).”  
A dietary supplement, such as amino acids, vitamins and minerals are under CAM when used for 
medicinal purposes and are not included under CAM when they are used to meet daily nutritional 
requirements. Different regulatory agencies have different definitions of ‘herbal drug’, ‘dietary 
supplement’ and ‘complementary medicine’ and examples of products that fall under each category 
[11-13].   
This review focuses on what is known of the toxicity of herbal medicine safety and issues that relate 
to it, such as quality and regulation. It also discusses herbal hepatotoxicity, its prevalence, 
mechanisms and patterns and types observed for herbs. 
1.3 Herbal medicine safety 
Although usually perceived as natural and harmless, herbal medicines contain pharmacologically 
active compounds with therapeutic activity and may cause significant side effects. For example, it is 
well known that plants containing pyrrolizidine alkaloids, apiole, safrole or lignans may cause liver 
toxicity, plants containing terpenes or saponins may cause kidney irritation and sesquiterpene 
lactones and furanocumarins are toxic to the skin [6]. In addition, it is well known that some plants 
produce toxic substances, which deter herbivores such as viscotoxins, lectins or cyanogenetic 
glycosides [6]. Table 1.1 lists some herbal medicines and their common side effects. Ironically, plant 
derived chemicals are used as prototypes in the drug design process to develop safe and effective 
medicines. Approximately 70% of conventional prescription-only drugs developed over the last 25 
years were originally derived from plant sources. These plant-derived substances however, are 
regulated as drugs with the fundamental understanding that these should be consumed under 
recommendations of health care professionals.  
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Accurate and thorough herbal safety assessment is limited by the amount of research in the field. 
Herbal medicine regulation is generally less tightly controlled than conventional drugs and herbal 
medicines have a relatively easy route into the market with less pharmacovigilance than 
conventional drugs. Furthermore, pharmacovigilance systems currently in place were initially 
designed for conventional medicines and application to herbal medicines requires modifications to 
the system to address issues specific to herbs [14]. Thus comprehensive and reliable herbal safety 
assessments have been challenging. For example, numerous herbal safety assessments by regulatory 
agencies such as that for kava, greater celandine and black cohosh have been questioned.  
Table 1.1 A selection of herbal medicines and the adverse effects they may cause[6] 
Herb Adverse effects Toxic constituent 
Alfalfa 
(Medicago sativa L.) 
Systemic lupus erythematous syndrome Canavanine  
Aloe 
(A. barbadensis, A. ferox, others) 
Abdominal discomfort, melanosis coli Anthraquinones  
Arnica 
(Arnica montana L.) 
Gastroenteritis, dermatitis Helenalin, sesquiterpene 
lactones 
Chamomile, German 
(Matricaria recutita L.) 
Allergic reactions, vomiting Sesquitepene lactones 
(anthecotulid), anthemic acid 
Chaparral  
(Larrea tridentate Coville) 
Acute hepatitis  Unknown  
Cohosh, Black 
(Cimicifuga racemosa Nutt.) 
Nausea, vomiting  Unknown  
Comfrey  
(Symphytum officinale L.) 
Hepatotoxicity  Pyrrolizidine alkaloids 
Evening Primrose 
(Oenothera biennis L.) 
Nausea, laxation, headache Unknown  
Feverfew 
(Tanacetum parthenium L.) 
Gastrointestinal disturbances, 
hypersensitivity reactions 
Sesquiterpene lactones 
Garlic 
(Allium sativum L.) 
Nausea, vomiting, diarrhoea, contact 
dermatitis 
Sulphur containing compounds 
Ginkgo 
(Ginkgo biloba L.) 
Gastrointestinal upset, headache Unknown  
Ginseng 
(Panax ginseng Meyer) 
Hypertension, diarrhoea, insomnia, 
vaginal bleeding, skin eruptions, 
nervousness 
Unknown  
Hawthorn 
(Cratagus monogyna Jacq.) 
Nausea, sweating, rash on hands Unknown  
Horse chestnut 
(Aesculus hippocastanum L.) 
Hepatic injury Aescin  
Mistletoe 
(Viscum album L.) 
Hepatitis  Lectins, viscotoxins 
Nettle 
(Urtica dioica L.) 
Gastric irritation, oedema, oliguria Unknown  
Saw palmetto 
(Serenoa repens Hook) 
Gastric disturbance Unknown  
Senna 
(Cassia angustifolia Vahl.) 
Abdominal discomfort, water and 
electrolyte loss, melanosis coli, red urine 
Anthraquinones  
St John’s Wort 
(Hypericum perforatum L.) 
Photodermatitis  Hypericin 
 
20 
 
1.4 Herb-induced liver injury (HILI) and drug-induced liver injury (DILI) 
Drug-induced liver injury (DILI) is associated with over a thousand drugs and has recently been also 
attributed to herbal preparations [15]. DILI accounts for 9.5% of all suspected adverse drug reactions 
[16] and causes substantial morbidity and mortality [17]. Nearly 10% of DILI cases result in liver 
transplantation or death when presenting with hepatocellular jaundice[18]. Herb-induced liver injury 
(HILI) accounts for a significant proportion of DILI cases, though estimates vary widely especially in 
different populations. Although HILI or DILI events are usually rare, occurring in 1 in every 10,000 to 
1 in every 100,000 users [19], they are the most common reason for post-marketing drug withdrawal 
and terminating a new drug candidate’s development. So far more than 47 drugs have been 
withdrawn from the market [20]. Kava, black cohosh, chaparral and greater celandine are examples 
of herbs with regulatory action due to the number of hepatotoxicity case reports [21-24]. Examples 
of herbal hepatic injury include acute and chronic hepatitis, cholestasis, vascular lesions, cirrhosis 
and hepatic failure (also see Table) [4]. Although drugs undergo rigorous testing in pre-marketing 
phase II and III trials, these trials are capable of only detecting common adverse reactions because 
rare events cannot be detected in the relatively small populations [4]. 
The liver has a central role in the body to maintain metabolic homoeostasis. Liver functions include 
glycogen synthesis, breakdown and storage, lipid metabolism, albumin synthesis, synthesis of 
clotting factors and other proteins, metabolism of cholesterol and bile synthesis [25]. Hepatocytes 
remove toxins from the blood such as bilirubin and ammonia, which are products of metabolism. 
When these processes are disturbed symptoms of liver injury appear, such as hyperbilirubinaemia, 
accumulation of fat and hyperammonemia [25]. The liver is the first organ to receive blood from the 
gut and is the primary site of detoxification before the blood reaches the systemic circulation. It is 
therefore not surprising that it is a site of drug induced damage [4]. Metabolizing enzymes, such as 
cytochrome P450, glutathione-S-transferases, sulphotransferases and UDP-glucuronosyltransferases, 
are involved in xenobiotic transformations [26].  
1.5 HILI epidemiology 
The actual prevalence and incidence of herbal hepatotoxicity among cases of DILI is unknown. 
Figures vary widely in epidemiological studies with values of HILI as a percentage of DILI ranging 
from 0% to 73%. This surprisingly high variability may be due to a combination of factors, namely 
variable DILI and HILI diagnostic criteria, under-reporting of cases, selection bias, herbal quality 
issues and uncontrolled access and use of herbs [27]. The large differences in HILI incidence rates 
between countries may also reflect different population exposure to herbs and different regulatory 
framework in those countries. In addition, information on herbal hepatotoxicity is limited, for 
example, in some epidemiological studies herbal exposure patients are excluded [1, 20]. Most 
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information regarding the occurrence of toxicity is derived from anecdotal case reports and herbal 
medicines would benefit greatly from improved pharmacovigilance programs and greater inclusion 
in DILI studies. 
In the US and Spain, most studies found HILI accounts for 5-11% of DILI patients (Table 1.2). The 
study by Estes et al. in 2003 [28]stands out with 50% of the DILI cases attributed to herbs. It is 
important to note however, Estes and colleagues defined such cases as ones with exposure to a 
herbal product with no further information on how causality was ascertained. Herbal medicines are 
very commonly used by patients with liver injury [29] and the findings from Estes et al. re-illustrates 
this confounder again. Systematic and reliable causality assessment tools are critical in HILI 
assessment [30].  
In Asia however, Suk et al. and Wai et al.[27, 31] found HILI accounts for 71 to 73% of DILI cases. In 
Korea and Singapore, traditional herbal medicine is commonly available, sometimes used without 
regulation and widely accepted as an alternative to modern medicine. Both of these studies found 
that traditional herbal medicine is a more common cause of liver injury than conventional drugs. In 
these studies, ‘herbal medicine’ included proprietary herbal medicines, traditional Chinese medicine, 
traditional Malay medicine, herbs prescribed and compounded by Oriental Medicine doctors or 
pharmacists and herbs compounded by laypersons. These studies illustrate how HILI aetiology in an 
Asian population can be strikingly different to a Western population, in which anti-infectives are 
usually the most common culprits. Wai et al. looked further into the HILI cases, screening the 
implicated herbs for possible adulterants using analytical methods. The results reveal that 29% of 
the preparations contained adulterants, all of which are known to cause liver injury, such as 
metformin, dexamethasone and berberine. The herbs were all proprietary products and this finding 
emphasises the importance of herbal medicine quality control.  
In contrast, Jeong et al. [32] found a surprising zero incidence of herbal hepatotoxicity. The study 
methodology was very different to the previous two studies and was conducted in two Oriental 
hospitals enrolling patients who received herbal remedies for 10 days or more and who did not have 
previous or current liver disease. Interestingly, the authors claim that the DILI incidence (2.3%) is 
higher than in other studies due to the prospective nature of the study and conclude herbal 
medicines are safe as monotherapy, however, risks of side effects increases when they are used 
together with conventional medicines.  These results may be limited by the small sample size, 
participation of only two hospitals in close geographic location and that the patients were very 
closely monitored allowing changes to medications at the earliest signs of harm or lack of efficacy. 
Devarbhavi et al.[33] also reported low HILI incidence in India. This was also unexpected and the 
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authors postulated that herbal remedies are consumed after hepatic symptoms appear and 
contamination in the herbal remedies may cause significant non-hepatic damage that obscures 
underlying HILI. 
Available epidemiological evidence (Table 1.2) confirms that HILI constitutes a significant proportion 
of DILI cases. It is also apparent that HILI numbers vary widely between different countries, with 
higher numbers in Asian populations exceeding the number of conventional drug DILI events. It 
would be logical to expect a highertoxicity frequency in populations that use more herbal remedies, 
such as in China and India. However it is also important to note that the Western population is also 
reported to consume herbal medicines regularly [31] and other factors such as herbal product 
quality and host genetic polymorphisms in the different populations may also play a significant role. 
Incidentally  there is little difference between Spain and Iceland, both of which regulate herbal 
medicines as prescription and over-the-counter products and require products to meet  safety 
standards comparable to conventional drugs [34], and the US, which regulates herbs as dietary 
supplements and does not require  efficacy or safety information in the approval process.  
 
Table 1.2 Herb hepatotoxicity cases among drug induced hepatotoxicity (DILI) cases 
Reference Country (date) Study type Methods  Causality  HILI 
Ibanez 2002 
[35] 
Spain  
(1993-1998) 
Prospective, 
N=103 
Cases from 12 hospitals. Exclusion criteria included 
alcohol above set limit, drug overdose, malignancy, 
congestive heart failure and others. 
Hepatologists, 
gastroenterologist, 
ad hoc  
11% 
Andrade 2005 
[36] 
Spain  
(1994-2004) 
Prospective, 
N=446 
Cases from the Registry of Hepatotoxicity, a 
multicenter study. Cases excluded for non-drug causes 
of liver disease. 
Expert opinion and 
CIOMS scale 
2% 
Chalasani 
2008 [37] 
USA  
(2003-2008) 
Prospective, 
N=300 
Cases from the DILIN network – an ongoing multi-
centre study. Acetaminophen toxicity excluded. 
Expert opinion and 
RUCAM scale 
9% 
Suk 2012[27] Korea 
 (2005-2007) 
Prospective, 
N=371 
Cases of DILI from 17 referral hospitals were enrolled. 
Expert opinion and 
RUCAM scale 
73% 
Wai 2007 [31] Singapore  
(2004-2007) 
Prospective, 
N=31 
Cases from a tertiary hospital. Cases excluded if had a 
drug overdose. 
Expert opinion 71% 
Devarbhavi 
2010 [33] 
India 
 (1997-2008) 
Retrospective, 
N=313 
Cases from one hospital DILI database. Patients 
excluded if alcohol intake was above set limit. 
RUCAM scale 1.3% 
Estes 2003 
[28] 
USA  
(2001-2002) 
Retrospective, 
N=20 
Cases from two hospitals, admitted for fulminant 
hepatic failure. No mention of exclusion criteria.  
Expert opinion 50% 
Russo 2004 
[38] 
USA  
(1990-2002) 
Retrospective, 
N=270 
Multi-centre, cases from United Network for Organ 
Sharing. Study excluded prior transplant and non-drug 
causes of liver injury. Herbal products may or may not 
be specified.  
Not mentioned 5.1% 
Reuben 2010 
[39] 
USA  
(1998-2007) 
Prospective, 
N=10 
Multi-centre, cases from 23 academic centres.  
Expert opinion 10% 
Jeong 2012 
[32] 
Korea  
(2008-2010) 
Prospective, 
N=313 
Cases from two oriental hospitals. Patients excluded if 
had previous liver injury or life expectancy below 12 
months 
RUCAM scale 0% *  
Bjornsson 
2013 [40] 
Iceland  
(2010– 2011) 
Prospective,  
N=96 
Cases from the national university hospital. 
Acetaminophen toxicity was excluded 
RUCAM scale 16% 
* DILI was 1.9% 
CIOMS = Counsel for International Organization of Medical Sciences (refers to RUCAM scale)  
RUCAM = Roussel Uclaf Causality Assessment Method  
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1.6 Risk factors 
Idiosyncratic DILI susceptibility occurs when a combination of host genetic factors, environmental 
factors and drug toxic potential act in concert. On their own, the drugs or their metabolites may not 
be sufficient to cause toxicity and the susceptibility factors may increase the likelihood of 
hepatotoxic events. While these factors are relatively well identified for conventional drugs, little is 
known for herbal medicines. Therefore, further understanding of HILI presentations and 
susceptibility factors is required to improve patient safety. Factors known to contribute or 
predispose to toxicity are summarised in Table 1.3. 
1.7 HILI toxicity profiles 
Drugs and herbal medicines may cause hepatotoxicity with distinct clinical patterns or phenotypes 
typical of that particular drug or herb. These typical hepatotoxicity phenotypes are essential in DILI 
or HILI diagnosis and causality assessment, which also includes a detailed clinical history and 
elimination of other causes[19]. For example, clinical patterns include immuno-allergic hepatitis, 
which is characteristic of sulphonamides and penicillins among other drugs, and cholestatic 
hepatitis, which is characteristic of amoxicillin with clavulanic acid and flucloxacillin among other 
drugs [19]. Information regarding clinical presentation, hepatotoxicity phenotype, hypersensitivity 
features and very importantly, strength of the causality are difficult to identify and must frequently 
be obtained from multiple sources. Furthermore, different sources provide different hepatotoxicity 
information which at times may be directly contradictory. Therefore, this information was compiled 
from numerous sources to generate hepatotoxicity profiles of herbal medicines commonly 
suspected in clinical cases (Table 1.4) thereby creating a new and thorough one-stop resource in 
HILI. In cases of contradicting information, both views are presented.  
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Table 1.3 Idiosyncratic DILI susceptibility factors 
Susceptibility factor Examples from DILI Examples from HILI 
Age  Toxicity is more common at the extremes of age. Some 
disorders are age dependent, e.g. Reye’s syndrome in childhood 
due to aspirin and chronic hepatitis in old age due to isoniazid. 
 Older patients and those with co-morbidities are more likely to 
take several drugs, thus increasing drug-drug interactions. 
 Older patients are more likely to take herbal 
medicines. 
 Older patients who take multiple drugs are more 
likely to experience herb-drug interactions. 
Gender   Women are more sensitive to flucloxacillin, methyldopa and 
nitrofurantoin hepatotoxicity. 
 Men are more sensitive to azathioprine and co-amoxiclav 
hepatotoxicity. 
 Studies differ on gender susceptibility. 
 Women found to be more sensitive to greater 
celandine, chaparral and green tea toxicity [41-43].  
Race   Caucasians are more sensitive to abacavir and flucloxacillin 
hepatotoxicity. 
 African-Americans are more sensitive to anticonvulsant 
hepatotoxicity. 
 Kava toxicity was not seen in traditional use 
populations; however it was evident in the Western 
population, which is known to have 6% prevalence of 
CYP 2D6 deficiency. 
Nutritional status  Fasting may cause glutathione depletion and increase risks of 
hepatotoxicity. 
 Obesity, fasting and glutathione depletion may 
exacerbate hepatotoxicity. For example, 
hepatotoxicity is more likely when green tea 
concentrated extracts were taken on an empty 
stomach than when taken in the fed state [44].  
 Toxic diterpenoids are potent inducers of hepatocyte 
apoptosis in conditions of glutathione depletion [45]. 
Systemic disease  May predispose to hepatotoxicity, e.g. hyperthyroidism in 
halothane toxicity. 
 
Genetic polymorphisms   Detoxification: genetic polymorphisms in UDP-
glucuronosyltransferases, sulphotransferases and glutathione-S-
transferases may affect efficiency of paracetamol detoxification 
and therefore alter DILI threshold. 
 Mutations in UGT1A1, causing Gilbert’s syndrome, increases 
chances of DILI. 
 Oxidation: mutations in cytochrome P450 may predispose to 
DILI. 
 Biliary transport: mutations in the bile salt export pump 
increase likelihood of oestrogen cholestasis. 
 Immune response: polymorphisms in human leukocyte antigen 
(HLA) may influence immune reactions, e.g. increased HLA-
DRB1*15 and decreased HLA-DRB1*07 have been found in 
patients with co-amoxiclav induced liver injury and 
polymorphisms in HLA-DRB*5701 are associated with 
flucloxacillin  induced liver toxicity. 
 CYP 2D6 deficiency found in a kava hepatotoxicity 
case and it is suspected to have predisposed to the 
toxicity.  
 Genetic predisposition suspected for Herbalife®   
hepatotoxicity due to family links in some cases [46]. 
 CYP 2D6 deficiency found in a case of senna 
hepatotoxicity, impairing detoxification[45, 47]. 
 Ma Huang (Ephedra sinica) hepatotoxicity is 
associated with C282Y and H63D mutations in the 
haemochromatosis gene, which leads to extra 
hepatic iron that predisposes to hepatotoxicity [48]. 
 
Drug-drug interactions  Drugs that induce the cytochrome P450 enzymes, such as 
phenytoin, carbamazepine and rifampicin, or drugs that inhibit, 
such as erythromycin, paroxetine and omeprazole, may 
predispose to DILI.  
 Some herbs affect CYP450 enzymes and through 
herb-drug interactions increase hepatotoxicity risks. 
 E.g. kava has been shown to have an inhibitory effect 
on CYP450 and thus has high potential for herb-drug 
interactions. 
 E.g. ginkgo exposure led to hepatotoxicity in a case 
report and found to be due to herb-drug interaction 
[49]. 
Pregnancy   Ironically, herbal medicine use is preferred in 
pregnancy though studies on herbal safety in this 
population are lacking e.g. nausea treatment with 
ginger rather than metoclopramide (pregnancy 
category A) [50]. 
Underlying liver disease   High percentage of patients with liver disease self-
medicate with herbs, e.g. silymarin  [29, 51].  
 Pre-existing liver lesions predispose to hepatotoxicity 
[45] 
Other factors  Renal function 
 Chronic alcohol abuse 
 Herbal product quality: misidentification of plant, 
contamination, adulteration, inadequate storage, 
mislabelling of final product 
 Natural variation in plant content due to growth 
conditions, harvest time and other factors. 
 Patient self-medication without professional advice. 
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Table 1.4 Summary of the hepatotoxic profile of herbs that have been implicated in drug-induced liver injury (DILI) 
Herb name 
(Scientific 
name) 
Herbal induced liver injury pattern 
Notes Ref 
Toxicity profile Clinical phenotype 
ADR type 
(hypersensitivity 
features) 
Liver 
injury 
pattern 
Mechanism 
Strength of 
causality 
         Aloe vera Liver injury symptoms appear after 3 to 24 weeks. Injury 
is rarely severe and is self-limiting, resolves on 
discontinuation. 
Acute viral hepatitis Immune features 
are rare 
H  Cases had idiosyncratic features Positive re-
challenge in 
one report 
 [52] 
Black cohosh 
(Actaea 
racemosa, 
Cimicifuga 
racemosa) 
Symptom onset ranges from 1 to 48 weeks, but is usually 
within 2 to 12 weeks. The clinical presentation is typically 
jaundice and a markedly hepatocellular pattern of injury 
with liver biopsy histology resembling acute viral 
hepatitis. 
Inf  Idiosyncratic 
reaction which may 
be immunologically 
mediated 
Inf  Unknown  STRONG [52] 
WEAK [53] 
 [52, 
53] 
Cascara Time to symptom onset ranges from few days to 2 
months. May be mild or severe, but resolves rapidly on 
discontinuation.  
Inf  No immune 
features in most 
cases 
H  Injury has been attributed to Anthraquinones, which 
cause direct toxicity. However, published cases show 
idiosyncratic liver injury features.  
  [52] 
Chaparral 
(Larriea 
tridentata) 
Symptom onset is  3 to 12 weeks. Patients present with 
jaundice and raised ALT. Some cases have been severe, 
requiring liver transplant. Symptoms subside within 1-17 
weeks of discontinuation. 
Acute viral hepatitis [52] 
Cholestatic hepatitis: high 
serum transaminases, 
bilirubin & alkaline 
phosphatase [4] 
No immune 
features present 
usually  
H  Toxic constituent inhibits cyclooxygenase, 
lipoxygenase and several CYP450s leading to toxicity. 
STRONG[54] Also called 
creosote bush or 
greasewood 
[4, 52], 
[1] 
Dai-saiko-to 
(TJ-8) Sho-
saiko-to (TJ-9) 
Symptom onset is 1.5-3 months. Improves after 
withdrawal and reoccurs with rechallenge. Liver histology 
shows centrilobular confluent necrosis or spotty necrosis, 
micro vesicular fatty change, acidophilic degeneration 
and granuloma. 
Autoimmune hepatitis Inf  Inf  Unknown  Positive re-
challenge in 
some reports 
[55] 
TJ-8 and TJ-9 
contain at least 7 
herbs and differ 
in the proportion 
of the herbs 
[1, 55] 
Distaff thistle 
(Attractylis 
gummifera) 
Symptom onset is acute with symptoms of nausea, 
abdominal pain and headache occurring within a few 
hours of ingestion. Toxicity symptoms are associated 
with a syndrome of neuro-vegetative symptoms, hepato-
renal failure and hypoglycaemia. Death is frequent and is 
due to fulminant hepatic failure [4]. Treatment is 
supportive and liver transplant is an option [1]. 
Acute hepatitis, fulminant 
hepatic failure [4] 
Inf  Inf  Two diterpenoid glycosides (atractyloside and 
carbodyatractyloside) inhibit mitochondrial oxidative 
phosphorylation by interacting with adenine 
nucleotide translocator, a mitochondrial protein [1]. 
The Krebs cycle and other mitochondrial functions 
are inhibited leading to oxidative stress, glutathione 
depletion and increased lipid peroxidation. The toxic 
constituents are selectively toxic to hepatocytes and 
kidney epithelia [4]. 
STRONG [1] Toxicity is 
associated with 
topical 
application as 
well [1]. Toxins 
are in higher 
concentration in 
the plant roots 
during the spring 
[4] 
[1, 4, 
55] 
Fenugreek  No reports of hepatotoxicity. Studies show 
hepatoprotective effects.  
   Has potential to cause herb-drug interactions due to 
its high fibre, coumadin, estrogenic-like effects. 
  [52] 
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Table 1.4 Summary of the hepatotoxic profile of herbs that have been implicated in drug-induced liver injury (DILI) 
Herb name 
(Scientific 
name) 
Herbal induced liver injury pattern 
Notes Ref 
Toxicity profile Clinical phenotype 
ADR type 
(hypersensitivity 
features) 
Liver 
injury 
pattern 
Mechanism 
Strength of 
causality 
         Germander 
(Teucrium 
chamaedrys) 
Most cases occur after 2 months of intake at standard 
doses. Symptoms are non-specific (anorexia, nausea, 
abdominal pain and jaundice) with increased ALT. 
Jaundice resolves after 8 weeks of cessation. Patients 
with accidental re-exposure developed relapse and 
cirrhosis [1]. 
Acute chronic hepatitis and 
acute liver failure 
Inf  Inf  Furan neo-clerodane diterpenoids are metabolised 
by CYP450 3A into highly reactive and toxic epoxides. 
These epoxides may be neutralised by glutathione 
conjugation.  In cases of glutathione deficiency, the 
epoxides react with hepatic cell proteins and lead to 
cell death by inducing apoptosis [4]. 
  [1, 4] 
 Other herbs from the same Teucrium genus have also 
caused liver toxicity. T. Polium is associated with acute 
severe cholestasis, cholestatic hepatitis and acute liver 
failure. Other plants from the genus are T. capitatum and 
T. viscidum. Hepatotoxic neo-clerodane diterpenoids 
have also been isolated from other genera [1]. 
       
Ginkgo  No reports of hepatotoxicity clearly linked to ginkgo, in 
the form of elevated liver enzymes or clinically apparent 
liver injury. Ginkgo may be used to treat acute or chronic 
liver injury.  
Inf Inf Inf Inf   [52] 
Ginseng  
(Panax 
Ginseng) 
No reports of hepatotoxicity clearly linked to ginseng, in 
the form of elevated liver enzymes or clinically apparent 
liver injury. Liver injury reported in patient taking a 
potentially toxic drug together with ginseng. Toxicity 
resolved when ginseng was withdrawn and was due to a 
herb-drug interaction [49]. 
Inf Inf Inf Ginseng may affect CYP450 enzymes and cause 
significant herb-drug interactions that may lead to 
liver injury or other adverse effects.  
  [52] 
Greater 
Celandine 
(Chelidonium 
majus) 
Symptoms may appear after 30 - 60 days. Leading 
symptom is jaundice, occasionally preceded by fatigue, 
nausea, vomiting, epigastric pain, itching & dark urine. 
Some cases have been severe, but no reported cases of 
liver transplant or death. Symptoms subside on 
withdrawal of herb. No corticosteroid treatment is 
necessary. 
Toxic hepatitis: 
hepatomegaly (very often), 
serum transaminases and 
bilirubin level over the 
normal range, negative to 
RNA and antibodies for 
common viruses, cell 
necrosis & sometimes 
fibrosis [21]. 
Acute viral hepatitis [52]. 
Idiosyncratic 
metabolic  
H [41] Unknown STRONG[41]  Toxicity is 
independent of 
dose. Recurrence 
with re-exposure 
has been 
reported and 
should be 
avoided. 
[41][2
1, 52] 
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Table 1.4 Summary of the hepatotoxic profile of herbs that have been implicated in drug-induced liver injury (DILI) 
Herb name 
(Scientific 
name) 
Herbal induced liver injury pattern 
Notes Ref 
Toxicity profile Clinical phenotype 
ADR type 
(hypersensitivity 
features) 
Liver 
injury 
pattern 
Mechanism 
Strength of 
causality 
         Green tea 
(Camellia 
sinensis) 
Onset  in 3 months, and resolves quickly on stopping. 
Fatal instances have been described. 
Liver histology shows inflammatory reactions, 
cholestasis, occasional steatosis and necrosis [1] 
Acute hepatitis like 
syndrome. 
No immune 
features 
H in most 
cases, 
otherwise 
C or M 
Epigallocatechin-3-gallate can induce reactive 
oxygen species formation and affect mitrochondrial 
membrane potential[1]. Has a component of direct 
hepatotoxicity (due to dose dependency) [52]. 
Positive re-
challenge in 
some cases [1] 
Randomised 
controlled trials 
show significant 
protective role of 
green tea against 
various liver 
diseases 
(decreased ALT 
and AST levels) 
[52]. 
[1, 52] 
Herbalife ® - 
(certain 
products) 
Contains green tea in some products (see green tea). 
Median time of symptom onset is 5 months (range 0.5 to 
144 months) [56] and treatment is on average 9 months 
(range 16 days to 3 years). Main symptoms were fatigue, 
loss of appetite and jaundice. Liver tests return to normal 
on product cessation. Two patients required liver 
transplant [57, 58]. 
Inf Inf H in most 
cases 
Toxins and microbial contamination suspected. Some 
formulations contain(ed) green tea, aloe vera, heavy 
metals, guarana and ephedra, which may cause the 
toxicity. 
STRONG [57, 
59] 
WEAK [60, 61] 
One report 
fulfilled criteria 
for positive re-
challenge [62].  
[58] 
Hoodia 
(Hoodia 
gordonii) 
 
No reports of hepatotoxicity clearly linked to hoodia 
intake. 
Inf  Inf   Alkaline phosphatase and bilirubin were found to be 
slightly higher in patients taking hoodia in a short 
term study. 
  [52, 
63] 
Horsechestnut 
(Aesculus 
hippocastanum
) 
Symptoms appear after 4 to 8 weeks. Usually mild and 
self-limited. Resolves rapidly on withdrawal. 
Inf  No immune 
features. 
Likely to be 
idiosyncratic. 
H or M Unknown. Likely to be idiosyncratic.   [52] 
Hydroxycut® Contains ephedra in formulations pre 2004.Contains 
green tea (see ephedra, green tea). AIH like features and 
ALF that needed transplant have been described [1]. 
Patients usually present with jaundice, fatigue, nausea, 
vomiting and abdominal pain. Some cases required liver 
transplant. [64] 
Inf Immune features in 
some cases [64]. 
H in most 
cases 
Inf  
 
  [1, 52, 
64] 
Impila or Zulu 
remedy 
(Callilepsis 
laureola) 
Mortality rate is 90% by 5 days. Acute liver and renal failure Inf  Inf  Toxicity in Hep G2 cells involves depletion of cellular 
glutathione. Toxicity is reduced with N-acetylcystein 
supplementation to the cells to prevent glutathione 
depletion [1]. 
STRONG [1]  [1] 
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Table 1.4 Summary of the hepatotoxic profile of herbs that have been implicated in drug-induced liver injury (DILI) 
Herb name 
(Scientific 
name) 
Herbal induced liver injury pattern 
Notes Ref 
Toxicity profile Clinical phenotype 
ADR type 
(hypersensitivity 
features) 
Liver 
injury 
pattern 
Mechanism 
Strength of 
causality 
         Jin Bu Huan 
(Lypocodium 
serratum) 
Toxicity appears 7-52 weeks (mean 20 weeks) after 
ingestion and resolves within 2-30 weeks (mean 8 
weeks). Liver biopsy shows mild hepatitis, moderate 
fibrosis and micro vesicular steatosis with or without 
eosinophilia. Symptoms include rash or fever [1]. 
Acute and chronic 
cholestatic hepatitis. 
Immunologic 
idiosyncratic [1] 
Inf  Immune mediated process [1]   [1] 
Kava Kava 
(Piper 
methysticum) 
Symptom onset is 2-24 weeks, then present with nausea, 
fatigue and raised serum aminotransferase levels. Can be 
severe and requires liver transplant. 
Cholestatic hepatitis or 
hepatic necrosis [65]. 
Idiosyncratic, 
immunoallergic [4, 
55, 65] 
M[1] Not clear but may involve cofactors - alterations in 
hepatic microsomal CYP450, cycloxygenase 
inhibition, P-glycoprotien and glutathione [1]. Poor-
metaboliser phenotype of CYP450 2D6 found in 
some individuals with kava induced hepatitis [4]. 
STRONG (one 
case had 
positive re-
challenge), but 
reaction is very 
rare, not found 
in indigenous, 
not in 
experiments. 
Toxicity is 
associated with 
daily overdose, 
more than 250mg 
of kava lactones, 
prolonged 
treatment and 
using aerial parts 
of the plant [1]. 
[1, 4, 
52, 55, 
65] 
Ma Huang 
(Ephedra 
sinica) 
On average, the time to onset of symptoms is 12 weeks. 
Presenting symptoms are fatigue, nausea, abdominal 
discomfort and jaundice. Recovery is in 1-6 months. 
Acute liver failure and liver transplantation have been 
reported [52]. 
Resembles acute viral 
hepatitis [52]. Liver injury 
may be severe hepatitis, 
acute liver failure and as 
fulminant exacerbation of 
autoimmune hepatitis (AIH) 
[1]. 
Immunologic [66] 
Immuno-allergic 
features are 
uncommon [52]. 
H [52] Unknown    [1, 52, 
66] 
Mistletoe  Two reports to MHRA were associated with 
hepatotoxicity ADRs [67]. One other report of mistletoe 
hepatotoxicity [68]. 
Inf Inf Inf Inf Inf No further 
information 
found. 
[68][6
7] 
Noni Latent for 2-8 weeks. Resolves rapidly on 
discontinuation.  
Acute hepatitis  No immune 
features 
H  Possibly due to Anthraquinones, however, cases 
have features characteristic of idiosyncratic liver 
injury and studies have not demonstrated evidence 
of intrinsic toxicity. 
  [52] 
Pennyroyal Oil 
(Mentha 
pulegium) 
Toxicity symptoms appear within a few hours. 
Cardiovascular collapse is the usual presentation and 
some patients develop acute liver injury. 
The clinical pattern is that of 
acute hepatic necrosis 
No immune 
features present 
Inf  CYP450 (CYP 1A2, 2E1) convert pulegone into 
hepatotoxins that deplete glutathione.  
 Not 
recommended for 
oral intake. One 
tablespoon (15 
ml) can cause 
multi-organ 
failure.  
[52] 
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Table 1.4 Summary of the hepatotoxic profile of herbs that have been implicated in drug-induced liver injury (DILI) 
Herb name 
(Scientific 
name) 
Herbal induced liver injury pattern 
Notes Ref 
Toxicity profile Clinical phenotype 
ADR type 
(hypersensitivity 
features) 
Liver 
injury 
pattern 
Mechanism 
Strength of 
causality 
         Pyrrolizidine 
alkaloids (PA) 
(Found in 
symphytum 
(comfrey) 
officanale, 
crotalaria, 
senecio 
longilobus, 
heliotropium) 
Onset and severity are variable. In the acute form, 
patients experience abdominal pain often with jaundice 
and markedly elevated ALT. Patients may rapidly 
deteriorate and die. PA associated VOD typically presents 
with ascites, oedema and hepatomegaly. Acute VOD is 
fatal in 15-20% of cases, 15% continue to live with a 
protracted course of liver injury and 50% completely 
recover. Management is mainly supportive. Defibrotide 
may be effective for severe VOD following 
haematopoietic stem cell transplant[1].  
Veno-occlusive disease 
(VOD) is the typical injury, 
newly termed sinusiodal 
obstruction syndrome – it’s 
a non-thrombotic 
obliteration of the lumen of 
terminal centrilobular 
hepatic veins. The resulting 
hepatic obstruction causes 
hepatic congestion and 
centrilobular necrosis, 
which leads to either acute 
liver failure or liver fibrosis 
and cirrhosis [4]. 
Metabolic (directly 
toxic) [4].  
Inf  PA’s are transformed into pyrrole derivatives by 
CYP450s, which then act as alkylating agents. 
Unbound pyrrols are highly reactive 
hepatocarcinogens. Phenobaribtal increases the 
toxicity - it induces CYP450 3A4, 2B6 and several 
isoenzymes of the 2C family [65]. The damage beings 
with the sinusiod endothelial cells, which leads to 
obstruction of the sinusiodal lumen and also the 
blood flow. Liver histology shows non-thrombotic 
occlusion of small terminal hepatic venules, which 
lead to sinusiod dilatation and eventually 
haemorrhagical centrilobular necrosis [1]. 
STRONG [1, 4] Toxicity is dose 
dependent and 
reproducible in 
animals[65]. PA 
hepatotoxicity is 
well recognised 
for over 70 years 
[1] 
[4, 52] 
Saw Palmetto  
(Serenoa 
repens) 
Symptoms appear 1-2 weeks after ingestion, and resolve 
in 1-3 months on stopping. No reports of fatalities or liver 
transplantation. 
Clinical features resemble 
acute viral hepatitis 
No immune 
features present. 
Inf  Unknown    [52] 
Senna 
(Cassia 
acutifolio, C. 
angustifolio) 
Time to onset is 3 to 5 months, with mild to moderate 
severity. The toxicity resolves after discontinuation. 
Inf  No immune 
features present. 
H Appears to be idiosyncratic    [52] 
Shou Wu Pian 
(Polygonum 
multiflorum) 
Symptoms may appear after a few days to 6 months and 
includes fatigue, right upper quadrant pain and jaundice. 
Clinical presentation 
resembles acute viral 
hepatitis 
Immune features 
are rare  
H or M Unknown    [52] 
Skull cap 
(Scutellaria 
lateiflora) 
Symptom onset is 6 to 24 weeks and recovery is rapid on 
withdrawal. Some cases have resulted in acute liver 
failure.  
Inf  No immune 
features 
H Unknown    [52] 
St John’s Wort Although widely consumed, there are no reports of 
hepatotoxicity. 
Inf Inf Inf May increase likelihood of liver injury due to its 
many herb and drug interactions. 
  [52] 
Usnic acid Symptoms appear after 2 to 12 weeks (fatigue, nausea, 
jaundice). Resolves rapidly when discontinued, however, 
there have been few severe cases with acute liver failure, 
liver transplantation or death.  
Acute viral hepatitis No immune 
features 
Directly toxic. 
H  Directly toxic. Mechanism probably involved 
uncoupling of oxidative phosphorylation in 
hepatocytes, which leads to hepatocyte apoptosis 
and lysis. 
STRONG Induces acute 
liver injury in 
animal models.  
[52] 
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Table 1.4 Summary of the hepatotoxic profile of herbs that have been implicated in drug-induced liver injury (DILI) 
Herb name 
(Scientific 
name) 
Herbal induced liver injury pattern 
Notes Ref 
Toxicity profile Clinical phenotype 
ADR type 
(hypersensitivity 
features) 
Liver 
injury 
pattern 
Mechanism 
Strength of 
causality 
         Valerian 
(Valerian 
officinalis) 
Latency varies between 3 to 12 weeks and recovery is in 
2-4 months after stopping. Some cases were severe with 
hepatic failure.  
Inf  No immune 
features. 
H or M Unknown    [52] 
H = hepatocellular liver injury 
M = mixed hepatocellular injury 
Inf = information not found 
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1.8 Causality assessment in HILI 
In a case presentation with liver disease, it is important to ascertain use of drugs and 
complementary medicines, which are a possible cause of the liver damage. Although DILI can 
be severe and fatal, it can be reversed with discontinuation of the harmful drug. Continued 
use of the agent, on the other hand, while facing liver damage can cause serious irreversible 
consequences [52]. The number of medical drugs has increased and the number of people 
who use them has also increased, making DILI a growing challenge[52]. 
Causality assessment for herb-induced liver injury maybe complicated by several patient, 
clinician and herbal related factors, as described below [4]: 
 Self-medication with herbals is common among patients 
 Patients may not recognize herbal remedies as ‘medicines’ or ‘drugs’ in the 
conventional sense, and do not associate them with safety concerns 
 Herbal medicines are usually perceived as safe, given their ‘natural’ origin and long 
standing use as evidence of their safety 
 Patients consuming herbal medicines are unlikely to mention their intake 
 Doctors and other health care professionals may not specifically ask about herbal 
intake. No specific diagnostic tests exist for drug or herbal induced hepatotoxicity 
and diagnosis is by exclusion of other factors making clinical history taking of vital 
importance [6] 
 Herbal preparations may cause harm due to adulteration, misidentification or 
contamination 
 Herbal preparations are usually a mixture of several ingredients or preparations of 
the same product may be different due to different plant harvest seasons and 
variable extraction procedures 
 Herbs and drugs may interact, thus posing a danger in patients with impaired liver 
function 
 Scientific information on herbal toxicology is very limited with relatively few  
rigorous clinical studies [6] making a HILI diagnosis difficult in a herbal preparation 
not previously suspected of hepatotoxic reactions 
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1.9 Mechanism of drug-induced liver injury 
Drugs or their metabolites may cause toxicity either directly to the liver, called intrinsic 
hepatotoxicity, or by eliciting an immune response that leads to liver injury, called 
idiosyncratic hepatotoxicity [19]. The mechanisms of liver injury for each are different. Drugs 
that cause direct toxicity lead to dose-dependent and predictable damage within a short 
latency time. Drugs that cause an immune reaction on the other hand, usually show dose-
independent toxicity with longer latency periods [17]. Idiosyncratic hepatotoxicity may be of 
two types, a hypersensitivity type and a metabolic type (Figure 1.2).  
 
Figure 1.2 Summary of drug induced hepatotoxicity types [17, 19] 
Intrinsic or direct hepatotoxicity is exemplified in paracetamol hepatotoxicity. When 
consumed in large doses, paracetamol causes hepatocellular necrosis [17]. Damage results 
from one of paracetamol’s metabolites, N-acetyl-p-benzoquinone imine (NAPQI). The 
glutathione reaction that clears NAPQI, becomes saturated. NAPQI then reacts with cellular 
proteins via covalent bonds, leads to mitochondrial dysfunction, oxidative stress and 
ultimately cellular damage and death. Other examples of intrinsic hepatotoxins include 
alcohol, carbontetrachloride and phosphorus [17, 26]. 
Idiosyncratic hepatotoxicity occurs in a small number of patients consuming a medication 
and accounts for most DILI cases [26]. Toxicity is not reliably reproduced in animal models 
and satisfactory experimental animal models are lacking [17]. Toxicity is usually dose-
independent and the traditional view is that idiosyncratic DILI cannot be predicted based on 
dose. Some dose dependency does exist however, case reports have shown a reduction in 
dose led to improvement and disappearance of hepatotoxicity. Other reports have shown an 
increase in dose was associated with liver injury in a patient who previously had no signs of 
Hepatotoxicity  
Idiosyncratic  
(lacks experimental 
reproducibility, low human 
incidence) 
Hypersensitivity  
(latency 1-6 weeks, dose-
independent, 
hypersensitivity reactions - 
rash, fever, eosinophilia, 
may not respond to 
rechallenge) 
Metabolic 
 (1-52 weeks latency, dose-
dependent, no 
hypersensitivity reactions, 
responds to rechallenge) Intrinsic 
 (experimentally 
reproducible, high human 
incidence, short latency 
period - days, dose-
dependent) 
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hepatotoxicity at the lower dose [69]. Liver injury may manifest after varying periods of 
latency, from a few days to months after exposure. Examples of drugs causing such toxicity 
are isoniazid, sulphonamides, valproate, rifampicin, co-trimoxizole and phenytoin [17, 26].  
The liver is a site that is rich in foreign antigens from the gastrointestinal tract and may be 
considered as an immunologic organ with the high number of innate immune cells [17, 70]. 
The innate immune system is the first line defence against invading pathogens and 
important for the survival of the body. In the liver, innate immune cells include monocytes, 
neutrophils, dendritic cells, natural killer cells, NK T cells and Kupffer cells.  These cells 
initiate and maintain hepatic inflammation via cytokine regulation, which is designed to 
overcome tissue injury and infection [70]. Hepatic inflammation, however, is a common 
trigger of liver disease. The liver immune-cell composition, with 50% of cells being natural 
killer cells and natural killer T cells, favours adaptation and tolerance. The tolerance 
environment in the liver explains the low incidence of DILI. Injury occurs when these 
tolerance mechanisms are defective in susceptible individuals [17].  
An important concept in the mechanism of idiosyncratic DILI is the inflammatory stress 
hypothesis. According to this hypothesis, bacterial lipopolysacharide released as a result of 
inflammation along with drug metabolites together have the potential to precipitate DILI. 
Generally drugs and their metabolites are not immunogenic, however, hypersensitivity 
reactions, including rash, fever and eosinophilia, may be present with the liver injury [19]. 
Drug metabolites bind with cellular proteins to form a hapten that activates the resident 
natural killer cells and macrophages in the microvascular and sinusoidal system. This sets in 
motion CD4 cell stimulation and clonal expansion via interaction with the major 
histocompatability complex class II. These activated cells migrate from the liver to the skin 
where they cause the observed hypersensitivity reactions [17].  
At the cellular level, drugs may harm the liver by causing immunological reactions, necrosis, 
steatosis, cholestasis, vascular or sinusoidal lesions or neoplasia [19]. At the molecular level, 
liver injury may occur via the mechanisms listed in Table 1.3. 
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Table 1.5 Mechanisms of drug induced liver injury at the molecular level [26] 
Peroxidation of lipids 
Denaturation of protein 
Adenosine triphosphate depletion 
Mitochondrial dysfunction 
Free radical generation 
Electrophilic radical generation and hapten formation 
Biotransformation through CYP450 
Binding of active metabolite to nuclear cytoplasmic molecules 
Binding or blockage of transfer of RNA 
Binding or blockage of bile transporters 
Attachment to membrane receptors 
Disruption of calcium homeostasis 
Disruption of the hepatocellular cytoskeleton 
 
1.10 Patterns of drug induced liver injury 
Drug-induced liver injury can be classified into three patterns based on their histologic 
features and serum liver enzyme elevations. These classifications, hepatocellular, cholestatic 
and mixed hepatocellular-cholestatic injury are summarised in Table 1.6.  
Table 1.6 Liver injury pattern [52] see [30] 
 Hepatocellular Cholestatic injury Mixed hepatocellular-
cholestatic injury 
Resembles Acute viral hepatitis Bile duct obstruction or 
choledocholithiasis 
 
Biopsy Marked liver cell necrosis 
and inflammation and 
mild bile stasis 
Bile stasis, portal 
inflammation and 
proliferation and injury of 
bile ducts and ductules 
Hepatocyte necrosis and 
inflammation with 
marked bile stasis 
Symptoms Fatigue and weakness 
predominate 
Jaundice and itching 
predominate. May have 
upper right quadrant pain 
Fatigue and itching 
ALT Markedly elevated (>10 
times) 
Minimally or modestly 
increased  
 
AST Markedly elevated (>10 
times) 
Minimally or modestly 
increased 
 
GGT Modestly increased Predominantly elevated  
Serum alkaline 
phosphatase 
Modestly increased Predominantly elevated  
R Ratio >5 ≤2  Between 2 and 5 
Bilirubin   Increased more than 
would be expected for 
the level of liver injury 
 
Examples Green tea Greater celandine Typical of many drugs and 
this pattern is most 
characteristic of DILI. 
Occurs rarely in other 
forms of acute liver 
disease 
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In addition to the above classification, drug induced liver injury may also be classified 
according to an overall clinical pattern into twelve phenotypes. These are summarized in 
Table 1.3. 
Table 1.7 Clinical patterns of drug induced liver injury 
Acute hepatic necrosis 
Acute hepatitis 
Cholestatic and mixed hepatitis 
Serum enzyme elevations without jaundice 
Pure or bland cholestasis 
Acute fatty liver with lactic acidosis 
Non-alcoholic fatty liver disease 
Chronic hepatitis 
Sinusoidal obstruction syndrome 
Nodular regenerative hyperplasia 
Liver tumours  
Immunoallergic hepatitis 
Autoimmune hepatitis 
Acute liver failure 
Vanishing bile duct syndrome  
Cirrhosis  
1.11 Herbal medicine quality 
For pharmaceutical products to be of high quality, the active ingredient and finished product 
must meet a set of tests and limits every time a batch is manufactured. These specifications 
monitor parameters where variation in the product would affect the quality or safety of the 
product and therefore ensure that the product meets the required quality every time. 
Manufacturers demonstrate product quality through testing, for example, stability testing, 
impurity testing, microbiological testing amongst many others [71]. Although herbal product 
manufacture must comply with good manufacturing practice (GMP), achieving consistent 
herbal product quality is a challenge. Misidentified herbs, contamination, adulteration and 
impurities are of a particular concern. In addition, herbal variability and standardisation is 
difficult and batch and product variability is reported [30]. In a review of herbal safety alerts 
in 2010, Shaw and colleagues found that 336 of 390 (86%) of warnings from drug regulatory 
authorities were for adulterated or contaminated herbal products in the United Kingdom 
(UK), US, Australia (AU), Canada, Singapore and Hong Kong [14].These considerations are 
important in the causality assessment of herbal induced liver injury.  
1.12 Heavy metal contamination 
High levels of heavy metals, such as lead or mercury, are a concern in herbal products for 
oral intake. Their regular intake leads to accumulation in various body organs resulting in 
adverse effects. Among the heavy metals, lead (Pb), mercury (Hg), cadmium (Cd), and 
arsenic (As) are commonly found in herbal medicines [73]. In Asia, heavy metal 
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contamination of herbals is a serious problem [73]. Traditionally though, heavy metals are 
incorporated into traditional Asian medicines intentionally based on the time-honoured 
belief that metals such as lead, copper, gold, iron, mercury, silver, tin and zinc are important 
for health and their imbalance leads to disease [74]. Traditional herbal formulators are 
aware of some of the potential harm of metals and attempt to incorporate them in ‘safe’ 
ways. In Ayruvedic medicine for example, a procedure for making processed lead, 
nagabhasma, involves several heating steps that make the metal glow and alternately 
dipping in several herbal mixtures. Subsequently it is combined with arsenic sulphide. 
Despite these methods for ‘safe’ incorporation, heavy metals are often present in excessive 
amounts [74]. Heavy metal contamination may also arise from growth conditions and 
processing. Plants take up heavy metals from metal rich soil, irrigation water, fertilizers and 
pesticides [73].  
1.13 Pathogenic microorganisms 
Raw herbal products and unprocessed food naturally contain saprophytic organisms, which 
are harmless at low levels. However, inadequate or prolonged storage allows certain 
microorganisms to multiply to dangerous levels or produce significant amounts of toxins [74] 
making fungal and microbial contamination  a concern for herbals. Herbal medicines may be 
exposed to contamination in the field, post-harvest and in the production and distribution 
process. Alfatoxins, ochratoxin A, fumonisins, deosynivalenol and dzearlenone are 
mycotoxins that have been detected in medicinal plants worldwide. Mycotoxins are a type of 
microbial toxins that are secondary metabolites produced by fungi, especially Aspergillus, 
Penicillium and Fusarium species. These mycotoxins are able to cause a multitude of adverse 
effects including hepatotoxicity, nephrotoxicity, immunotoxicity, neurotoxicity, 
carcinogenicity and teratogenicity [73].   
1.14 Adulteration 
Adulterated herbal medicines contain active pharmaceutical ingredients not included on the 
label for the intended use of the herbal product. Undeclared pharmaceutical actives are of a 
big concern to regulatory authorities and consumers. Patients taking adulterated herbals 
may be exposed to actives that are contra-indicated, cause adverse reactions, consume an 
overdose or interact with other medicines they may already consume. In addition, herbal 
products are likely to be consumed for long periods of time, making adverse reactions due to 
adulteration more of a concern. Although dishonest and illegal, such adulteration has 
become widespread [74]. Constant surveillance by drug authorities is required to detect 
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adulterated products and has led to several market withdrawals. Table 1.8 gives examples of 
adulterants found in herbal medicines.  
Table 1.8  Examples of herbal products and adulterants found in the past [73, 74] 
Pharmacological class  Adulterant(s) 
Phosphodiesterase inhibitors Sildenafil, tadalafil 
Analgesic, anti-inflammatory Aminophenazone, aminopyrine, diclofenac, dexamethasone, 
dipyrone, phenylbutazone, indomethacin, flucinolone, mefenamic 
acid, aspirin, paracetamol, ketoprofen, phenacetin, peroxicam 
Corticosteroids Clobetasol propionate, flucinonide, prednisone, betamethasone 
Antihistamines Chlorpheniramine, cyproheptadine, promethazine 
 Theophylline  
Weight loss agents  Fenfluramine 
Antidepressants Barbitruates, bromine 
Antipsychotics Diazepam, chlormezanone 
Diuretics, antihypertensive Hydrochlorothiazide 
Glucose reducing agents Glibenclamide, metformin 
Blood thinners Warfarin 
Sedatives Estazolam, chlordiasepoxide,   
Stimulants Caffeine, ephedrine 
1.15 Botanical misidentification 
Herbal plants may be easily misidentified when their appearance or nomenclature is similar 
or confusing [73]. Although it may seem that misidentification of similar plants is 
inconsequential, plant active constituents may be different and advertent or inadvertent 
substitution can lead to serious adverse events. An example of that is a case where Japanese 
star anise was confused with Chinese star anise in herbal teas for infant colic. The products 
were sold in Europe and resulted in a wave of convulsive disorders in Denmark, Spain and 
France. Convulsions were due to sesquiterpene lactone anisatin, found in Japanese star 
anise, which is neurotoxic causing symptoms of  tremors, spasms, hypertonia, 
hyperexcitability, nystagmus and vomiting [74]. Other examples of botanical confusions are 
given in Table 1.3. Although these examples may not be related to hepatic toxicity, a number 
of herb-induced liver toxicity cases have questioned the true identity of the consumed 
herbal product[30]. 
Table 1.9 Examples of herbal plants and their botanical adulterants (adapted from [74] 
Herb  Botanical adulterant  
Clemantis Gentiana sp. Podophyllm hyxandrum 
Gentiana sp.  Podophyllum emodi 
Plantago sp.  Digitalis lanata  
Chinese star anise (Illium verum) Japanese star anise (Illium anisatum; I. religiosum) 
Panax ginseng Mandragora officinarum, Rauwolfia serpentine and Cola 
spp.  
Vaccinium myrtillus Atropa belladonna 
Eleutherococcus senticosus Periploca sepium 
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1.16 Variable composition 
Medicinal plants are complex and contain many phytochemicals and have variable 
composition. Due to the inherent complexity of herbs and their extracts, their constituents 
cannot be completely defined or enumerated [75]. In a whole plant, there may be at least 
50,000 compounds (including compounds present in small amounts) and it is estimated that 
the number of plant metabolites likely exceeds 200,000 [75]. Furthermore, within one plant 
the chemical profile differs in different parts of the plant, from the roots to stems to 
rhizomes to leaf tips. In addition, for the same plant, this composition may be different 
under different conditions, such as climate, growing conditions, time of harvesting, post-
harvest storage conditions in terms of light, humidity, temperature and processing factors 
such as drying and extracting [76]. For example, alkaloids in greater celandine undergo daily 
variations reaching a maximum in the evening in summer and around midday in winter. 
These changes are due to light and temperature variation [77]. Two plants of the same 
species growing in close proximity may also be different in composition. Therefore, batch-to-
batch and manufacturer-to-manufacturer variation exists. For example in an analysis of eight 
St John’s Wort products, it was found that variation in the hyperforin content was 0.01 – 
1.89 and ranged between 57 to 130% of the label claim [78]. 
In traditional Chinese and Ayurvedic medicine, interactions between different 
phytochemicals and different plants form the basis of therapy. It has been shown that 
therapeutic effect and toxicological profile of whole plants are different to their individual 
constituents [75]. The therapeutic and toxic effects are also not necessarily the sum of 
individual parts because it has also been shown that constituents act synergistically. In an in 
vitro study using cranberry (Caccinium macrocarpon Aiton, Ericacaeae), the whole fruit and 
specific phytochemical constituents were tested for anticancer activity. The experiments 
showed that the specific phytochemicals, anthocyanins, proanthocyanidins, ursolic acid and 
flavonols were able to inhibit cell proliferation individually; however, they had less activity 
than the whole fruit extract. This work shows that cranberry tumour inhibition could be due 
to the synergistic activity of the individual compounds [79]. Study of herbal toxicity, although 
less explored than efficacy, is also complex due to the complex nature of the plants. 
Extrapolation of individual constituent toxicity to the entire plant or the plant extract is of 
doubtful reliability.  
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1.17 Standardisation 
Standardisation of processed herbal products is important for consistency and quality of the 
herbal product. It is especially important for herbs given they have inherent variability. In 
order to achieve batch-to-batch consistency, herbal manufactures may use one or more 
active constituents to standardise against. This is done by producing a standard herbal 
extract with known standard quantities of the actives and sometimes the toxins may be 
removed [76]. Standardization is to some extent possible for herbs with known actives, 
however, many herbs have unknown actives. In this case, manufacturers standardise against 
certain ‘marker’ compounds that may be characteristic of the plant and present in sufficient 
quantities. This method makes a few assumptions about the selected marker compound and 
the unknown actives.  
1.18 Herbal medicine regulation 
Herbal medicine regulation is generally based on the ‘low-risk’ classification of herbal 
products in various countries. This is in sharp contrast to the pharmacological activity and 
toxicity risks of herbal constituents presented in section 1.3 and 1.4in this review. Current 
herb and drug regulation is mostly well suited for conventional drugs and not well adapted 
to the special characteristics of herbal medicines.  
1.19 Australia 
In Australia, complementary medicines are regulated under the Therapeutic Goods Act 1989. 
In this context, ‘complementary medicine’ includes herbs, vitamins, minerals, supplements, 
homoeopathic and certain aromatherapy preparations [13].  
For a manufacturer that intends to sell their complementary medicine in Australia, they 
must have their product listed or registered on the Australian Register of Therapeutic Goods 
(ARTG). Listed medicines are of lower risk, whereas higher risk medicines must be registered. 
Most complementary medicines are of low risk and are therefore listed in the ARTG. In 
comparison all prescription medicines and most over-the-counter medicines are registered.  
The quality, safety and efficacy assessment process begins after complementary medicines 
are listed and available in the market. The TGA approves for listing around 1800 new 
complementary medicines each year. Due to this large number, not all applications are 
assessed. Instead a selected number go through review and this can be a random sample or 
targeted reviews of products suspected of non-compliance. The TGA uses a risk 
management approach to use the limited resources for reviewing medicines in a way that 
gives greatest overall benefit to the Australian public. Medicines are therefore prioritized, 
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for example medicines involving a new or emerging issue, are of national or international 
significance, could significantly mislead the public or may result in immediate or potential 
health harm to the patients are higher priority.   
1.19.1 Quality, safety and efficacy requirements 
Quality requirements for complementary medicines containing simple ingredients such as 
amino acids or vitamins are essentially the same as other medicines. However, complex 
herbal preparations that contain multiple actives or are complex and difficult to characterize 
are given special consideration.  
Herbal ingredients and finished products must meet a set of tests and limits every time to 
ensure product quality. The British Pharmacopoeia, US Pharmacopoeia, European 
Pharmacopoeia and Therapeutic Good Orders are the official standards accepted in 
Australia. When a monograph is included in these pharmacopoeias, it forms the minimum 
standards the substance and product must achieve. Complex herbal preparations may be 
controlled using macro components such as nitrogen or sodium content. Other tests may 
include solvent content, viscosity, colour, texture, smell and pH. Significant components in 
the preparation will need more complex tests. Minor components in a complex herbal 
preparation, such as a specific alkaloid, may have a significant effect on the safety and 
quality of the product and will therefore need to be controlled. Manufacturers may use 
monographs for similar substances as a model and adapt them to their herbal preparation. 
Safety is to some extent already accounted for because listed complementary medicines 
may only contain low-risk active ingredients that have already been assessed by the TGA as 
low risk. In addition, traditional use is not sufficient as a safety assessment. Therefore the 
safety assessment of complementary medicines takes into account the overall formulation, 
its therapeutic purpose, dosage, duration of use, patient groups and likelihood it will 
interfere with critical medications. The manufacturer is therefore required to include 
references to toxicological studies and records showing any harmful effects of the herbal 
ingredients used.  
Establishing efficacy of the complementary medicine is largely based on traditional use of 
the product. The manufacturer is required to provide evidence from published literature and 
research to show traditional use. In cases where this data is insufficient to show efficacy, the 
manufacturer is required to provide supplemental clinical evidence.  
 41 
 
1.19.2 Registering a complementary medicine on the ARTG 
Some complementary medicines such as Arthro-Aid (Glucosamine 750mg capsules) have 
undergone rigorous assessment and testing to be registered in the ARTG. Registration means 
that the medicine meets high quality, safety and efficacy standards. All applications are in 
the Common Technical Document format and a full dossier is required [80]. Wherever 
possible, the TGA has made guidelines the same as international ones. However, the 
Australian regulatory requirements are as a whole unique to Australia and are contained in 
the Therapeutic Goods Act 1989, Therapeutic Goods Regulations 1990 and other orders, 
notices and determinations.  
1.19.3 Pharmacovigilance 
Prior to November 2012, the Australian Pharmacovigilance Guide outlined 
pharmacovigilance requirements.  This has recently undergone review and now replaced by 
the Australian Requirements and Recommendations for Pharmacovigilance Responsibilities 
for Sponsors of Medicines. The new guidelines clearly state mandatory and non-mandatory 
reporting requirements are with separate consideration for listed medicines. In summary, 
the manufacturer is required to forward adverse effects received of their listed or registered 
their product to the TGA within 15 calendar days if they are serious. Significant safety issues 
must be communicated in writing within 72 hours and non-serious adverse reactions are to 
be preserved in record and submitted when required by the TGA.  
1.20 United States 
In the US, the Food and Drug Administration (FDA) regulates medicinal products, devices, 
veterinary products and food products[12]. Herbal substances and herbal products are 
regulated as dietary supplements by FDA’s Centre for Food Safety and Applied Nutrition 
because they are under the “food” umbrella. A dietary supplement includes vitamins, 
minerals, herbs, amino acids and dietary substances.  
The role of the FDA in regulating dietary supplements is to take action against any unsafe 
dietary supplement in the US market. FDA regulation is through post marketing evaluation of 
the product. This means that FDA has the task to prove that a marketed product lacks safety. 
Under the DSHEA of 1994, the manufacturer of a dietary supplement is responsible for 
ensuring that a dietary supplement or dietary ingredient is safe before it is marketed. This 
means that manufacturers do not need FDA approval before marketing dietary supplements. 
However, any manufacturing facility that processes, packages, labels, holds dietary 
supplements or markets in the US must have registration with the FDA as a food facility 
before manufacturing or selling any products. Included in this registration is any facility that 
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is involved in the testing or quality control of the product. To gain this registration or 
approval, the manufacturer must comply with the Dietary Supplement Current Good 
Manufacturing Practices (cGMPS) for quality control, as required by the FDA Final Rule 21 
CFR 111, 2003. In addition, the manufacturer or distributor whose name appears on the 
product label is responsible for reporting to the FDA all adverse events reported to them 
associated with the use of the dietary supplement in the US.  
Manufacturers are legally required to ensure their products are safe and label claims are 
substantiated by adequate evidence and are not misleading. There is no requirement for a 
manufacturer or distributor to disclose any safety information to consumers or the FDA. 
However, for new dietary ingredients that have not been present in the food supply prior to 
1994 require a premarket notification for manufacture or distribution. The notification has 
to contain the basis on which the manufacturer or distributor has decided that the dietary 
supplement will reasonably be expected to be safe. The FDA may then determine the 
application satisfactory and approve it or it may question its safety. 
To monitor the market place for illegal products, the FDA uses the information obtained 
from inspections of dietary supplement manufacturers and distributors, the internet, 
consumer or trade complaints, occasional laboratory analysis of selected products and 
adverse events related to the products that are reported to the FDA. The FDA does not 
analyse dietary supplements before they are sold to consumers and the manufacturer is 
responsible for ensuring that their products are safe and the label is accurate and correct. 
The main way FDA uses its resources in protecting the public is by focusing funds on public 
health emergencies where products have caused injury or illness, and then focuses on 
products thought to be fraudulent or unsafe. The remaining funds are used for routine 
monitoring of products picked from market shelves or from inspections. From 2002 to 2006, 
the FDA has conducted 588 domestic inspections of dietary supplement manufacturers, 
issued more than 350 “warning letters”, seized products worth more than $13.4 million and 
supervised the destruction of $3 million worth of dietary supplements that were either 
promoted with unsubstantiated claims, unapproved or unsafe[81]. The FDA has also refused 
the importation of more than 4,000 foreign shipments of dietary supplements because they 
were potentially unsafe or misbranded[81]. 
Manufacturers of dietary supplements are required to submit adverse drug reaction reports 
involving products marketed in the US when reported to them from consumers. Serious 
adverse effects must be reported within 15 business days and records for both serious and 
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non-serious adverse effects must be maintained for six years[82]. These records may be 
checked during an FDA inspection.  
1.21 Europe 
The European Medicines Agency (EMA) is a decentralized body in the European Union that is 
responsible for the scientific evaluation of medicines developed by pharmaceutical 
companies to be approved for use in the European Union (EU). Individual member states 
have their own medicine agencies, which are responsible for regulating therapeutic products 
and medical devices.  
Herbal medicine registration falls in the decentralized pathway category and applications for 
herbal substance or product licensing needs to be made with the individual member states 
of Europe.  
Today, a herbal product must fall in one of the categories below to reach the European 
market: 
1. Traditional medicine use – a herbal is granted registration based on sufficient safety 
and quality data and credible efficacy. This means that there is sufficient evidence of 
traditional use of the product. The data on traditional use must be sufficient to show 
that they are not harmful in the specified indications and the pharmacologic effects 
are plausible. 
2. Well-established medicine use – the herbal is granted registration with safety, 
quality and efficacy data. The product is granted marketing authorization by the 
individual member states or by the European Medicines Agency under certain 
conditions. The efficacy data does not have to come from clinical trials and can be 
demonstrated through detailed references to the published scientific literature that 
the product has well-established medicinal use with recognized efficacy and 
acceptable safety. 
3. Full dossier –the product is authorized for marketing with a full dossier containing all 
the product specific safety, quality and efficacy. The application can be to individual 
member states or the EMA. This is a full marketing authorization, which is the same 
as for any regular medicine. 
The greatest focus, regardless of which pathway is used for the herb to reach the market, is 
demonstration of the quality of the product. After registration or a marketing license is 
granted, the product is continually monitored through a pharmacovigilance network. When 
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adverse drug reaction reports since registration show that the risk benefit balance is no 
longer favourable, the EMA takes action to protect public health.  
1.22 CHAPTER 1 SUMMARY 
Key points in chapter 1 are summarised below: 
 Herbal products are widely used by individuals to improve their health, prevent or 
aid in treating disease. Their use has recently increased dramatically in developed 
countries as people seek more ‘natural’ remedies and herbs form a dominant and 
leading part of traditional therapy found in many healing traditions.  
 Conventional drugs based on plant derived substances, such as digitalis, are 
regulated as drugs. However, ‘herbal remedies’ are usually perceived as natural and 
harmless. Hoewever, they contain pharmacologically active compounds with 
therapeutic activity and may cause significant side effects. 
 Safety concerns have surfaced regarding herb use with the increased awareness of 
their pharmacological activity. Amongst the various adverse events herbal medicines 
have caused are hepatotoxic reactions that can be sufficient to halt a new drug’s 
development or withdraw existing drugs from the market.  
 HILI accounts for a significant proportion of DILI cases, though estimates vary widely 
especially in different populations. In the US and Spain, most studies found HILI 
accounts for 5-11% of DILI patients and in Asia HILI accounts for 71 to 73% of DILI 
cases 
 On their own, drugs or their metabolites may not be hepatotoxic. However, when a 
combination of host genetic factors, environmental factors and drug toxic potential 
factors are present and act in concert, they may elicit an immune idiosyncratic DILI 
reaction.  
 Direct liver injury is dose-dependent and predictable with a short latency. Immune 
mediated liver injury is usually dose-independent with longer latency. Idiosyncratic 
hepatotoxicity may be of two types, a hypersensitivity type and a metabolic type. 
 HILI may present with a set of distinct clinical patterns or phenotypes, similar to DILI. 
HILI may also present with immune features or be classified according to 
hepatocellular, cholestatic or mixed liver injury. For example, aloe vera case 
presentation resembles acute viral hepatitis and has been associated with an 
immune reaction in rare occasions and is of a hepatocellular nature. This 
information is very important for HILI causality assessment, yet it is difficult to locate 
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in the literature, frequently information is not available or the literature evidence 
maybe contradictory. Table 1.4 is a new and thorough overview of herb’s 
hepatotoxicity profiles.  
 Although herbal product manufacture must comply with good manufacturing 
practice (GMP), achieving consistent herbal product quality is a challenge. 
Misidentified herbs, contamination, adulteration and impurities are of a particular 
concern. 
 Herbal medicine regulation is generally based on the ‘low-risk’ classification of 
herbal products in various countries.  
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2 CHAPTER 2: PHARMACOPHORE MODELLING 
2.1 Pharmacophore modelling methods 
A pharmacophore is a concept that is used to describe the three-dimensional arrangement 
of chemical groups that are essential for a chemical compound or ligand to interact with a 
receptor. The IUPAC definition of a pharmacophore “is the ensemble of steric and electronic 
features that is necessary to ensure the optimal supramolecular interactions with a specific 
biological target structure and to trigger (or to block) its biological response” [83]. A 
pharmacophore therefore refers to the special arrangement of chemical features in three-
dimensional space and does not represent a real molecule. It accounts for the common 
chemical features of a group of compounds with activity toward a specific receptor.   
Chemical groups such as hydrogen bond donors, hydrogen bond acceptors, hydrophobic 
groups, aromatic groups and positively charged or negatively charged groups, are examples 
of pharmacophoric features that may interact with a biological receptor site (Figure 2.1). 
Features may be located on the atom itself or be projected points assumed to be located on 
the receptor. Figure 2.2 shows an example of a pharmacophore that represents the essential 
binding between the 5HT2c antagonists and their receptor.   
 
 
 
Figure 2.1 Examples of donor, acceptor, negatively charged and positively charged groups that can be 
identified as pharmacophoric features 
Donor 
 
Acceptor 
 
Negative Charge 
 
Positive charge 
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Figure 2.2 Pharmacophore model for 5HT2c antagonists representing essential features for the antagonists to 
bind with their receptor (hydrogen bond acceptor (green), positive ionizable group (red) and hydrophobic group 
(cyan), the grey structures are the 5HT2c antagonists overlaid on each other showing overlap of the 
pharmacophoric features)[84]. 
 
 Three methods that can be used to search for a pharmacophore model[85]: 
1. Ligand-based pharmacophore modelling. In this method, the pharmacophore 
model is based on a set of compounds that are known to interact with a specific 
receptor. These compounds are called the training set. It is often used when a set of 
active ligands is known but the receptor structure they act on is unknown. The first 
step in pharmacophore model elucidation is ligand conformer generation to account 
for the flexibility in the molecule. Then pharmacophoric features are identified. 
Ligands are then overlaid to find a common arrangement of features in the set[84, 
85].  
2. Structure-based pharmacophore modelling. In this method, the pharmacophore 
model is based on the three-dimensional structure of a specific receptor binding site 
with or without a bound ligand. This method is useful when the receptor binding site 
structure is known, from an X-ray crystal structure for example, and can be used 
when there are no known actives for a specific receptor. In this method, the 
receptor binding site is first analysed for complementary chemical features that may 
be involved in the activation of the receptor. Then pharmacophore hypotheses are 
generated based on the arrangement of all or some of these features.   
A pharmacophore model may be applied in pharmacophore-based virtual screening, in 
which the model is used to screen a chemical database for compounds possessing the three-
dimensional arrangement of the chemical features. It may also be used for pharmacophore-
based de novo design, in which a new chemical structure is designed with a new chemical 
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scaffold that contains the same spatial chemical feature arrangement as the pharmacophore 
model [85, 86].  
Pharmacophore modelling has been successfully employed in drug design to obtain new 
molecules with activity toward the receptor. These molecules are suitable as lead 
compounds in drug discovery. For example, five novel bioactive compounds that induce the 
farnesoid X receptor were found using structure-based pharmacophore modelling. The 
validated pharmacophore model (Figure 2.3) was used in virtual screening of the Chinese 
Herbal Medicine database and revealed mostly lanostane-type triterpenes as potential 
ligands for the farnesoid X receptor. Five of these compounds were found to induce the 
receptor in a dose-dependent manner in a gene reporter assay. Docking studies enabled a 
structure-activity relationship evaluation of the interaction (Figure 2.4) [87]. Another 
example is new biologically active inhibitors for the c-Myc-Max heterodimer formation 
found using pharmacophore models generated using ligand-based pharmacophore 
modelling from existing inhibitors. The validated pharmacophore model was used in virtual 
screening to identify hits, which were then tested in vitro and showed good inhibitory 
activity in the micromolar range [88]. Another example is the discovery of new PPARγ 
agonists from a training set of known agonists for safer and more effective anti-diabetic 
drugs. The validated pharmacophore model was used to screen the Chinese Natural Product 
Database and led to the discovery that methyl oleanonate exhibits agonist activity[89].  
 
 
Figure 2.3 Pharmacophore model comprising five hydrophobic features, one hydrogen bond acceptor and 27 
exclusion volume spheres (ligand: fexaramine) 
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Figure 2.4 Best fitting pharmacophore model in farnesoid X receptor binding site (ligand is MFA-1). Crucial 
interactions are shown in ball and stick style. 
 
2.2 Hepatotoxicity models 
Pharmacophore modelling is a useful tool in understanding idiosyncratic HILI and DILI. This 
section will briefly look into currently available tools for the study of idiosyncratic HILI and 
DILI and their limitations to illustrate how pharmacophore modelling can be beneficial in this 
area. 
Herbal hepatotoxicity is often idiosyncratic and idiosyncratic hepatotoxicity is a rare event, 
which occurs in a subset of predisposed individuals. Several host genetic and environmental 
factors have been identified as predisposing factors in idiosyncratic hepatotoxicity (See 
section 1.6). Therefore it is a challenge to find a model replicating this toxicity. Currently no 
satisfactory in vivo or in vitro methods exist to predict or model this toxicity [197] and the 
mechanisms of the toxicity remain poorly understood. Nevertheless, current in vivo and in 
vitro models provide useful information to understand mechanisms behind the observed 
toxicity and to relate it to human herb hepatotoxicity cases.  
Designing in vivo or in vitro tests for herb hepatotoxicity brings special challenges. A single 
herb may contain multiple active compounds and herbal medicine may be composed of 
multiple herbs (See section 1.16). This leads to questions about which plant extracts or 
constituents are suitable for testing and their extraction methods.   
2.2.1 In vitro models 
Over 90% of drug candidates fail the clinical trial phase for unacceptable toxicity, 
pharmacokinetics or activity[90]. It is an ultimate goal to develop in vitro models for DILI 
prediction during the lead optimization phase. In vitro models will also provide invaluable 
mechanistic information at the cellular level. In an in vitro study, the cells are exposed to the 
toxicant directly and interact with it continuously until it is removed from the medium. The 
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liver cell culture model is the most widely used to investigate toxic effects at the cellular 
level and an isolated perfused organ is used to assess organ physiology and morphology[91]. 
A precision cut liver slice is used as a bridge between these two approaches to investigate 
cellular effects in a tissue specific background [92]. These models have specific advantages 
and disadvantages that make each suitable for different purposes (Table 2.1). All in vivo data 
however have imperfect extrapolation to human toxicity. For example, troglitazone 
exposure to cells required a high concentration in the absence of albumin and resulted in 
100% cell death but in humans the toxicity is only manifested in susceptible individuals [93]. 
Therefore, the development of a suitable model for idiosyncratic hepatotoxicity is vitally 
important.  
 
Table 2.1 In vivo models for evaluating hepatotoxicity 
 Advantages Disadvantages 
Cell culture All species possible, including humans 
Can investigate several compounds at 
different concentrations 
Cryptopreservation prolongs storage 
No bile measurement 
Cell-to-cell interaction lost 
Anatomy not preserved 
Immortalized liver cell lines have 
reduced CYP450 activity 
Precision cut liver 
slice 
Retain some degree of tissue organization 
and cell-to-cell interaction  
All species possible, including humans 
Can investigate several compounds at 
different concentrations 
Bile flow cannot be studied 
May have poor diffusion of oxygen and 
nutrients 
Relatively short viability 
 
Perfused organ Three-dimensional liver structure preserved, 
with cell-to-cell interaction 
Real time bile collection and analysis possible 
Allows study of haemodynamic parameters 
Closest to in vivo model 
Short term viability  
Small number of compounds can be 
assessed at a time 
Animal organs are different in size, 
function and geometry to human liver 
Complex set up 
 
2.2.2 In vivo models and clinical studies 
There are no animal models for immune DILI or delayed non-immune DILI[93]. However, in 
vivo screening provides some useful liver safety information and is currently a main hepatic 
safety assessment method[90]. Mice and rats are most frequently used as models and larger 
animals such as guinea pigs, rabbits and dogs are also used. Hepatotoxicity may be induced 
using agents such as carbon tetrachloride, acetaminophen, alcohol and cyclosporine-A. 
Interestingly, it has been found that co-administration of lipopolysaccharide (LPS) with a 
hepatotoxic agent in animal models led to toxicity at doses of the agent that would 
otherwise not cause toxicity [91, 94].  LPS is a major constituent of gram-negative bacteria 
cell wall and is removed by Kupffer cells and macrophages in the liver[91]. LPS up regulates 
co-stimulatory factors on antigen presenting cells through toll-like receptor 4 and increases 
the release of TNF-α and inflammatory prostaglandins [91, 94]. These effects are consistent 
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with the danger hypothesis (See section8.6) and therefore provide an important tool to 
examine mechanisms of drug-induced liver injury.    
Ideally, an animal model would closely resemble the disease or condition it is compared to. 
However, there are clinical, morphological, biochemical and functional differences between 
animal models and humans that limit the extrapolation of animal data to humans[91]. For 
example, 38-51% of human liver effects were not evident in previously conducted animal 
studies [90].  
Rare idiosyncratic reactions are unlikely to manifest in clinical trials due to the small number 
of patients recruited. Therefore, it is necessary to use markers of hepatic injury as predictors 
of drugs with increased likelihood of causing liver injury when exposed to a large population. 
This is commonly done by detecting changes in serum liver enzyme levels such as alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin and alkaline phospatase. 
Of these markers, ALT abnormalities are frequently present in liver injury cases and are very 
commonly due to hepatocyte death[93]. Therefore, it is considered a sensitive signal for liver 
injury, though it may not always be liver specific. An ALT level three times above the upper 
limit of normal is considered a signal for idiosyncratic liver toxicity.  When accompanied by 
other liver enzyme elevations, the liver injury signal is more likely to be liver specific. Hy’s 
law is predictive of severe cases of acute liver failure and states that if elevated serum 
transaminases are accompanied by jaundice, this is associated with approximately 10% 
mortality (range 5-50%)[90]. Although clinical studies are executed well and to acceptable 
standards, a significant number of drugs have reached the market with hepatotoxicity risk 
sufficient for a market withdrawal. In vivo models would be invaluable in preventing such 
occurrences.  
2.2.3 Toxicogenomics, proteomics, metabonomics 
Despite the improvements in vivo and in vitro in testing for and understanding mechanisms 
of idiosyncratic drug-induced liver injury, the number of serious adverse effects is growing 
[95]. Toxicogenomics is an emerging technology with potential to identify toxicity 
biomarkers specific to a particular organ and type of toxicity, which is lacking in current in 
vivo and in vitro studies. It is a powerful tool in toxicology research that allows high-
thoroughput screening of compounds. Studies may be categorized under toxicoproteomics, 
toxicometabonimics or toxicotranscriptomics (Table 2.2). A metabolomic study would start 
with a data acquisition step in which a biological tissue or fluid is profiled, followed by a 
bioinformatics step in which data is analysed for patterns, outliers and easily identifiable 
 52 
 
biomarkers and finally an application step in which patterns that emerged from the results 
are mapped to specific metabolic pathways [95]. 
These technologies can be applied to herbal medicines. For example, in a 
toxicotranscriptomics study use of the DNA micro-array, which allows parallel monitoring of 
thousands of genes, generated a comprehensive profile of gene expression for Echinacea 
extract. It was possible to analyse expression patterns from generated results, such as the 
up-regulation of NFkB, CCL2, CCL5 and IL-8, and down-regulation of IFN-α and LILRB3 mRNA. 
These enabled detection of an immuno-modulatory action of the Echinacea extract[73].  In 
summary, although these profiling approaches provide useful information and aim to 
overcome shortcomings of in vivo and in vitro toxicity assessments, they are yet to reach 
their full potential. Currently toxicogenomics is significantly limited by unfocused outcomes 
for measurement [93].    
Table 2.2. Definition of terms [73] 
Toxicogenomics is the study of a toxin’s effect on gene transcription, protein expression and metabolite profiling 
 Definition  Limitations 
Toxicoproteomics The study of a toxin’s effect on cell 
transcription level and activity 
Toxic effect may be localized to the 
cell(s) with no systemic effect 
No information on the mRNA stability 
mRNA transcription levels may not 
affect protein levels  
Toxicometabonomics The study of a toxin’s metabolites and 
biomarkers 
Biomarkers may not indicate toxicity 
Toxicotranscriptomics The study of a toxin’s effect on gene 
transcription 
Gene transcription may not translate 
into a physiological effect 
 
2.3 Pharmacophore modelling for herbal hepatotoxicity 
In vivo and in vitro studies have attempted to identify the culprit phytoconstituents in herbal 
hepatotoxicity pathways; however the mechanisms behind this toxicity and receptors 
involved are mostly unknown. In vivo and in vitro studies have so far been narrow and 
specific in their approach by their nature because they consider only one herb at a time and 
investigate a relatively small number of phytoconstituents. Pharmacophore modelling 
overcomes limitations of previously described in vivo, in vitro and toxicogenomic studies and 
is an advantageous method as a first step in creating a model for the toxicity. It is also 
advantageous for analysing herb-induced liver injury because pharmacophore modelling 
allows the use of a wide approach to investigating a large set of phytoconstituents derived 
from multiple herbs that share hepatotoxicity features.  
 53 
 
A group of herbs that cause liver injury with the same or similar features, patterns or type of 
liver injury may be doing so via the same pathways. These herbs may therefore have in 
common the constituents that interact with the same proteins in pathways leading to 
toxicity.  Pharmacophore modelling aims to reveal the structural features important to the 
ligand-protein interaction that is part of the toxicity pathway, which the herb 
phytoconstituents would be expected to share.  
Few pharmacophore modelling studies have been conducted on herbal medicines and this 
study is the first of its kind. Two studies in the literature employed similar research methods. 
The studies by Matthews et al. (2009) and Ursem et al.(2009) used adverse event data from 
the FDA AERS to identify clusters of pharmaceutical drugs linked with liver injury and renal 
injury[96-98]. The proportional reporting ratio (PRR) was used to determine compounds for 
the training set in quantitative structure activity relationship (QSAR) models to predict the 
toxicity. Using similar methodology, a study by Frid and Matthews (2010) used QSAR models 
to predict drug induced cardiac toxicity using population data to form the training set[99].  
 
2.4 Aims of this study 
The aims of this study are: 
1. To find associations between herbal medicine exposure and hepatotoxic reactions 
using disproportionality analysis on population data from pharmacovigilance 
systems 
2. To find shared structural patterns (pharmacopohore hypotheses) among molecular 
constituents of plants with evidence for liver injury  
Signal detection in the first part of the study, together with literature reports, will provide 
the evidence for selecting herbs with shared hepatotoxicity features. This approach, namely 
using population data in order to gain insight into molecular features essential for 
interaction, is a valuable approach in studying rare events. This is the first study of its kind 
that aims to examine idiosyncratic HILI using pharmacophore modelling to identify clues for 
toxicity mechanisms. 
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3 CHAPTER 3: METHODS – SIGNAL DETECTION 
3.1 Choice of database 
In order to identify a suitable database of adverse drug reaction reports, a preliminary 
search of several databases was conducted to identify the number of cases with herb 
exposure.  
For the preliminary search, a pharmacovigilance database containing adverse reactions was 
selected if it was searchable online. These databases were the Australian Therapeutic Goods 
Administration [100]and Canadian Therapeutic Product Directorate spontaneous reporting 
databases[101]. The US Food and Drug Administration Adverse Event Reporting System 
(AERS) was searched using SPSS (See sections below).  
Database choice for the remainder of the study depended on a number of factors such as 
database size, database source population, database time period covered, database data 
quality in terms of entry standardization, the number of cases with herb product exposure 
and hepatotoxicity and database accessibility.  
Herbs were included in the preliminary search if they have evidence or suspicion of liver 
injury in the literature (Table 3.1). The inclusion criterion for herbs for the preliminary search 
is that they are listed in any of the literature reviews on herbal hepatotoxicity [1, 4, 74, 102]. 
Herb inclusion criteria for the actual study are more thorough and are detailed in section 3.5. 
Herb search terms included their common name(s), botanical name and brand names. Both 
the Canadian and Australian databases have corrected entries in to the ‘drug name’ fields, 
which do not contain any spelling errors and use the Medical Dictionary for Regulatory 
Activities (MedDRA) for adverse event recording. The search was conducted twice for each 
herb to include reports for all adverse events and then for only those with adverse events 
with liver injury. Liver injury in a case was defined as any term under ‘hepatic and 
hepatobiliary disorders,’ which is a high-level group term in the MedDRA dictionary (See 
section3.7). 
Online searches contained both original and duplicate reports.  
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Table 3.1 Herbs included in preliminary search of spontaneous reporting system databases 
Aloe vera Green tea Noni 
Atractylis gummifera Herbal medicine
1 
Crotalaria
2 
Ayurvedic herbs
1
 Herbalife® Heliotropium
2
 
Ba Jiao Lian He Shou Wu / Ho Shou Wu Senecio longilobus
2 
Black cohosh Hoodia Symphytum officinale
2
 
Bol Gol Zhee Horse chestnut Paeonia lactiflora 
Cascara sagrada Hydroxycut® Pennyroyal oil 
Chaparral Hyssop Sassafras 
Chi R Yun Impila Saw palmetto 
Chinese medicine
1 
Indian medicine
1
 Senna 
Comfrey  Isabgol Sho Saiko To 
Dai Saiko To Jin Bu Huan Shou Wu Pian 
Fenugreek Kava Skullcap 
Germander Ma Huang St John's Wort 
Ginkgo Milk thistle Valerian 
Ginseng Mistletoe Yohimbine 
Greater Celandine
 
  
1
 These are unspecific terms to gain information on the number of unspecific entries in the database 
2
Contains  pyrrolizidine alkaloids 
 
3.2 Database set-up and cleaning process 
The US FDA AERS was chosen as the database for this study (See section 7.1). 
The US FDA AERS data is available online [103] in its raw form in quarterly files. Files in ASCII 
format were downloaded for the years 2004 to 2011. Data for previous years was not made 
available online; therefore the search used data from 2004 till the most up to date quarterly 
release at the time of analysis. The data was assembled using Microsoft Access to combine 
demographic, drug intake, patient reaction, patient outcome and data source information 
together to form one complete flat database. 
Database cleaning and analysis were conducted using SPSS software (V 21.0). Duplicate 
reports were identified and removed using the case number and the Individual Safety Report 
(ISR) number for each report. These are used as case identifiers in the FDA AERS data. An ISR 
number is unique to each report, whereas the same case number is assigned to multiple 
reports for the same case if linked correctly. In such cases, the report with the latest ISR was 
retained and other reports removed from the database. 
All remaining reports were retained even if they contained missing information such as age 
or gender. 
There are up to 326 entries for ‘drug name’ for each report in the AERS data, each in a 
separate column. Searching all of the ‘drug name’ columns took considerable amount of 
time and therefore a search was conducted to find the amount of information contained in 
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the columns. From these results it was concluded that the search would be limited to the 
first 24 columns, which contained over 98% of the data. 
3.3 Identifying herb and hepatotoxicity associations 
Each report in AERS contains information about the drugs taken by the patient, entered in to 
the ‘drug name’ columns and adverse reactions experienced, entered in the ‘PT’ columns. In 
order to find associations between herb intake and liver injury events all cases with either 
herb intake reported or with liver injury reactions had to be identified. The sections below 
explain how these two steps were carried out. 
3.4 Definition of a herbal medicine 
Herbal medicines are referred to as ‘botanicals’ in the US regulatory system. The definition 
of a botanical according to the FDA is: 
“A botanical drug product consists of vegetable materials, which may include plant 
materials, algae, macroscopic fungi, or combinations thereof.  
A botanical drug product may be available as (but not limited to) a solution (e.g., 
tea), powder, tablet, capsule, elixir, topical, or injection.  
Botanical drug products often have unique features, for example, complex mixtures, 
lack of a distinct active ingredient, and substantial prior human use. Fermentation 
products and highly purified or chemically modified botanical substances are not 
considered botanical drug products” [104] 
A botanical product may be classified as a botanical drug when it is intended for use to 
diagnose, cure, mitigate or treat disease in humans. More commonly, a botanical is classified 
and treated as a dietary supplement when it is intended to promote health, reduce the risk 
of health-related condition or supplement the diet [104]. 
3.5 Herbal medicine inclusion and exclusion criteria 
Herbs were included based on two criteria: 
1. They have been suspected of being hepatotoxic using literature evidence  
2. They are popular and widely consumed herbs using published herb sale data 
In order to find suspected hepatotoxic herbs, a thorough literature review was conducted 
selecting all published review articles that contained herbal medicines with hepatotoxicity 
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evidence. The search terms used were ‘herb’, ’plant extract’, ’medicinal herb’, ’liver injury’, 
‘dietary supplement’, ‘complementary therapy’, ‘phytotherapy’, ‘traditional medicine’, 
‘botanical’, ‘liver disease’, ‘liver injury’, ’drug induced liver injury’ and ’hepatotoxicity’ as free 
text search terms. In addition, Medical Subject Headings (MeSH) used in the search were 
‘drugs, Chinese herbal’, ‘plants, medicinal’, ‘phytotherapy’,  ‘plant extract’, ‘plant 
preparations’, ‘medicine, East Asian traditional’, ‘medicine, Chinese traditional’, ‘plants’, 
‘botany’, ‘complementary therapies’, ‘medicine, traditional’, ‘liver’, ‘drug-induced liver 
injury’, ‘liver diseases’, ‘hepatocytes’, ‘fatty liver’, ‘liver diseases, alcoholic’ and ‘liver 
diseases’ and included all subheadings. The search was conducted in ScienceDirect, Medline 
and Pubmed and limited to sources in the English language. Herbal medicines identified by 
their brand name in the literature were included as the brand name. The strength of 
evidence for herbs meeting the inclusion and exclusion criteria varied from clinical reports of 
suspicion to well documented positive re-challenge cases, which are considered the gold 
standard for causality assessment in drug- or herb-induced liver injury[1, 4, 54, 74, 102, 105].  
Herbs were excluded if they were used mainly for external application.  
Popular herbs were identified using published use and sale data in the US[106]. 
3.6 Selecting search terms for selected herbal medicines 
Data entry into the ‘drug name’ field in the AERS data is not coded according to a herb or 
drug dictionary, instead entries are what appears on the report, ad verbatim. This includes 
unspecific descriptions of the medicine, misspellings, contradictions and other reporting 
errors.  
It is very critical to include all the herbs that have been reported in the database and not 
miss any case out. There were two issues in the database relating to this critical step: 
1. Some reports are not herb species specific. Herbs are entered in to AERS as they 
appear on the report, without a systematic coding process similar to adverse 
reaction coding. Therefore when ‘ginseng’ is entered, it could refer to Panax 
ginseng, or Panax quinquefolius (American ginseng) or other plants that may also be 
called ginseng such as Eleutherococcus senticosus (Siberian ginseng) or Withania 
somnifera (Indian ginseng). This means that searching with ‘ginseng’ as a search 
term will retrieve results for all the plants called ginseng even though they are not 
true ginseng and would limit interpretation of a signal. There are numerous other 
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examples of possible name confusions, such as Chelidonium majus (greater 
celandine) and Ranunculus ficaria (lesser celandine), which are unrelated. 
2. Some reports use the brand name without mention of the herbal or other 
ingredients. There is no registry of herbal products sold in the US because 
registration of a dietary supplement (includes herbs) is not required before 
marketing. There are only two requirements prior to marketing a herbal product: 
the company must be registered with the FDA as compliant with the Dietary 
Supplement GMP Practices and submit any received adverse reaction reports. Only 
‘new’ dietary ingredients need a pre-market notification (See section 1.20). This 
means that some reports of herbal products containing ginseng, for example, may 
not be detected unless that particular brand name is used as a search term and 
there is no registry to obtain the brand names of such products. It is important for 
this part of the study to identify all reports with herbexposure because a search 
strategy that inadvertently omits some reports would result in an inaccurate, 
misleading or completely missing signal of association. 
Therefore, in order to identify reports with herbal exposure a system was developed to 
capture all the possible key words that may be used to describe a particular herb. Two 
references were used to identify herb botanical names, common names and if available 
brand names. Search output was used to find key words used in the database not previously 
included. The process for identifying all search terms is summarised below.  
Methods used to identify all possible search terms for herbs: 
1. Herb is identified from the literature 
2. Botanical and common names identified from two sources: the Natural Medicines 
Comprehensive Database[107] and Herbal Medicines accessed through 
MedicinesComplete[108]. See ‘Appendix A. Herb search term’ for all search terms 
collected using these resources 
3. Identify brand names from above two sources if available 
Note: there are many multi ingredient products that may include some of the search 
herbs in this study in usually small amounts with other herbal ingredients. Multi-
ingredient products may change their composition over time and a comprehensive 
data source with multi-ingredient herbal product brand names and their ingredients 
was not identified. Compiling this data for all the study herbs from various data 
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sources was outside the scope of this study. Therefore brand names for multi-
ingredient products were not included in this study unless the herbal ingredients are 
listed in the entry. 
4. Predict common spelling mistakes and include as search terms 
5. Search AERS database using all the search terms identified 
6. Search AERS database using part of the search terms in order to identify other 
mistakes e.g. search ‘valer’ for ‘valerian’  
7. Look through output to identify other names (common or brand) or spelling 
mistakes present in the database that have not yet been included and include them 
8. Review all search terms for errors 
9. Use the new updated list of search terms to identify herbs 
10. Using the output, investigate low report numbers for herbs expected to have high 
reports. If new search terms not previously identified are found, repeat search using 
the new list of search terms. 
3.7 Selecting search terms for liver injury 
In the AERS data adverse reactions are coded according to the Medical Dictionary for 
Regulatory Activities (MedDRA, V3.1). The MedDRA dictionary is a rich, highly specific, 
hierarchical and medically oriented dictionary designed for use by drug regulators and the 
pharmaceutical industry as a shared international standard. Terms describing adverse 
reactions are in a hierarchical system with five levels arranged from fine detailed 
descriptions at the Lowest Level Term (LLT) and slightly less specific Preferred Terms (PTs) to 
more general High Level Group Terms and System Organ Class, which describes anatomical 
or physiological systems (Figure 3.1). PTs under the HLGTs ‘hepatic and hepatobiliary 
disorders’ and ‘hepatobiliary investigations’ were used to detect cases with liver injury (See 
Appendix B. Liver injury terms and their occurrences in FDA AERS data).  
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Figure 3.1 MedDRA hierarchy 
PT’s were also grouped according to mechanistic and phenotypic groups in order to 
investigate different patterns of hepatotoxicity and to facilitate the second part of the study, 
which examines common chemical structural patterns among herbs with the same toxicity 
pattern (Table 3.2).  
3.8 Confounders 
Drugs that have been documented to cause liver injury are confounders and were identified 
from two databases of DILI drugs[109]. The first is the Liver Toxicity Knowledge Base 
Benchmark Dataset (LTBK-BD) that defined drugs with ‘most-DILI concern’ as those with an 
FDA black box warning for its potential to cause liver injury or those withdrawn from the 
market. The second database collected drugs with evidence for liver injury in humans and 
these were classified as ‘hepatotoxic positive’[109]. There is approximately 90% agreement 
between the two lists and any drug that was classified as both ‘most-DILI concern’ and 
‘hepatotoxic positive’ was included in the study as a confounder (Table 3.3). 
Other confounders included in the study were age, alcohol and tobacco use. 
 
 
System Organ Class (SOC) 26 – highest level of terminology and distinguished by anatomical, 
physiological system, etiology or purpose e.g. Hepatobiliary disorders  
High Level Group Term (HLGT) 333 – descriptor of one or more HLT’s  
e.g. Bile duct disorders 
High Level Term (HLT) 1,699 – descriptor of one or more PT’s   
e.g. Cholestasis and jaundice 
Preferred Term (PT) 18,483 – represents a single medical concept  
e.g. Jaundice hepatocellular 
Lowest Level Term (LLT) 67,159 – lowest level terminology  
e.g. Perinatal jaundice due to hepatocellular damage 
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Table 3.2 Liver injury groups with search terms for each group 
Immune Steatosis Necrosis Cholestasis 
Hepatic 
failure 
Jaundice Liver vascular 
Liver 
injury, 
death 
Any liver injury 
term plus one of: 
Allergic hepatitis 
Dermatitis allergic 
Hypersensitivity 
Skin reaction 
Steven-Johnson 
syndrome 
Type 1 
hypersensitivity 
Type 2 
hypersensitivity 
Type 3 immune 
complex mediated 
reaction 
Type 4 hyper 
sensitivity 
reaction 
Allergy to 
chemicals 
Drug eruption 
Drug 
hypersensitivity 
Toxic skin 
eruption 
Idiopathic 
urticaria 
Urticaria 
Autoimmune 
disorder 
Fixed eruption 
Fever 
Pyrexia 
Febrile  
Lymphadenopathy 
Eosinophil 
Rash  
Temperature 
Hyperthermia 
Hepatic 
steatosis  
Acute fatty 
liver of 
pregnancy 
Fatty liver 
alcoholic 
Non-alcoholic 
steatohepatitis 
Hepatic 
necrosis 
Necrosis  
Cholestatic 
pruritis 
Cholestasis 
Cholestasis 
of 
pregnancy 
Hepatitis 
cholestatic 
Jaundice 
cholestatic 
Cholestatic 
liver injury 
acute 
Acute 
hepatic 
failure 
Chronic 
hepatic 
failure 
Hepatic 
failure 
Hepatorenal 
failure 
Subacute 
hepatic 
failure 
 
Jaundice  
Jaundice 
acholuric  
Jaundice 
extrahepatic 
obstructive 
Jaundice 
cholestatic  
Jaundice 
hepatocellular 
Jaundice 
neonatal 
Venoocclusive 
liver disease 
Splenicinfarction 
Retrograte 
portal vein flow 
Portal vein 
occlusion 
Portal vein 
stenosis 
Hepatic artery 
occlusion 
Ischaemic 
hepatitis 
Hepatic vein 
stenosis 
Hepatic vein 
occlusion 
Hepatic 
ischaemia  
Hepatic 
infarction 
Hepatic artery 
stenosis 
Biliary ischaemia 
Any 
liver 
injury 
term 
plus 
one of: 
Death 
Sudden 
death 
 
 
Table 3.3 Drugs known to cause drug-induced liver injury included as confounders 
Acetaminophen    
Allopurinol  
Amodiaquine  
Amoxicillin  
Amoxicillin + clavulanic acid  
Atomoxetine   
Atorvastatin  
Azathioprin 
Azithromycin     
Carbamezapine  
Celecoxib  
Ciprofloxacin 
Cyproheptadine  
Deferasirox  
Diclofenac 
Duloxetin   
Erythromycin  
Etanercept  
Flucloxacillin  
Flutamide 
Interferon beta  
Isoniazid  
Lamotrigine  
Levofloxacin  
 Mercaptopurine  
Methyldopa  
Minocycline  
Nevirapine    
Nimesulid  
Nitrofuran  
Oxacillin  
Paroxetine  
Phenytoin 
Posaconazole  
Propylthiouracil  
Rifampicin 
Roxithromycin    
Sulfamethoxazole  
Sulfasalazin    
Sulindac  
Telithromycin  
Terbinafine    
Ticlopidin     
Trimethoprim   
Trimethoprim +         
Sulfamethoxazole 
Trovafloxacin  
Valproate  
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3.9 Case definitions 
A case with at least one entry with any of the search terms for a particular herbal medicine 
was considered a case with exposure to that particular herb. 
A case with at least one adverse reaction for liver injury was considered a case with liver 
injury. 
3.10 Statistical measures 
The reporting odds ratios (ROR) and Chi squares were the measures of disproportional 
reporting. The reporting odds ratios (ROR) with 95% confidence intervals (CI) were 
calculated from a forward step logistic regression model using SPSS software. Confounders 
were included in the model. Chi square values (p<0.05) and ROR’s were also obtained from 
univariate tabulations for specific liver injury phenotypes.  
3.11 Definition of signal 
A ‘signal’ was defined as an ROR greater than 1 and a lower 95% CI greater than 1. 
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4 CHAPTER 4: METHODS – PHARMACOPHORE DETERMINATION 
4.1 Herbal medicine selection 
Herbs for the pharmacophore determination in this study were selected based on the type 
of liver injury they caused. Herbs were first grouped according to liver injury features 
present using the signal detection results. In addition, the extensive literature evaluation 
was used to find other herbs that belong to the same categories, but were not detected in 
the signal detection analysis.  
A herb was selected for the pharmacophore analysis if it satisfied either condition below: 
1. The herb appeared with an immune signal in the signal detection part of this study 
(Table 4.1), OR  
2. There was literature evidence for immune liver injury (Table 4.2) 
Eight herbs (ephedra, ginkgo, ginseng, kava, mistletoe, primrose, senna and valerian) were 
included from signal detection results from this study and an additional five herbs (aloe vera, 
black cohosh, cascara, Jin Bu Huan and Shou Wu Pian) were included from literature 
information. The overlap between the two sources of evidence for herb immune liver injury 
was little and is shown in Figure 4.. 
It was also possible to use alternate liver injury groupings, such as liver injury mechanisms 
(idiosyncratic and direct toxicity) or liver injury patterns (hepatocellular, cholestatic and 
mixed) (see Appendix C. Alternative groupings for herbs that have literature evidence for 
liver injury). It was decided that hypersensitivity features were the most appropriate 
grouping because it was possible to clearly differentiate between the two categories, i.e., 
with immune liver injury or without, and preliminary investigation into the herb 
phytoconstituents revealed that the number of constituents using this liver injury grouping 
would be sufficient for this study.  
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Table 4.1 Herb liver injury signals in groups using signal detection results 
Immune features No immune features  Unknown 
Ephedra / Ma Huang 
Ginkgo biloba 
Ginseng 
Kava 
Milk thistle  
Mistletoe  
Evening Primrose 
Senna 
Valerian  
Unspecified Chinese medicine 
Unspecified herbal medicine 
Hoodia 
Soy 
Black cohosh 
Green tea 
Echinacea  
Noni 
Isabgol 
 
 
All other drugs searched for were 
not found in the database 
Note: Herbalife® cases have immune features and Hydroxycut® cases have no immune features. These are brand 
names however, with unspecified products/ingredients and were therefore not considered for pharmacophore 
determination 
 
Table 4.2 Herb liver injury groups using evidence from the literature 
Immune features No immune features Unknown 
Aloe vera (rare) 
Black cohosh 
Cascara (rare) 
Jin Bu Huan 
Kava 
Ma Huang 
Shou Wu Pian (rare) 
 
Chaparral 
Horsechestnut 
Noni 
Pennyroyal oil 
Pyrrolizidine alkaloids 
Saw palmetto 
Senna 
Skullcap 
Valerian 
Dai saiko to 
Sho saiko to 
Distaff Thistle 
Germander 
Greater Celandine 
Green Tea 
Hoodia 
Impila/zulu remedy 
  Not considered hepatotoxic:  
St John’s Wort 
Fenugreek  
Ginkgo 
Ginseng  
No information found: 
Soy  
Isabgol  
Evening primrose  
 
 
Figure 4.1 Venn diagram showing overlap between the two sources of evidence for herb immune liver injury 
(*Milk thistle is confounded by indication and was not included in analyses) 
Ginkgo 
Ginseng 
Herbalife ® 
Milk thistle*  
Mistletoe  
Primrose 
Senna 
Valerian  
Aloe vera (rare) 
Black cohosh 
Cascara (rare) 
Jin Bu Huan 
Shou Wu Pian (rare) 
Kava 
Ma Huang / 
ephedra 
Study Results Literature Evidence 
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4.2 Identifying herb constituents 
A whole plant contains at numerous different chemical constituents, which may differ 
depending on the plant part, species  and other factors [75]. A pharmacophore search is 
conducted with up to approximately 50 ‘active’ chemicals or chemical groups. Therefore, a 
strategy was used to select the most appropriate phytoconstituents. The chemical 
constituents of selected herbs were identified using the literature [108, 110] and grouped 
according to their taxonomy (Table 4.3) (See Appendix D. Chemical constituents of herbs 
considered for  pharmacophore analysis). From this taxonomical or chemical grouping it was 
clear that certain groups, such as alkaloids and flavanoids, were common to most included 
herbs whereas other groups, such as volatile oils, were only present in a few herbs. It would 
be unlikely for chemical groups present in a small fraction of herbs included in this analysis 
to contain chemical features shared by phytoconstituents from other included herbs. 
Therefore only the most commonly shared groups were included for analysis. 
Chemicals in a constituent group were included in analysis if they are present in the plant 
part used for medicinal purposes AND they meet either of the two conditions: 
1. There are at least four herbs that share the group, OR 
2. There is evidence or suspicion in the literature of a certain constituent or group of 
constituents involved in the liver injury 
Analysis did not include possibility of adulteration with other plant species, which is a 
frequent cause of herb induced liver injury. Metabolites were excluded from the analysis. 
All constituents in any of the alkaloid, flavanoid, terpenoid, anthraquinone, iridoid or lactone 
groups were therefore included in the analysis. These molecules, or ligands, formed the 
training set for the pharmacophore model. 
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Table 4.3 Herb chemical constituents grouped according to their chemical class to identify chemical groups common 
to herbs with immune liver injury 
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Ginkgo Biloba                  
Ginseng                   
Kava                   
Ephedra                  
Mistletoe                   
Evening primrose *                  
Senna                   
Valerian                  
Black cohosh                  
Cascara                  
Aloe vera                  
Jin Bu Huan                  
Shou Wu Pian                  
* no constituents were identified in the literature other than volatile oils 
 
4.3 Pharmacophore search strategy 
Eight strategies were used to search for a pharmacophore (Schrödinger, PHASE V3.4).  The 
individual strategies fall into two types: 
1. Forest strategy/Collective strategy. The pharmacophore model was based on all the 
groups (either herb or chemical). For example, in search strategy 1, ligands were 
grouped into their herbal origin and pharmacophore hypotheses were derived from 
these groups (Table 4.4, Table 4.5). 
2. Tree strategy/Individual strategy. The overall pharmacophore model was based on 
pharmacophore hypotheses from individual groups. In this strategy, the first step 
was to generate pharmacophore hypotheses for each group of ligands according to 
herb origin and chemical class. Then shared hypotheses among the individual groups 
may be further analysed. For example, in search strategy 7, toxic constituents were 
grouped according to their herbal origin. Pharmacophore hypotheses were 
generated for each individual group. Then any shared hypotheses across all the 
groups were further investigated (Table 4.4, Table 4.5). 
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Table 4.4 Summary of search strategies used for pharmacophore modelling 
  All phytoconstituents ‘Toxic’ phytoconstituents 
Forest strategy Herbal origin 1 3 
Chemical class 2 4 
Tree strategy Herb origin 5 7 
Chemical class 6 8 
 
 
Table 4.5 Description of search strategies used for pharmacophore modelling 
Strategy  All phytoconstituents ‘Toxic’ phytoconstituents 
 Forest strategy: pharmacophore models were determined in one step. The constituents were grouped 
and pharmacophore hypotheses were determined from ligands in each of these groups.  
1 This strategy included all phytoconstituents. 
Pharmacophore determined using grouping based 
on herb origin of the constituents.  
 
2 This strategy included all phytoconstituents. 
Pharmacophore determined using grouping based 
on constituent chemical class. 
 
3 
 
This strategy included only known ‘toxic’ 
phytoconstituents. Pharmacophore 
determined using grouping based on herb 
origin of the constituents. 
4  This strategy included only ‘toxic’ 
phytoconstituents. Pharmacophore 
determined using grouping based on 
constituent chemical class. 
 Tree strategy: pharmacophore models were determined in two steps. First, the constituents were 
grouped and pharmacophore hypotheses were found for each individual group. Second, overall 
pharmacophore hypotheses were obtained from the hypotheses found for individual groups. 
5 This strategy included all phytoconstituents. 
Pharmacophore determined using grouping based 
on herb origin of the constituents.  
 
6 This strategy included all phytoconstituents. 
Pharmacophore determined using grouping based 
on constituent chemical class. 
 
7 
 
This strategy included only ‘toxic’ 
phytoconstituents. Pharmacophore 
determined using grouping based on herb 
origin of the constituents. 
8  This strategy included only ‘toxic’ 
phytoconstituents. Pharmacophore 
determined using grouping based on 
constituent chemical class. 
 
4.4 Method optimization 
There are 4 steps in pharmacophore model development: preparing ligands, creating 
pharmacophore sites from a set of defined features, finding a common pharmacophore and 
scoring the hypothesis. In each step, parameters are selected and defined in order to 
determine the shared pharmacophores. Settings at each of these steps can be modified for 
optimal results (Table 4.6), which were systematically carried out for this study.  
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The settings for the first step, ligand preparation, were optimized and the optimal settings 
were then used for the remainder of the study. 
 
Table 4.6 Pharmacophore model development steps and parameters for  method optimization 
Step  Parameter(s) Definition  Method optimization  
Prepare ligands Energy minimization Generate 
conformers  
Conformers are generated 
for each ligand. The number 
of conformations, maximum 
relative energy difference, 
minimum atomic deviation 
and number of post-
minimization iterations have 
the most impact on 
conformer generation and 
pharmacophore model.  
See individual 
strategies 
Creating 
pharmacophore sites 
Define pharmacophore 
features (hydrogen bond 
acceptor, hydrogen bond 
donor, hydrophobic group, 
aromatic ring, negative and 
positive charged groups) 
Pharmacophoric features are 
defined by patterns can be 
included or excluded for 
each feature type. 
Select to include 
previously excluded 
pattern definitions to 
increase features 
identified 
Find common 
pharmacophore 
Maximum and minimum 
number of sites, minimum 
intersite difference, maximum 
tree depth and final box size 
These parameters determine 
how pharmacophore 
features from all the ligands 
and their conformers are 
determined to be shared 
among a group of ligands 
Number of sites = 6 
and then decreased 
systematically 
Minimum intersite 
distance = 2.0 Å and 
decreased 
systematically 
Maximum tree depth 
set to include all 
molecules 
Final box size = 1 Å 
and increased 
systematically 
Scoring hypotheses RMSD filter, vector score, 
feature tolerance and survival 
score formula 
In this step, pharmacophores 
with the best alignment to 
the actives are selected and 
scored 
RMSD = 1.2 Å and 
systematically 
increased if results are 
too few or reduced if 
results are too 
numerous 
 
4.5 Molecule preparation and conformer generation 
All included phytoconstituent chemical structures were either imported or drawn in 
(MaestroV9.3, Schrödinger, LLC, New York, NY, 2008), totalling 117 molecules. These 
molecules made up the training set in this study. All molecules were converted to three-
dimensional structures and were checked individually for structural correctness. All chemical 
structures were then energy minimized to a low gradient (to <0.05 kJ  -mol) to reduce the 
inter-atomic forces and bring potential energy surface to a stationary point using 
MacroModel (version  .6, Schr dinger, LLC, New York, NY, 2008) through the Maestro 
graphical interface. Geometric optimization is important in pharmacophore modelling 
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because it affects the final three-dimensional arrangement of the features. In addition, 
optimized structures are more likely to resemble the geometry of the active substance. 
Molecules were ionized at pH7.4 (if applicable), which is physiological pH. Chiralities present 
in molecules were retained and no new stereoisomers were generated because they do not 
occur naturally in the plants.  
Molecules can adopt more than one low-energy conformation. Therefore, conformer 
generation was carried out using the ConfGen search method. In this method, the peripheral 
groups are one rotatable bond away from the rest of the molecule, while all other bonds 
form the core. All core conformations are generated then peripheral group conformations 
are sampled one by one. Post processing minimization was carried out to eliminate 
suboptimal, high-energy or redundant conformers (OPLS_2005 force field). The maximum 
relative energy difference was set to 10kcal/mol molecules with a RMSD greater than 1.0Å 
were deemed redundant and eliminated (See   
 70 
 
Appendix E. List of training set ligands and summary of conformations generated). 
4.6 Pharmacophore model development 
The training set used depended on the search strategy. Molecules bigger than 500 Daltons 
were excluded because these molecules would likely contain features for hypotheses in the 
core of the molecule due to their large size rather than representing essential features for an 
interaction with a biological target. The remaining 99 ligands (See   
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Appendix E. List of training set ligands and summary of conformations generated) were 
grouped depending on the search strategy and all groups were considered ‘active’. 
Pharmacophore sites were created for the following features: hydrogen bond acceptors (A), 
hydrogen bond donors (D), hydrophobic group (H) and aromatic rings (R). A and D features 
were fully expanded to include all pattern definitions including those excluded in the default 
settings.  
Various settings were used to find the common pharmacophores depending on the search 
strategy. Settings for the first two steps, preparing the ligands and creating pharmacophore 
sites, were the optimal settings found in the method optimization and were kept constant in 
all search strategies. The number of pharmacophore features, minimum number of 
matching ligands or groups of ligands were changed for each search (detailed in Results).   
Generated hypothesis were subjected to a scoring process, which uses a ranking system to 
enable a rational identification of hypotheses appropriate for further investigation. A group 
of pharmacophores that are very similar to each other are called a surviving box and are 
treated as a group in the scoring process.  
The first step in the scoring process was alignment of the ligands to the hypotheses in a 
surviving box to calculate their alignment score, vector score and volume score. The 
alignment score is the root-mean-square deviation (RMSD) of the site positions, the vector 
score is the average cosine of pairs of features and the volume score is a measure of the 
overlap in volume between two pairs of structures. These three calculations s are used to 
determine an overall alignment score for each hypothesis. The pharmacophore with the 
highest multi-ligand alignment score was selected as a hypothesis for that box and the ligand 
that contributed this pharmacophore was a reference ligand for that hypothesis. Hypotheses 
with poor alignment scores were eliminated, retaining molecules with an RMSD below 1.2 Å, 
and hypotheses with poor feature matching were eliminated by retaining those with a 
vector score greater than 0.500. Lower scoring hypotheses were eliminated using a 10% cut-
off to the overall alignment score. A minimum number of 10 hypotheses was set to ensure a 
sufficient number of hypotheses were generated. This process is repeated for all surviving 
boxes. 
In the second step of the scoring process, the remaining hypotheses were ranked by a 
survival score. The survival score is useful in selecting hypotheses for further investigation 
and is based on the site score, vector score, volume score, selectivity score, number of 
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matching ligands, ligand energy and ligand activity (Equation 1). Hypotheses were also 
clustered to group together very similar hypotheses of a given variant. 
S = WsiteSsite + WverSvec +WvolSvol + WselSsel + W
m
reward - Wenergy + Wactivity (Equation 1) 
W’s are the weights and S’s are the scores.  
S is the survival score, Ssite is the site score, which is calculated from the alignment score and 
takes into account poor alignments in high scoring pharmacophores, Svec is the vector score 
and Ssel is the selectivity score, which is a measure of how rare a hypothesis is and calculated 
based on the number of molecules expected to match the hypothesis regardless of their 
activity. This means that higher selectivity is desirable because the pharmacophore is unique 
to a set of active ligands. Wmreward increases the survival score if the hypothesis has a greater 
number of matching ligands and m is calculated from the number of matching actives minus 
one. Wenergy is a penalty for hypotheses if the reference ligand energy is higher than other 
matching ligands and Wactivity is a penalty for hypotheses if the reference ligand activity is less 
than other matching ligands. 
The survival score, the number of matching ligands and visual inspection were the main 
criteria for hypothesis selection for the validation step of the study. Other factors considered 
in hypothesis selection were energy of the conformers, optimal contribution of the scoring 
parameters and optimal tolerance of each feature type.   
4.7 Hypothesis validation 
If a pharmacophore hypothesis is good, it will be able to distinguish between active and 
inactive molecules not used in the training set. A test set composed of ‘active’ compounds, 
and a decoy set composed of an equal mix of known actives and inactive compounds were 
used to validate the generated hypotheses. 
Active compounds (Table 4.7) were defined as drugs that cause hepatotoxicity and were 
withdrawn from the market [111]. 
Inactive compounds (Table 4.7) were defined as drugs with no known evidence for 
hepatotoxicity. Compounds that appear in both the LTKB-BD and Green et al. databases with 
‘no hepatotoxicity concern’ were considered inactive [111, 112].  
The decoy set was made by selecting all the inactive molecules and ‘doping’ a random 
selection of the active compounds to obtain an equal number of actives.  
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Specificity and selectivity were used as statistical tools for validation (Equations 2 and 3), 
where a ‘hit’ is a molecule that contained the pharmacophore features in its molecular 
structure and therefore was identified by the model. A pharmacophore hypothesis with 80% 
selectivity means that it can distinguish active ligands 80% of the time from a ligand set with 
a mix of active and inactive ligands. A sensitivity of 80% means that from a ligand set with 
only active compounds, only 80% of these ligands are identified by the hypothesis as active. 
The higher the selectivity and the sensitivity scores the better the hypothesis is at identifying 
active ligands and distinguishing them from inactive ligands. 
 
Selectivity (%) =    x 100   (Equation 2) 
 
  
Sensitivity (%) =    x 100   (Equation 3) 
 
 
 
Table 4.7 Active and inactive molecules used 
Actives (decoy set) 
Alatrofloxacin 
 Benzbromarone 
 Clometacin 
 Exifone 
 Lumiracoxib 
 Nimesulide 
 Pemoline 
 Pirprofen 
 Tolrestat 
 Isaxonine phosphate 
 Benoxaprofen 
 Cinchophen 
Inactives (decoy set) 
Diphenhydramine  
 Betaine  
 Paromomycin 
 Primidone 
  Isoproterenol 
 Phenoxybenzamine 
 Oxybutynin 
 Methysergide  
Clemastine  
 Ergocalceferol 
 Triiodothyronine  
 Digoxin 
Actives (test set)  
Alatrofloxacin 
 Alpidem 
 Bendazolic acid 
 Benoxaprofen 
 Benzarone 
 Benzbromarone 
 Benziodarone 
 Bromfenac 
 Cinchophen 
 Clomacron 
 Clometacin 
 Cyclofenil 
 Dilevalol 
 Droxicam 
 Ebrotidine 
 Exifone 
 Fenclozic acid 
 Fipexide 
 Ibufenac 
 Iproniazid 
 Lumiracoxib 
 Mebanazine 
 Moxisylyte 
 Nefazodone 
 Nialamide 
 Nimesulide 
 Niperotidine 
 Nitrefazole 
 Nomifensine 
 Oxyphenisatin 
 Pemoline 
 Perhexiline 
 Phenisatin 
 Phenoxypropazine 
 Pipamazine 
 Pirprofen 
 Suloctidil 
 Ticrynafen 
 Tilbroquinol 
 Tolcapone 
 Tolrestat 
 Troglitazone 
 Trovafloxacin 
 Xenazoic acid 
 Ximelagatran 
 Isaxonine phosphate 
 Tetrabamate 
 
Hits active          
Hits total 
Hits active          
Ligands active 
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In addition to the above standard validation, a comparison was made between the 
generated high scoring pharmacophores and the pharmacophore hypotheses generated 
from other studies in the literature investigating hepatotoxic drugs using similar methods. 
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4.8 CHAPTER 3 AND 4 SUMMARY 
In summary, key steps in the method were: 
Signal detection 
 The FDA AERS (2004 – 2011) data was used as the data source 
 Database cleaning involved identifying and removing duplicate case reports using 
case numbers and case ISR’s 
 Herb-hepatotoxicity associations were found by identifying cases with ‘herb 
exposure’ AND ‘liver injury’ 
 Herbs were included in the study if they have previous evidence or suspicion of 
causing liver injury in the literature OR if they are ‘popular’ herbs in the US 
determined from herb sale data 
 Herb exposure was defined as a case with any search term for included herbs, which 
included herb common name, botanical name, brand names and accounted for 
misspellings in the dataset 
 Liver injury was defined as a case with any preferred terms under ‘hepatic and 
hepatobiliary disorders’ and relevant terms under ‘hepatobiliary investigations’ in 
the MedDRA (V3.1) dictionary 
 Confounders were included in the analysis to correct signals. Confounders were 
defined as drugs with documented evidence for causing liver injury 
 Reporting odds ratios with 95% confidence intervals and p-values were used to 
measure association between herb exposure and a liver injury adverse event using a 
multivariate logistic regression model (SPSS, 21.0) 
 A signal was defined as an ROR greater than 1 with a lower 95% confidence interval 
limit greater than 1 
Pharmacophore modelling 
 Herbs were included if they either have an immune liver injury signal from signal 
detection work OR they have literature evidence for immune liver injury 
 Herb chemical constituents were identified from the literature. Constituents were 
included in the analysis if they belonged to a chemical group that is shared by at 
least four herbs OR if there is literature evidence or suspicion for the constituent 
being a cause of hepatotoxicity. Constituents were excluded if their size exceeded 
500 Daltons. These formed the training set ligands. 
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 All ligand structures were cleaned, minimised and conformers were 
generated(MaestroV9.3 and MacroModel V9.6, Schrödinger, LLC, New York, NY, 
2008) 
 The pharmacophore search method was optimized for the parameters at each step: 
preparing ligands, creating pharmacophore sites from a set of defined features, 
finding a common pharmacophore and scoring the hypothesis (Schrödinger, PHASE 
V3.4). ). Key settings for ligand preparation were energy minimisation gradient of 
<0.5kJ/Å-mol, ionization at pH 7.4, conformer generation using ConfGen search 
method, force field was OPLS_2005, maximum relative energy difference between 
conformers was 10kcal/mol and an RMSD cut-off of 1.0Å 
 Settings for finding a common pharmacophore were optimised for individual 
strategies 
 Pharmacophore hypotheses were derived using 8 strategies. The strategies can be 
classified into one that uses all the herb groups (forest strategy) or one that uses 
individual herb groups to identify herb specific hypotheses (tree strategy). The 
strategies can also be classified under ones that use all ligands and ones that use 
only those ligands that have been suspected of being toxic 
 Validation of selected hypotheses was carried out using a test set and a decoy set to 
measure hypothesis predictive power using sensitivity and specificity calculations 
 The test set was composed of drugs that have documented evidence of 
hepatotoxicity 
 The decoy set was composed of drugs that have evidence for toxicity and drugs that 
are completely free of hepatotoxicity 
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5 CHAPTER 5: RESULTS – SIGNAL DETECTION 
5.1 Pharmacovigilance database comparison 
Various pharmacovigilance databases were explored to determine the database of choice for 
this study. These databases were the Canadian (Therapeutics Product Directorate, TPD), 
Australian (Therapeutic Goods Administration, TGA) and United States (Food and Drug 
Administration, FDA) pharmacovigilance databases.  The number of cases with herbal 
product exposure with and without hepatotoxicity is presented (Table 5.1). Herbal product 
entries are as they appear in the databases and may be specific or non-specific.  
5.2 Database cleaning 
A total of 998,879 reports were identified as duplicates and were deleted from the database. 
Duplicate cases were observed to be from the same reporter with updated information on 
the patient or from multiple sources for the same patient. It was important to clean the 
database of duplicate reports because otherwise that would severely bias signal detection.  
5.3 Database characterisation 
The FDA Adverse Event Reporting System (AERS) database contained 326 columns for drug 
name entries. Some reports contained at least one entry in the first ‘drug name’ column and 
others contained up to 326 entries. It was found that 98.2% of the data was contained in the 
first 24 columns and therefore it was decided that only the first 24 drug name columns 
would be included in the search (See   
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Appendix F.  Number of entries in ‘DRUGNAME’ column in FDA AERS data). 
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Table 5.1 Herbal exposure and hepatotoxicity report numbers in pharmacovigilance databases 
Herb common name 
Canadian (TPD) 
(1/1/1965 – 30/9/2012) 
Australian (TGA) 
(1/1/1971 – 19/9/2013) 
United States (FDA) 
(1/1/2004 - 31/12/2011) HMP 
exposure 
HMP + liver 
injury 
HMP 
exposure 
HMP + liver 
injury 
HMP 
exposure 
HMP + liver 
injury Aloe vera 3 0 8 0 98 3 
Atractylis gummifera 0 0 0 0 0 0 
Ayurvedic herbs* 2 0 5 0 - - 
Ba Jiao Lian 0 0 0 0 0 0 
Black cohosh 9 2 39 12 272 26 
Bol Gol Zhee 0 0 0 0 0 0 
Cascara sagrada 7 0 7 0 15 0 
Chaparral 1 1 2 2 4 0 
Chi R Yun 0 0 0 0 0 0 
Chinese medicine* 11 2 27 7 377 75 
Comfrey  0 0 0 0 4 0 
Dai Saiko To 0 0 0 0 0 0 
Fenugreek 6 0 10 2 5 1 
Germander 2 2 0 0 0 0 
Ginkgo 33 2 108 5 1409 103 
Ginseng 26 1 41 3 209 25 
Greater Celandine 0 0 1 1 6 1 
Green tea 15 0 2 1 179 17 
Herbal medicine* 64 3 505 34 3113 404 
Herbalife* 5 0 17 4 20 8 
He Shou Wu 0 0 0 0 0 0 
Ho Shou Wu 0 0 0 0 0 0 
Hoodia 4 1 0 0 14 5 
Horse chestnut 1 0 4 2 27 2 
Hydroxycut 57 2 24 2 33 5 
Hyssop 0 3 0 0 0 0 
Impila 0 0 0 0 0 0 
Indian medicine* 0 0 0 0 - - 
Isabgol 0 0 0 0 881 48 
Jin Bu Huan 2 2 0 0 0 0 
Kava 18 3 15 7 20 7 
Ma Huang 2 0 1 0 2686 193 
Milk thistle 6 2 14 1 290 49 
Mistletoe 0 0 0 0 41 4 
Noni 1 1 6 0 4690 306 
PA - crotalaria 0 0 0 0 0 0 
PA - heliotropium 0 0 0 0 0 0 
PA - senecio longilobus 0 0 0 0 0 0 
PA - symphytum officinale  0 0 0 0 - - 
Paeonia spp 0 0 0 0 - - 
Pennyroyal oil 1 0 0 0 0 0 
Sassafras 0 0 0 0 0 0 
Saw palmetto 11 0 25 1 926 41 
Senna 5 2 138 16 7433 670 
Sho Saiko To 0 0 0 0 0 0 
Shou Wu Pian 0 0 1 1 0 0 
Skullcap 3 3 3 3 5 0 
St John's Wort 49 2 97 2 209 13 
Valerian 19 1 52 7 189 34 
Yohimbine 7 0 0 0 11 0 
Total 370 35 1152 113 23166 2040 
PA =contains pyrrolizidine alkaloid  
HMP = herbal medicinal product 
* =  non-specific entry 
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5.4 General information 
The FDA AERS database (2004 – 2011) contained a total of 3,680,623reports and 2,681,744 
non-duplicate cases. The total number of adverse events entered was 7,581,711.  
Age and gender distribution data for the entire database from 2004 to 2011 are shown in 
Figure 5.1. These may be compared to the US population age and gender distribution as per 
census data (Figure 5.2). It can be seen that adverse reactions are not commonly reported 
for people less than 20 years old even though they represent an equal proportion of the 
population compared to the 50 to 60 years age group. This is likely due to increased 
medicine use in older age.  Adverse drug reaction reports peak in the 51-60 age group for 
females and is slightly skewed to the right for males, which peaks at the 61-70 age group. 
Overall, there are fewer reports for males.  
The FDA receives a variable number of reports each year (Figure 5.3). The number of reports 
received by the FDA is steadily increasing each year. In this study however, the steady 
increase rate is less than the apparent exponential rate the FDA reports (Figure 5.4) because 
duplicate cases have been removed. 
 
 
Figure 5.1 Gender and age distribution in AERS data, 2004 – 2011(466,030 female and 272,798 male reports 
were incorrectly entered or missing and not included in graphs) 
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Figure 5.2 US age and gender statistics, 2012 census data [113] 
 
 
Figure 5.3 Number of non-duplicate cases reported in AERS over time (2004 – 2011).The number of reports for 
2011 is likely to be greater than that calculated because some 2011 reports may be included in the 2012 data 
files, which were not used in this study. 
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Figure 5.4 Number of adverse event cases received (entered and not entered) by the FDA over time [114]. All 
reports, including follow-ups and duplicates are included. The increased reporting appears exponential, 
however a significant proportion are duplicate reports. 
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5.5 Liver injury reports 
A total of 171,845 (6.41%) non-duplicate cases in the AERS dataset contained at least one 
liver injury term as an adverse reaction. The age and gender distribution of liver injury 
reports follows the age and gender distribution in the general data (Figure 5.5, Figure 5.7), 
which is slightly skewed toward older age and peaking in the 51 to 60 age group. There is no 
apparent significant difference between the genders in the reporting of liver injury reactions, 
despite the fact that there are greater reports for females in the entire database (Figure 5.6) 
indicating that gender may not be a predisposing factor for liver injury. 
Although overall the number of reports to the FDA for any ADR has been increasing, liver 
injury reports have been steady from 2004 to 2010 (Figure 5.7). This is also true for liver 
injury with herb exposure.  
 
Figure 5.5 Liver injury cases overlayed against all cases of any adverse drug reaction (cases with incorrect or 
missing information not shown above, 938,905 all cases and 23,266 liver injury cases) 
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Figure 5.6 Age and gender distribution in liver injury cases 
 
 
Figure 5.7 Number of non-duplicate cases reported in AERS over time (2004 – 2011) 
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5.6 Liver injury groupings 
A total of 121 individual liver injury terms were included. Detailed frequencies for each liver 
injury term are summarised in Appendix B. Liver injury terms and their occurrences in FDA 
AERS data. In over 85% of cases, only 21 of the 121 terms were used for liver injury and 
these were  ‘ALT increased’, ‘AST increased’, ‘hepatic enzyme increased’, ‘liver function test 
abnormal’, ‘liver disorder’, ‘jaundice’, ‘jaundice acholuric’, ‘blood bilirubin increased’, 
‘hepatic failure’, ‘GGT increased’, ‘hepatic function abnormal’, ‘hepatitis’, ‘ascites’, ‘hepatic 
steatosis’, ‘transaminase increased’, ‘cholestasis’, ‘hepatotoxicity’, ‘hepatomegaly’, ‘hepatic 
cirrhosis’, ‘liver injury’ and ‘acute hepatic failure’. Liver injury was also divided into 5 
mechanistic groups (Figure 5.8).  
 
Figure 5.8 Numbers of cases with liver injury terms and their subgroups 
 
5.7 Herbal medicine liver injury in general 
Herbs included in the search with evidence or suspicion of hepatotoxicity are in Table 5.2 [1, 
4, 74, 102, 105]. 
 
Cases (non liver 
injury ADR's), 
2509899 
Cholestasis and 
jaundice, 15371 
Hepatic 
failure, 9757 
Steatosis , 4080 
Necrosis , 3151 
Hepatic 
vascular 
disorders, 
1732 
Cases (liver injury 
ADR's), 34091 
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Table 5.2  Herbs or herbal products identified in literature with previous evidence for or suspicion of 
hepatotoxicity 
Herb Evidence for liver injury* Herb Evidence for liver injury* 
Aloe Positive re-exposure Impila / Zulu remedy Clinical case reports 
Aloe vera Clinical case reports Isabgol / psyllium Clinical case reports 
Arrow root Clinical case reports Jin Bu Huan  Positive re-exposure 
Atractylis gummifera Clinical case reports Kambala Clinical case reports 
Ayurveda herbs Clinical case reports Kava Positive re-exposure 
Ba Jiao Lian No clinical case reports, may 
cause raised liver enzyme 
levels 
Ma Huang / Ephedra Clinical case reports 
Bai Fang Clinical case reports Margosa oil2 Clinical case reports 
Black cohosh Clinical case reports Melatonin No clinical case reports 
Boh Gol Zhee Clinical case reports Mistletoe Positive re-exposure 
Borage  Noni Clinical case reports 
Bush tea Clinical case reports Oil of cloves2  
Camphor2  Oleander Clinical case reports 
Cascara sagrada Clinical case reports Onshido Clinical case reports 
Chaparral Positive re-exposure Oxeye daisy Clinical case reports 
Chaso Clinical case reports Pennyroyal  Clinical case reports 
Chi R Yun Clinical case reports Pro-Lean ® Clinical case reports 
Chinese medicine, traditional Positive re-exposure Pycnogenol® Clinical case reports 
Coltsfoot Clinical case reports Red yeast rice Clinical case reports 
Comfrey1 Clinical case reports Sassafras Clinical case reports 
Crotalaria (rattlebox)1 Clinical case reports Saw palmetto Clinical case reports 
Dai Saiko To / Xiao Chai Hu 
Tang 
Positive re-exposure Senecio longilobus1 Clinical case reports 
Evening primrose  Senna Positive re-exposure 
Fenugreek No clinical case reports, may 
interact with drugs 
Shen Min Clinical case reports 
Germander Positive re-exposure Sho Saiko To Positive re-exposure 
Gotu Kola Clinical case reports Shou Wu Pian Clinical case reports 
Greater Celandine Positive re-exposure Shu Ling Clinical case reports 
Green tea Positive re-exposure Skullcap Clinical case reports 
Groundsel Clinical case reports St John's wort No clinical case reports, may 
interact with drugs 
Guarana Clinical case reports Stonecrop Clinical case reports 
Heliotropium1 Clinical case reports Valerian Clinical case reports 
Herbalife® Positive re-exposure Venencapsan ® Clinical case reports 
Ho Shou Wu / He Shou Wu Positive re-exposure Venoplant ® Clinical case reports 
Hoodia No clinical case reports, may 
cause raised liver enzyme 
levels 
Wolf's foot Clinical case reports 
Horse chestnut Clinical case reports X-Ellis ® Clinical case reports 
Hydroxycut®  Clinical case reports Yohimbine No clinical case reports 
Hyssop No clinical case reports   
1Contains pyrrolizidine alkaloids 
2Excluded from analysis because they may also be used externally 
*Notes on evidence for liver injury: positive re-exposure is considered the gold standard for causality assessment in HILI and 
DILI. 
Clinical case reports vastly differ in quality of causality assessment and reporting detail. They are evidence of association. 
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Herbs included in the study from published use and sale data in the US (Table 5.3)[106]. 
 
Table 5.3  List of popular or widely used herbs or dietary supplements included in the study 
Aloe vera Garlic 
 
Green tea Soy 
 Billberry 
 
Ginger Milk Thistle 
 
St John’s Wort 
 Cranberry 
 
Ginkgo biloba 
 
Pycnogenol® Valerian 
 Echinacea 
 
Ginseng 
 
Saw Palmetto 
 
Yohimbine  
 Evening primrose 
 
Grapeseed 
 
  
 
There were a total of 49,323 reports with herbal product use, and of these, 3,059 reports 
were associated with a liver injury adverse event. There are slightly greater reports for 
females with herbal exposure and a liver injury adverse event (Figure 5.9, Table 5.4). Also 
herbal liver injury appears to occur more often in older age, peaking at the 61-70 age group 
(Figure 5.10, Table 5.4). This mirrors herbal product use in the database, which is more 
common in older age. In a study on herb use patterns in the US in 2007 it was found that 
being 45-64 years of age was associated with herb use in addition to other factors such as 
being uninsured, educated and taking other medications [115]. These results are in 
agreement with this study, which shows herbal hepatotoxicity is more common in older age 
with 73% of cases being 51-80 years (Figure 5.10).  
 
Figure 5.9 Age and gender distribution for cases with herbal product use and liver injury (8,578 reports with 
incorrect or missing information are not shown above) 
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Table 5.4Summary of age and gender statistics for cases with herbal product exposure 
Statistic Entire database Herbal product 
use 
HILI Liver injury 
Average Age (yrs) 34.36  47.87  50.92 39.90 
Median Age (yrs) 38.00  56.00  57.00 46.00 
Total males (% of all 
cases) 
1,498,883 (35.52%) 21,026 (42.63%) 1,420 (46.42% 45,393 (44.05%) 
Total females (% of 
all cases) 
952,697 (55.89%) 25,928 (52.57%) 1,572 (51.39%) 501,08 (48.62%) 
Total cases 2,681,744 49,323 3,059 103,052 
Note: percentages for males and females may not add to 100% because a percentage of cases do not report 
gender 
 
 
Figure 5.10 Liver injury reports compared with and without herbal product use and herbal liver injury 
 
5.8 Disproportionality analysis 
Reporting odds ratios were obtained for herb exposure-hepatotoxicity associations using 
univariate and multivariate analyses. Multivariate logistic regression reporting odds ratios 
are corrected for confounders (Figure 5.11). Univariate results, details of multivariate results 
and confounders in the equation are in Appendix G. Univariate disproportionality analysis 
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detailed results and Appendix H. Confounders in logistic regression model. Significant 
reporting odds ratios (which are above 1 with a lower 95% confidence interval above 1) are 
usually interpreted to imply there is a significant association between exposure to the herb 
and a liver injury adverse event. Interpretation of each signal is summarised in Table 5.5 (See 
section 7.6 for details). Further investigation of herb exposure and liver injury cases revealed 
signals for specific liver injury phenotypes or mechanistic groups (Table 5.6). This data 
provides new information for the herb’s hepatoxicity profile and may be compared to 
published information. This comparison is made in Table 5.6and the literature sources are 
detailed in Table 1.4. For example, ephedra had significant signals for steatosis, necrosis and 
hepatic failure in addition to a general liver injury signal and an immune liver injury signal. 
The literature, however, only provides information for ephedra hepatotoxicity as being 
associated with jaundice and liver failure.  
Herbs with significant liver injury signals with immune features were further analysed in the 
second part of the study to determine whether it is possible to identify one or more 
common pharmacophores among the phytoconstituents.  
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 Figure 5.11 Reporting odds ratios for herb-hepatotoxicity associations (from multivariate logistic 
regression model) 
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Table 5.5  Summary of study signals and their interpretation 
Herb  Study Signal Literature concern* Signal interpretation 
Kava Immune HILI Y  
Valerian  Immune HILI Y  
Milk thistle Immune HILI Protective  
Herbalife ® Immune HILI Y  
Chinese medicine Immune HILI Y (for specific herbs)  
Unspecified herb Immune HILI Y (for specific herbs)  
Ginseng  Immune HILI   
Senna Immune HILI Y  
Ginkgo  Immune HILI   
Ephedra  Immune HILI Y  
Hoodia  HILI   
Hydroxycut ® HILI Y  
Black cohosh HILI Y  
Soy  HILI   
Green tea HILI Y  
Noni HILI Y  
Garlic  Protective   
Isabgol  Protective Y Contradiction  
Evening primrose HILI (univariate)   
Echinacea  HILI (univariate)   
Mate  Non-significant Y  
Greater celandine  Non-significant Y  
Guarana  Non-significant Y  
Mistletoe  Non-significant Y  
Aloes  Non-significant Y  
Horse chestnut  Non-significant Y  
Bilberry  Non-significant   
Borage  Non-significant   
Fenugreek  Non-significant   
St John’s Wort Non-significant   
Saw palmetto  Non-significant Y  
Grapeseed  Non-significant   
Cranberry  Non-significant   
Ginger  Non-significant   
Aloe vera Non-significant   
Red yeast rice Non-significant Y  
Y = Yes  Adds further evidence for HILI concern  Does not add evidence for safety or toxicity 
Confounded signal 
*This table does not contain herbs that did not contain a liver injury adverse event (See Appendix 
G. Univariate disproportionality analysis detailed results) 
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Table 5.6 Summary of significant signals for specific liver injury phenotypes 
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Herbalife®           Jaundice 
Hoodia 
          
No HILI 
evidence 
Kava           ? 
Unspecified 
Chinese 
medicine 
          
- 
Valerian           - 
Hydroxycut®            Jaundice 
Unspecified 
herb 
          
- 
Ginseng 
          
No HILI 
evidence 
Soy  
          
No HILI 
evidence 
Black cohosh           Jaundice 
Green tea           Cholestasis  
Senna           - 
Evening 
Primrose 
          
No HILI 
evidence 
Ginkgo 
          
No HILI 
evidence 
Ma Huang / 
Ephedra 
          
Jaundice, 
liver failure 
Echinacea  
          
No HILI 
evidence 
Noni           - 
Isabgol           - 
* See Table 1.4 
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5.9 Specific herb investigations 
Specific herbs were further investigated to further understand their observed signals. 
Gender data at the herb level are presented in Table 5.7. 
 
Table 5.7  Gender statistics for specific herbs (percentage of 
all cases) 
Herb  Male Female 
Kava 57.1% 42.9% 
Valerian  23.5% 64.7% 
Milk thistle 53.1% 44.9% 
Herbalife ® 25.0% 75.0% 
Chinese medicine 52.0% 48.0% 
Unspecified herb 45.5% 50.7% 
Cannabis 57.9% 42.1% 
Ginseng  44.0% 56.0% 
Senna 50.7% 48.4% 
Ginkgo  38.8% 57.3% 
Ephedra  37.3% 62.2% 
Hoodia  20.0% 80.0% 
Hydroxycut ® 100.0% 0.0% 
Black cohosh 3.8% 88.5% 
Soy  29.4% 67.6% 
Green tea 11.8% 88.2% 
Noni 64.4% 34.6% 
Glucosamine  32.2% 66.1% 
Garlic  44.7% 55.3% 
Melatonin 57.4% 42.6% 
Isabgol  31.3% 66.7% 
Primrose 22.7% 68.2% 
Echinacea  27.8% 66.7% 
Vitamin A 47.3% 45.2% 
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5.9.1 Senna 
Senna is commonly used to treat constipation and may be easily obtained over-the-counter 
in the US. It was suspected that gender differences might underlie the signal for senna since 
it is known that females may abuse this laxative to lose weight[116]. Age and gender 
distribution shows no gender differences (Figure 5.12) therefore ruling out gender as a 
confounder or pre-disposing factor for senna hepatotoxicity in this database.  
 
Figure 5.12 Senna liver injury cases: age and gender distribution in FDA AERS data (2004-2011). There are a 
large number of cases reporting age as ‘0’ and it was not possible to determine if these were incorrect entries or 
not. 
5.9.2 Herbalife ® 
Herbalife® is a trade name for a number of products. Herbalife exposure was accepted as a 
case with any Herbalife product and contained the key word ‘HERBALIFE’ with no further 
product specific divisions. Table 5.8is a summary of the entries that contained ‘HERBALIFE’ 
and their frequency.  
 
Table 5.8  Herbalife® entries in FDA AERS (2004-2011) 
Drug name entry Frequency 
HERBALIFE FORMULA 1 1 
HERBALIFE PRODUCTS 1 
HERBAL LIFE (HERBAL PRODUCTS) 1 
HERBALIFE 4 
HERBALIFE (HERBALIFE PRODUCTS) 1 
HERBALIFE PRODUCTS 15 
HERBALIFE PRODUCTS (HERBAL 
EXTRACTS NOS) 
2 
HERBALIFELINE 1 
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5.9.3 Ginseng 
It was not possible to conduct the search specifically for Panax ginseng, which is true 
ginseng, due to poor data quality. Therefore, the signal for ‘Ginseng’ may also contain 
reports for other plants also called ginseng, such as American ginseng and Siberian ginseng 
even though they are different plant species. Cases which contained any search term used to 
identify ginseng exposure were used to derive all the information contained in the entry 
field. These entries for ginseng were collected (Table 5.9) to find out the contents of the 
reports that contributed to the signal for ginseng. Ginseng was most frequently reported as 
‘GINSENG’ with no other information regarding plant species or plant part used (See section 
7.12 for details). It is also possible to see from this table that a herb of interest was only 
detectable if present in multi-ingredient products if the entry contained a description of the 
product’s ingredients.  
 
Table 5.9 Ginseng entries in FDA AERS (2004-2011) 
Drug name entry Frequency 
AMERICAN GINSENG 1 
ASIAN GINSENG 3 
DAI-KENCHU-TO (GINGER+GINSENG+JAPANESE 
PEPPER) 
2 
FAT BURNERS-GINSENG  1 
GINSENG 185 
GINSENG AND ROYAL GELLY 1 
GINSENG EXTRACT 2 
GINSENG W/VITAMINS 10 
GISNENG GINKGO BILOBA (GINSENG) 1 
KOREAN GINSENG 4 
KOREAN GINSENG ROOT 1 
NINJIN-TO (GINSENG) 1 
PANAX GINSENG 5 
PANAX GINSENG EXTRACT 1 
PANAX GINSENG ROOT 1 
RADIX PSEUDOGENSIGN 1 
RUSSIAN GINSENG 1 
SIBERIAN GINSENG 9 
SIBERIAN GINSENG ROOT 1 
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6 CHAPTER 6: RESULTS – PHARMACOPHORE DETERMINATION 
6.1 Method optimization 
The first two steps in pharmacophore modelling are ligand preparation and creating sites. In 
this study the key parameters that have the most impact on study results were altered to 
find the optimal settings. It was found that altering the number of conformations, maximum 
relative energy difference, post minimization iterations, minimum atomic deviation and the 
search method did not improve the results (Table 6.1).  
Each pharmacophore feature is defined by a set of SMiles ARbitrary Target Specification 
(SMARTS) patterns, which is is a language used to specify submolecular features accurately. 
H and R features are an exception and are defined using algorithms that enable a faster 
search than would be possible using a SMARTS pattern. Each pattern is also assigned a 
vector, point or group geometry to describe the site (Table 6.2).It was found that including 
non-standard feature definitions, which were excluded by default, for the ‘A’ and ‘D’ feature 
types improved the number of hypotheses found and this was applied for the study runs. For 
example, the SMARTS patterns [O- OH]C(=O),[#7;X3][*]=[O S] and [N;X3](C)(C)[C;X3], which 
define A features, were included as non-standard definitions and were identified in the 
ligand training set. A, D and R features were the most common features. N and P features 
were present in the ligand training set but were relatively rare. It was also found that using 
the mixed Monte-Carlo Multiple Minimum/Low Mode (MCMM/LMOD) search method 
produced a greater number of pharmacophores. This method, however, takes a significantly 
longer amount of time, which would make the method impractical using 99 ligands. 
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Table 6.1  Method optimization 
Constant settings: Pharmacophore generation: pharmacophore sites = 3, minimum number of matching ligands = 
7 out of 20, minimum intersite distance = 2.0 Å, final box size =1 .0 Å, maximum tree depth = 7. Score actives – 
filtering: retain ligands with RMSD below 1.2, keep ligands with vector score above 0.5, keep the top 10%, and 
keep at least 10 and at most 50. Score actives – survival score formula: vector score*1, site score*1, volume 
score*1, ^(Number of matches-1)*1, reference ligand relative conformational energy*0, reference ligand 
activity*0. 
Run  Search method 
Number of 
conformations 
Maximum 
relative 
energy 
difference  
Post 
minimization 
iterations  
Maximum  
RMSD 
(conformer 
elimination) 
Number of 
hypotheses 
generated 
Number of 
ligands 
matching 
1 ConfGen 1000 10 50 1.0 Å 42 7 - 9 
2 ConfGen 2000 10 50 1.0 Å 41 7 - 9 
3 ConfGen 1000 10 100 1.0 Å 41 7 - 9 
4 ConfGen 1000 15 50 1.0 Å 42 7 - 9 
5 ConfGen 1000 10 50 2.0 Å 29 7 - 9 
6 
ConfGen (A 
and D features 
included) 
1000 10 50 1.0 Å 51 7 - 9 
7 
Mixed 
MCMM/ 
LMOD 
1000 10 50 1.0 Å 53 7 - 9 
 
In summary, the optimal settings found for the first two steps of the pharmacophore 
modelling were: 
Generate conformers: 
Number of conformers per rotatable bond = 100 
Maximum number of conformers per structure = 1000 
MacroModel search method = ConfGen 
Sampling = Rapid 
Preprocess minimization steps = 100 
Postprocess = minimize, then eliminate high-energy and redundant conformers with 50 
minimization steps 
MacroModel options: 
Forcefield = OPLS_2005 
Solvation treatment = distance dependent dielectric 
Maximum relative energy difference = 10 kcal/mol 
Eliminate redundant conformers using RMSD of 1.0Å 
Create sites: 
Include all patterns for feature types A and D including standard and non-standard 
definitions. Feature type definitions were not changed for H, N, P or R features (Table 6.2). 
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Table 6.2 Pattern definitions used to identify features in pharmacophore modelling 
Pattern Geometry Pattern Geometry Pattern Geometry 
Acceptor (A)  Donor (D)  Hydrophobic (H)  
 [N;X1]#[#6]  vector  [#1][O;X2]  vector  [a]F  group 
 [N;X1]#CC  vector  [#1]S[#6]  vector  [a]Cl  group 
 [N;X2](=C~[C c])C  vector  [#1][C;X2]#[C;X2]  vector  [a]Br  group 
 [N;X2](O)=N[a]  vector  [#1][NX3]C(=[NX2])[#6]  vector  [a]I  group 
 [N;X2](=N-O)[a]  vector  [#1][#7]  vector  [a]C(F)(F)(F)  group 
 [n;X2]1ccccc1  vector  [#1]OC(=O)  point  [a][CH2]C(F)(F)(F)  group 
 [n;X2]([a])([a])  vector  [#1]O[S;X3]=O  point  [a]O[CH3]  group 
 [N;X2](=C~[C c])(~[*])  vector  [#1]O[S;X4](=O)(=O)  point  [a]S[CH3]  group 
 [N;X3](C)(C)[N;X3]C  vector  [#1]O[P;X3]=O  point  [a]OC(F)(F)(F)  group 
 [N;X2](=C)(~[*])  vector  [#1]O[P;X4]=O  point  C(F)(F)(F)  group 
 [N;X2](~[C c])=[N;X2]  vector  [#1]n1nnnc1  point  F  group 
 [n;X2]1c[nH]cc1  vector [#1]N([S;X4](=O)(=O))(C(F) 
(F)(F)) 
 point  Cl  group 
 O=[S;X4](=O)([!#8])([!#8])  vector  [#1]([NH2;X3 
NH3]([#6;X4])) 
 point  Br  group 
 [O;X2]C  vector  [#1]([NH;X3 
NH2]([#6;X4])([#6;X4])) 
 point  I  group 
 [O;X2]N  vector  [#1]([NH;X4]([#6;X4]) 
([#6;X4])([#6;X4])) 
 point  default_aromatic_ 
surface 
 group 
 [O;X1]=[C c]  vector  [#1][NX3]C(=[NX2])[NX3]  point  default_aliphatic_ 
surface 
 group 
 o  vector  [#1][NX3]C(=[NX3+])  point  C[S;X2]C  group 
 [O;X2](C)C  vector  [#1][NX3+]=C[NH2]  point  [S;X2]CC  group 
 [O;X2]c1ncccc1  vector  [#1][NX3]C(=[NX2])  point  [S;X2]C  group 
 [O;X2]~[a]  vector  [#1][NX3][#6](=[NX2 
NX3+])[#6] 
 point   
 O=PO([!#1])  vector     
 [O;X2]  vector     
 [S;X2](C)C  vector     
 [S;X2](=C)N  vector     
 O=C[O- OH]  point     
 [O- OH]C(=O)  point     
 [nH]([a])[a]  point     
 [#7;X3][*]=[O S]  point     
 [N;X3](C)(C)[C;X3]  point     
 [N;X3][a]  point     
 N(=N=N)[#6]  point     
 [NH2](C(=O)[NH2])  point     
 [NH](C=O)(C=O)  point     
 [NH2](S(=O)(=O)[#6])[#6]  point     
 [NH](S(=O)(=O)[#6])[#6]  point     
 n1c([NH2])ccnc1([NH2])  point     
 o1nccc1  point     
 99 
 
 o1cncc1  point     
 o1cccc1  point     
 [O;X2]C=O  point     
 [O;X2]  point     
 
Positive (P)  N (Negative)  Aromatic (R)  
 [NX3][#6](=[NX2 
NX3+])[#6] 
 group  O=C[O-]  group default aromatic 
vector 
Group 
[NX2 NX3+]=[#6]([NH;X3]) 
([NH;X3]) 
 group  O=C[OH]  group   
 [NX2 NX3+]=[#6]([NX3]) 
([NX3]) 
 group  [S;X4](=O)(=O)([OH])  group   
 n1c([NH2])ccnc1([NH2])  group  [S;X4](=O)(=O)([O-])  group   
 [NX2 NX3+]=C([NX3]) 
c1ccccc1 
 group  [S;X3](=O)([OH])  group   
 [NH2;X3 NH3]([#6;X4])  group  [S;X3](=O)([O-])  group   
 [NH;X3 NH2]([#6;X4]) 
([#6;X4]) 
 group  [P;X4](=O)([OH])([OH])  group   
 [NX3 
NH]([#6;X4])([#6;X4]) 
([#6;X4]) 
 group  [P;X4](=O)([OH])([O-])  group   
 N1CCCCC1  group  [P;X4](=O)([O-])  group   
 [+]  group  [P;X4](=O)([OH])  group   
 [c;X2]1ccnc([NH2])n1  group  n1nc[nH]n1  group   
 c1([NH2])ccn[c;X2]n1  group  n1ncnn1  group   
 [N;X3][C;X3]=[O;X1]  group  [#1]N([S;X4](=O)(=O))(C(F) 
(F)(F)) 
 group   
 [N;X3][S;X4](=O)(=O)[*]  group  [-]  group   
 [NH2][*]= @[#7]  group  [-][+]  group   
 [NH]([#6])[*]= @[#7]  group     
 N([#6])([#6])[*]= @[#7]  group     
 n1ccccc1  group     
 [+][-]  group     
Geometry defined: 
Point: the site is located on a single atom  
Vector: the site is located on a single atom and is assigned directionality using  vector(s)  
Group: the site is located in the centre of a group of atoms 
Patterns identified in blue text are non-standard definitions of the feature type they describe. These were 
included in the study. 
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6.2 Forest/collective strategy 
In the forest strategy, ligands were grouped according to either their herbal origin or 
chemical class and pharmacophore hypotheses were generated using all the groups in one 
step (Table 6.3). 
Table 6.3 Description of search strategies used for pharmacophore modelling 
Strategy  All phytoconstituents ‘Toxic’ phytoconstituents 
 Forest strategy: pharmacophore models were determined in one step. The constituents were grouped 
and pharmacophore hypotheses were determined from ligands in each of these groups.  
1 This strategy included all phytoconstituents. 
Pharmacophore determined using grouping based 
on herb origin of the constituents.  
 
2 This strategy included all phytoconstituents. 
Pharmacophore determined using grouping based 
on constituent chemical class. 
 
3 
 
This strategy included only known ‘toxic’ 
phytoconstituents. Pharmacophore 
determined using grouping based on herb 
origin of the constituents. 
4  This strategy included only ‘toxic’ 
phytoconstituents. Pharmacophore 
determined using grouping based on 
constituent chemical class. 
 
Settings for pharmacophore model development were optimized (Table 6.4). In this strategy, 
the greatest limitation was that hypotheses had a low matching ligand percentage in the 
final step (less than 60%). This was mostly because there was very high variability in the 
chemical structures of the included constituents. The tree strategy was an attempt to 
identify hypotheses with higher percentage of ligands matching. 
In strategy 1(Constituents included: all, Grouping: herb origin), runs 1 and 2 generated 5 
point pharmacophores with mostly A and D features. There was high overlap between the 
matching ligands of different hypotheses, which frequently included flavones and chalcones. 
It was also observed that the pharmacophore was located partially on the glucoside moieties 
in some ligands that contained them, which is undesirable. High scoring hypotheses had 
between 9 and 15 ligands matching out of the 99 ligands included in the search, which is 
considered to be low and not significant.  
Four and three-point pharmacophores were investigated in runs 3 to 6 with improved 
results.  Runs 3 and 4 had between 12 to 25 matching ligands, and runs 5 and 6 had between 
17 and 48. Although a three-point pharmacophore hypothesis may be expected to have less 
predictive power, the three point hypotheses (runs 5 and 6) had a greater proportion of 
matching ligands than the four-point pharmacophore hypotheses (runs 3 and 4). Two 
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pharmacophore hypotheses with high survival scores and relatively high percent matching 
ligands with well positioned pharmacophoric features (from visual inspection) were chosen 
for further investigation (next section).  
 
Table 6.4 Final settings used in building a pharmacophore model for herbs with immune liver 
injury 
Pharmacophore generation: minimum intersite distance = 2.0 Å, final box size =1 .0 Å, maximum 
tree depth = 7. Score actives – filtering: retain ligands with RMSD below 1.2, keep ligands with 
vector score above 0.5, keep the top 10%, and keep at least 10 and at most 50. Score actives – 
survival score formula: vector score*1, site score*1, volume score*1, ^(Number of matches-1)*1, 
reference ligand relative conformational energy*0, reference ligand activity*0. 
Search 
strategy 
Run Number of 
pharmacophore 
features 
Number of groups (or 
number of ligands for tree 
strategy) 
Number of 
matching groups 
1 1 5 7 6 
1 2 5 7 7 
1 3 4 7 6 
1 4 4 7 7 
1 5 3 7 6 
1 6 3 7 7 
2 1 5 6 6 
2 2 5 6 5 
2 3 4 6 6 
2 4 4 6 5 
2 5 3 6 6 
2 6 3 6 5 
3 1 5 5 5 
3 2 5 5 4 
3 3 4 5 5 
3 4 4 5 4 
3 5 3 5 5 
3 6 3 5 4 
 
In strategy 2(Constituents included: all, Grouping: chemical class), it was not possible to 
generate results from runs 1 or 2 because there is no shared five-point pharmacophore 
among the constituents when grouped in this way. Runs 3 and 4 produced only one variant 
with poor ligand matching rate between 17 to 29 ligands (17 – 29%). Run 5, with a three-
point pharmacophore, produced 4 variants with improved ligand matching rate that was 
between 16 to 48 (16 – 48%). Run 6 provided 7 pharmacophore variants and a similar ligand 
matching rate to run 5. Two hypotheses, AAR.609 and AAR.102 are very similar in three-
dimensional arrangement to pharmacophore AAR.532 (discussed later). 
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Strategy 3 (Constituents included: toxic only, Grouping: chemical class) used only 
constituents with literature evidence for possible toxicity. This may increase the likelihood of 
finding more refined pharmacophore hypotheses that describe the essential chemical 
features for hepatotoxicity. At the same time, the training set was now reduced to 24 ligands 
that are chemically diverse. It was not possible for runs 1 and 2 to work because no five-
point pharmacophore could be identified. Runs 3 and 5 also failed to work because no 
pharmacophores were common to all 5 groups. Run 4 produced four-point pharmacophore 
hypotheses with a low match rate between 5 and 9 ligands out of 24 (20.8% - 37.5%). The 
matching ligands were mostly (67 - 89%) hydroxyanthracenes from senna and 
anthraquinones from Shou Wu Pian. Mistletoe and ephedra ligands did not contribute to any 
hypothesis. Run 6 produced a three point pharmacophore with only 2 hypotheses. The 
ligand match rate was greater with 13 and 14 ligands matching (54 – 58%). Both hypotheses 
contained a hydrogen bond acceptor (A), hydrogen bond donor (D) and an aromatic ring (R). 
Ephedra and mistletoe ligands contributed to both hypotheses and made up 29 - 31% of 
matching ligands.  
Strategy 4 (Constituents included: toxic only, Grouping: chemical class) was not conducted 
because individual groups contained insufficient number of ligands. 
6.2.1 Validation of high scoring pharmacophore hypotheses 
 High scoring hypotheses from this strategy (strategy 1) were further analysed to determine 
their predictive power. Hypotheses were selected if they had a high survival score, relatively 
high number of matching ligands and if the model appeared acceptable on visual inspection. 
Other factors considered in hypothesis selection were energy of the conformers, optimal 
contribution of the scoring parameters and optimal tolerance of each feature type. Selected 
hypotheses and their sensitivity and specificity are presented in Table 6.5. 
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Table 6.5 Pharmacophore model validation from strategy 1 
Hypothesis 
Matching 
ligands 
(n=99) 
Hits active 
(decoy set) 
Hits all 
(decoy set) 
Percent 
matching (test 
set, n = 47 
ligands) 
Sensitivity Specificity 
Run 3 
AARR.809 17 3 4 19 % 30 % 75 % 
AARR.814 17 3 4 11 % 30 % 75 % 
AADR.32305 24 3 5 23 % 30 % 60 % 
AADR.32304 24 3 5 23 % 30 % 60 % 
AADR.32338 25 2 4 17 % 20 % 50 % 
AAHR.5431 10 4 5 32 % 40 % 80 % 
AAHR.4466 12 5 6 36 % 50 % 83 % 
AAHR.5298 16 2 3 19 % 20 % 67 % 
AAHR.5223 16 2 3 19 % 20 % 67 % 
Run 4 
AAHR.4267 18 4 5 32 % 40  % 80 % 
AAHR.4724 18 4 5 32 % 40 % 80 % 
AAHR.746 12 4 5 38 % 40 % 80 % 
AAHR.886 12 4 5 38 % 40 % 80 % 
AAHR.4261 12 4 5 32 % 40 % 80 % 
Run 5 
ARR.40 18 4 5 32 % 40 % 80 % 
ARR.41 48 4 5 32 % 40 % 80 % 
ARR.1 17 4 5 32 % 40 % 80 % 
ARR.114 31 6 9 60 % 60 % 67 % 
AAR.66 43 9 14 83 % 90 % 64 % 
Run 6 
AAR.645 37 3 5 38 % 30 % 60 % 
AAD.910 28 3 7 21 % 30 % 43 % 
AAR.532 41 7 9 62 % 70 % 78 % 
AAR.649 34 3 5 36 % 30 % 60 % 
AHR.339 17 2 3 40 % 20 % 67 % 
 
Two pharmacophore hypotheses, AAR.66and AAR.532, generated from strategy 1, runs 5 
and 6 respectively, showed promising results and are presented below. Both contained two 
hydrogen bond acceptors and one aromatic ring. They scored relatively high survival scores, 
had acceptable percentage matching ligands (highest was 48.5% ligands matching), 
acceptable sensitivity and specificity (Table 6.6). Details of matching ligands are in Appendix 
I. Ligands possessing structural features matching pharmacophore hypothesis. The three 
dimensional arrangement of the feature types in these hypotheses are shown (Figure 6.1 
and Figure 6.2) and examples of matching ligands possessing the pharmacophore hypothesis 
(Figure 6.). 
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Table 6.6  Pharmacophore hypotheses results 
 AAR.532 AAR.66 
Survival score 3.226 3.219 
Sensitivity  70% 90% 
Specificity 78% 64% 
Matching ligands 41.4% 43.4% 
 
 
Figure 6.1 AAR.532 pharmacophore hypothesis 
 
Figure 6.2 AAR.66 pharmacophore hypothesis 
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AAR.532 pharmacophore superimposed on the reference 
ligand, quercetin 
 
 
AAR.66 hypothesis superimposed on the reference 
ligand, dimethoxyflavanone 
 
AAR.532 superimposed on kava chalcone, flavokawain C 
 
AAR.66 hypothesis superimposed on kava chalcone, 
flavokawain A 
 
AAR.532 superimposed on senna hydroxyanthracene, 
rhein  
AAR.66 hypothesis superimposed on senna 
hydroxyanthracene, rhein 
Figure 6.3  Examples of matching ligands with respective pharmacophore hypothesis 
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AAR.532 superimposed on kava lactone, 
dimethoxydihydrokawain 
 
Figure 6.3 (Continued) Examples of matching ligands with respective pharmacophore hypothesis 
 
Further validation was carried out by comparing the generated hypotheses with hypotheses 
from similar work. In a study by Ho et al., prescription drugs with evidence for immune liver 
injury were used as a training set in pharmacophore model development [117]. The 
evidence for immune liver injury was derived from signals of association in the Australian 
spontaneous reporting system. The molecules were grouped with their metabolites and 
structural features common to these ligands was identified using PHASE (V 3.4, Schrödinger). 
The selected four-point pharmacophore, composed of two hydrogen bond acceptors (A1 
and A2), one hydrogen bond donor(D3) and one aromatic ring (R4) (AADR.15027) (Figure 
6.4), was further validated with a test set of active and inactive compounds. Active 
compounds were drugs that have been withdrawn from the market due to immune liver 
injury and inactive compounds were drugs devoid of any evidence for liver injury.  The 
pharmacophore hypothesis was accepted as a predictive model with a sensitivity of 75% and 
specificity of 85%. The study methodology used by Ho et al.[117], is comparable to this study 
and therefore forms an excellent comparator. The hypothesis AADR compares well with the 
AAR.532 hypothesis from this study. The two hydrogen bond acceptors and aromatic ring in 
the two hypotheses are situated in similar locations in three-dimensional space relative to 
each other. The distances are also similar. The AAR.532 hypothesis is slightly elongated 
(Figure 6.5 and Figure 6.6). The training set ligands differ dramatically between Ho et al and 
this study. Nevertheless, high scoring hypotheses from both studies converge on the three-
dimensional arrangement of three features.  Therefore the high similarity and convergence 
of results from these two studies further strengthens the evidence for the model as a 
descriptor for essential features in a molecule for an immune hepatotoxicity reaction. 
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Figure 6.4 Pharmacophore hypothesis AADR.15027 from Ho et al. 
 
 
Figure 6.5 Distances of pharmacophore hypotheses AADR.15027 and AAR.532 
 
 
Figure 6.6 Overlap between pharmacophore hypotheses AADR.15027 and AAR.532 (Molecular structure in 
background isallopurinol1-riboside, which is the reference ligand for AADR.15027) 
Angles 
A2 A1 D3 29.6 
A2 A1 R4 18.8 
D3 A1 R4 27.3 
A1 A2 D3 85.2 
A1 A2 R4 12.3 
D3 A2 R4 80.3 
A1 D3 A2 65.2 
A1 D3 R4 14.5 
A2 D3 R4 54.5 
A1 R4 A2 148.9 
A1 R4 D3 138.2 
A2 R4 D3 45.2 
2.777 Å 6.178 Å 
8.852 Å 6.433 Å 
2.653 Å 4.014 Å 
6.433 Å 
2.653 Å 4.014 Å 
7.062 Å 4.859 Å 3.497 Å 
A1 A2 
R4 
D3 
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6.3 Tree/individual strategy 
In the tree strategy, ligands were grouped according to either their herbal origin or chemical 
class. Then pharmacophore hypotheses were generated for each group in order to find 
those that are shared among the groups (Table 6.7). This strategy was an attempt to 
generate hypotheses that would have not been otherwise generated using the forest 
strategy, which may also have a higher percentage of matching ligands and therefore be a 
superior hypothesis. Settings are summarized in Table 6.8. It was only possible to investigate 
three-point hypotheses because some groups did not contain a four-point hypothesis.  
 
Table 6.7  Description of search strategies used for pharmacophore modelling 
Strategy  All phytoconstituents ‘Toxic’ phytoconstituents 
 Tree strategy: pharmacophore models were determined in two steps. Firstly, the constituents were 
grouped and pharmacophore hypotheses were found for each individual group. Secondly, overall 
pharmacophore hypotheses were obtained from the hypotheses found for individual groups. 
5 This strategy included all phytoconstituents. 
Pharmacophore determined using grouping based 
on herb origin of the constituents.  
 
6 This strategy included all phytoconstituents. 
Pharmacophore determined using grouping based 
on constituent chemical class. 
 
7 
 
This strategy included only known ‘toxic’ 
phytoconstituents. Pharmacophore 
determined using grouping based on herb 
origin of the constituents. 
8  This strategy included only ‘toxic’ 
phytoconstituents. Pharmacophore 
determined using grouping based on 
constituent chemical class. 
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Table 6.8  Final settings used in building a pharmacophore model for herbs with immune liver 
injury 
Pharmacophore generation: minimum intersite distance = 2.0 Å, final box size = 1.0 Å, maximum 
tree depth = 7. Score actives – filtering: retain ligands with RMSD below 1.2, keep ligands with 
vector score above 0.5, keep the top 10%, and keep at least 10 and at most 50. Score actives – 
survival score formula: vector score*1, site score*1, volume score*1, ^(Number of matches-1)*1, 
reference ligand relative conformational energy*0, reference ligand activity*0. 
Search 
strategy 
Run Number of 
pharmacophore 
features 
Number of groups (or 
number of ligands for tree 
strategy) 
Number of 
matching groups 
5 1 3 99 (Overall) 50 
5 2 3 17 (Kava) 10 
5 3 3 26 (Ephedra) 10 
5 4 3 6 (Black cohosh) 3 
5 5 3 11 (Mistletoe) 6 
5 6 3 23 (Valerian) 9 
5 7 3 10 (Shou Wu Pian) 7 
5 8 3 6 (Senna) 4 
5 9 3 5 (Ginkgo) 5 
5 10 3 9 (Ginseng) 8 
6 1 3 11 (Alkaloids) 6 
6 2 3 37 (Flavones) 27 
6 3 3 8 (Amides) 4 
6 4 3 7 (Lactones) 6 
6 5 3 18 (Iridoids) 9 
6 6 3 20 (Other) 5 
7 1 3 7 (Kava) 6 
7 2 3 3 (Ephedra) 3 
7 3 3 6 (Senna) 4 
7 4 3 4 (Mistletoe) 2 
7 5 3 4 (Shou Wu Pian) 4 
7 6 3 13 (Valerian) 9 
7 7 3 37 (Overall) 18 
 
For strategy 5(Constituents included: all, Grouping: herb origin), the results varied depending 
on the herb group. Kava, ephedra, black cohosh, mistletoe and valerian had fewer than 60% 
of the ligands matching the pharmacophore hypotheses in those groups. This was because 
of high variability in the chemical structures and small number of constituents. For example, 
black cohosh contained only 6 ligands and in order to generate variants, which would be the 
base for pharmacophore hypothesis generation, only 3 ligands (50%) were required to share 
features. Valerian on the other hand, contained 23 ligands. However, the variability in 
chemical structure was greater and a maximum of 9 ligands (39%) could contribute to the 
hypothesis. 
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Two hypotheses, AAH and AAR (Table 6.9), were found to be shared among 5 of the 8 groups 
and were taken for further investigation. Although the AAA hypothesis was common to 7 of 
the 8 groups, it was considered a poor hypothesis for ligand-target interaction because it 
only contained one feature type, which was A (hydrogen bond acceptor), and would not 
likely be a good predictor of other actives.  
Further investigation of the AAH and AAR hypotheses involved finding a three-dimensional 
arrangement of the feature types that is similar among the identified groups. For each 
group, the pharmacophore may be present in several different arrangements, for example, 
in the mistletoe hypothesis AAR.48 the two ‘A’ features were relatively close (2.804   apart) 
and both were 6-7   apart from the ‘R’ feature forming a triangular arrangement with long 
basal width. In another hypothesis in mistletoe, AAR.2 for example, the feature types were 
much closer in three-dimensional space to each other with distances between only 2.779 
and 3.782 Å. Distances of pharmacophoric features from other herbs that share either the 
AAH or AAR hypotheses were compared using clusters to group very similar hypotheses 
within each group (Table 6.10). It was found that although the overall hypotheses AAR and 
AAH were shared among the 5 groups, it was not possible to identify a pharmacophore 
hypothesis with similar three-dimensional arrangement that was also common.  
 
Table 6.9  Pharmacophore hypotheses in strategy 5 
Hypothesis 
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AAA Y Y Y Y Y Y  Y 87.5 
AAD Y Y Y Y     50 
AAH Y Y   Y Y  Y 62.5 
AAR Y  Y Y  Y Y Y 62.5 
ADD Y Y Y Y     50 
ADR Y  Y Y   Y  50 
AHR Y Y    Y  Y 50 
DDR Y  Y Y   Y  50 
Number of hypotheses 249 105 100 60 49 40 21 4  
Y  = pharmacophore variant is present in the hypotheses generated for that herb 
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Table 6.10  Distances between features in the hypotheses AAH and AAR found from strategy 5 
Entry  Site1  Site2  Distance Entry  Site1  Site2  Distance 
Kava Kava 
AAH.69  A2  A3 4.796 AAR.1  A2  A4 2.666 
AAH.69  A2  H5 5.617 AAR.1  A2  R10 2.797 
AAH.69  A3  H5 4.819 AAR.1  A4  R10 2.801 
        
AAH.32  A1  A3 2.938 AAR.63  A1  A2 4.14 
AAH.32  A1  H7 5.463 AAR.63  A1  R6 6.151 
AAH.32  A3  H7 6.85 AAR.63  A2  R6 6.891 
        
AAH.10  A1  A3 2.274 AAR.65  A1  A2 4.142 
AAH.10  A1  H4 2.441 AAR.65  A1  R6 6.1 
AAH.10  A3  H4 4.122 AAR.65  A2  R6 7.307 
        
AAH.58  A1  A4 4.137 AAR.51  A2  A5 4.799 
AAH.58  A1  H7 2.965 AAR.51  A2  R10 6.964 
AAH.58  A4  H7 5.376 AAR.51  A5  R10 5.824 
        
    AAR.2  A1  A3 2.938 
    AAR.2  A1  R8 2.805 
    AAR.2  A3  R8 3.69 
        
Mistletoe Mistletoe 
AAH.11  A8  A10 2.702 AAR.2  A3  A4 2.797 
AAH.11  A8  H15 4.996 AAR.2  A3  R12 3.782 
AAH.11  A10  H15 6.864 AAR.2  A4  R12 2.779 
        
AAH.41  A8  A10 6.459 AAR.34  A1  A2 2.862 
AAH.41  A8  H18 4.997 AAR.34  A1  R19 6.89 
AAH.41  A10  H18 3.478 AAR.34  A2  R19 5.961 
        
AAH.56  A1  A4 4.894 AAR.48  A2  A3 2.804 
AAH.56  A1  H8 4.9 AAR.48  A2  R19 6.956 
AAH.56  A4  H8 5.385 AAR.48  A3  R19 6.134 
        
AAH.17  A10  A11 3.936 AAR.32  A3  A4 2.946 
AAH.17  A10  H17 6.788 AAR.32  A3  R17 6.138 
AAH.17  A11  H17 5.375 AAR.32  A4  R17 4.025 
        
AAH.15  A9  A10 3.937 AAR.11  A4  A5 3.646 
AAH.15  A9  H16 6.889 AAR.11  A4  R19 2.807 
AAH.15  A10  H16 4.891 AAR.11  A5  R19 5.336 
        
Valerian Senna 
AAH.214  A5  A6 8.099 AAR.3  A2  A4 2.776 
AAH.214  A5  H12 4.215 AAR.3  A2  R12 3.756 
AAH.214  A6  H12 8.968 AAR.3  A4  R12 2.779 
        
AAH.138  A4  A7 6.546 AAR.24  A4  A5 5.265 
AAH.138  A4  H14 7.345 AAR.24  A4  R9 2.774 
AAH.138  A7  H14 4.043 AAR.24  A5  R9 5.825 
        
AAH.100  A3  A4 6.43 AAR.79  A1  A5 6.058 
AAH.100  A3  H5 3.641 AAR.79  A1  R12 7.891 
AAH.100  A4  H5 6.626 AAR.79  A5  R12 5.821 
        
AAH.151  A2  A3 7.257 AAR.18  A3  A4 6.073 
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AAH.151  A2  H5 3.652 AAR.18  A3  R9 3.69 
AAH.151  A3  H5 8.617 AAR.18  A4  R9 2.774 
        
AAH.152  A6  A7 7.575 AAR.15  A4  A5 5.075 
AAH.152  A6  H13 9.067 AAR.15  A4  R11 3.73 
AAH.152  A7  H13 3.725 AAR.15  A5  R11 2.774 
        
Black cohosh Shou Wu Pian 
AAH.4  A1  A2 2.281 AAR.13  A2  A3 4.801 
AAH.4  A1  H5 4.094 AAR.13  A2  R8 2.773 
AAH.4  A2  H5 2.138 AAR.13  A3  R8 2.772 
        
AAH.5  A2  A3 2.298 AAR.61  A3  A4 5.121 
AAH.5  A2  H9 4.034 AAR.61  A3  R10 2.759 
AAH.5  A3  H9 3.544 AAR.61  A4  R10 5.749 
        
AAH.6  A2  A3 2.3 AAR.21  A3  A4 6.004 
AAH.6  A2  H9 4.737 AAR.21  A3  R10 3.649 
AAH.6  A3  H9 4.735 AAR.21  A4  R10 2.759 
        
AAH.9  A1  A2 3.363 AAR.127  A3  A5 8.588 
AAH.9  A1  H8 4.192 AAR.127  A3  R10 2.775 
AAH.9  A2  H8 4.799 AAR.127  A5  R10 7.484 
        
AAH.11  A1  A3 3.566 AAR.15  A1  A5 4.979 
AAH.11  A1  H9 4.017 AAR.15  A1  R11 3.727 
AAH.11  A3  H9 5.092 AAR.15  A5  R11 2.775 
        
Overall Overall 
AAH.3  A1  A2 2.293 AAR.708  A1  A2 11.199 
AAH.3  A1  H3 2.809 AAR.708  A1  R9 2.753 
AAH.3  A2  H3 3.925 AAR.708  A2  R9 8.589 
        
AAH.60  A2  A5 2.251 AAR.693  A1  A6 9.997 
AAH.60  A2  H9 7.174 AAR.693  A1  R19 2.797 
AAH.60  A5  H9 7.609 AAR.693  A6  R19 9.059 
        
AAH.140  A1  A2 4.872 AAR.704  A4  A5 10.855 
AAH.140  A1  H6 4.895 AAR.704  A4  R11 8.371 
AAH.140  A2  H6 5.458 AAR.704  A5  R11 2.776 
        
AAH.52  A2  A3 2.906 AAR.692  A1  A5 9.759 
AAH.52  A2  H11 7.213 AAR.692  A1  R14 8.531 
AAH.52  A3  H11 5.273 AAR.692  A5  R14 2.778 
        
AAH.50  A1  A4 2.979 AAR.692  A1  A5 9.759 
AAH.50  A1  H8 5.464 AAR.692  A1  R14 8.531 
AAH.50  A4  H8 6.846 AAR.692  A5  R14 2.778 
 
For strategy 6(Constituents included: all, Grouping: chemical class), the results also varied 
depending on the chemical class group. Alkaloids, amides, iridoids and sesquiterpenes had 
low (less than 60%) numbers of matching ligands. In the alkaloid group, the variability was 
the highest and it was possible to generate only one variant with 6 of 11 ligands (54.5%). For 
this group, the final box size was increased to 1.5 Å in the next run in an attempt to increase 
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the number of shared variants. This resulted in three variants and generated 12 hypotheses. 
Constituents that did not belong to the major chemical groups were grouped together in the 
group ‘other’. This group contained the highest variability of all the groups and it was 
possible to obtain a minimum of one hypothesis with 5 of 20 ligands (25%) matching. 
Overall, only four possible hypotheses were shared among some of the groups (Table 6.11). 
The shared hypotheses in this strategy were not investigated further.  
Table 6.11  Pharmacophore hypotheses in strategy 6 
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AAA Y Y Y Y   Y 71 
AAH  Y Y  Y  Y 57 
AAR Y  Y Y   Y 57 
AHR   Y Y  Y Y 57 
Number of hypotheses 67 46 36 22 12 35 4  
Y  = pharmacophore variant is present in the hypotheses generated for that herb 
 
For strategy 7(Constituents included: toxic only, Grouping: herb origin), the number of 
ligands was relatively small because only ‘toxic’ constituents were included and the results 
varied for individual groups. Ephedra contained only 3 ligands and mistletoe and Shou Wu 
Pian contained 4. It was only possible to use 2 of the 4 ligands for mistletoe, however. Kava 
and senna had good percentage of matching ligands, 85.7% and 75% respectively. However, 
the match overall was poor (48%) and few of the generated pharmacophores were shared 
among all the groups (Table 6.12). Mistletoe and valerian did not share any pharmacophores 
with any other group. No shared pharmacophore hypothesis was taken from this run for 
further investigation. 
Table 6.12  Pharmacophore hypotheses in strategy 7 
Hypothesis 
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AAA Y Y     Y 43 
AAR Y Y  Y    43 
ADR Y  Y Y    43 
APR Y  Y Y    43 
DDR Y  Y Y    43 
Number of pharmacophores 70 36 29 17 3 3 3  
Y  = pharmacophore variant is present in the hypotheses generated for that herb 
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Search strategy 8 (Constituents included: toxic only, Grouping: chemical class) was not 
conducted because the number of ligands for individual groups was not sufficient for 
modelling.  
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6.4 CHAPTER 5 AND 6 SUMMARY 
Key findings are summarized below: 
Signal detection 
 The FDA AERS database (2004 – 2011) contained 2,681, 744 non-duplicate case 
reports 
 A total of 171,845 (6.41%) cases in FDA AERS (2004 – 2011) contained at least one 
liver injury adverse event term. There was no apparent significant difference in 
gender. 
 A total of 3,059 (1.30%) cases contained at least one liver injury adverse event term 
AND exposure to at least one herb included in the study. Results were further 
analysed by liver injury groupings. 
 Significant signals of association between herb exposure and hepatotoxicity (ROR > 1 
and lower 95% CI >1) were obtained from a multivariate logistic regression model, 
which was corrected for confounders. 
 Analysis of specific liver injury groupings revealed new information. Significant 
signals of association between herb exposure and liver injury with immune features 
were evident for kava, valerian, Herbalife®, ginseng, senna, ginkgo and ephedra.  
 Significant signals of association between herb exposure and liver injury (all groups) 
were also evident for hoodia, Hydroxycut®, black cohosh, soy, green tea and noni. 
 Ginseng, ginkgo, hoodia and soy had significant signals of association between herb 
exposure and liver injury; however, there is no evidence in the literature for 
hepatotoxicity concerns. Therefore, these signals present new information. 
 Significant signals of association were also evident for liver injury phenotypes (for 
various herbs) such as necrosis, cholestasis and jaundice.  
Pharmacophore determination 
 In method optimization, it was found that including all the SMARTS patterns to 
define ‘A’ and ‘D’ features were important to improve the number of hypotheses 
found. Settings for pharmacophore generation and scoring actives were optimized 
individually for each search strategy because the ligand groups differed in each case.  
 The most successful strategies were strategies 1 and 5. These two strategies used all 
the ligands in the training set and grouped them into their herbal origins. Strategies 
2, 3, 6 and 7 provided little advantage over other strategies. Strategies 4 and 8 were 
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not carried out because of the small number of constituents.  There was high 
variability in chemical structure among the constituents in most strategies and 
therefore they had a low ligand match rate. 
 Hypotheses were selected for further investigation or validation using a combination 
of its survival score, number of matching ligands and visual inspection. Other factors 
considered were energy of the conformers, optimal contribution of the scoring 
parameters and optimal tolerance of each feature type. 
 Hypotheses were tested for their validity using a test set of known hepatotoxic drugs 
(actives) and a decoy set of actives and inactives in order to determine sensitivity 
and specificity. 
 Two pharmacophore hypotheses emerged from strategy 1, AAR.532 and AAR.66. 
These hypotheses showed acceptable sensitivity and specificity (between 64% and 
90%, see Table 6.6).  
 Hypothesis AAR.532 compared well with the AADR.15027 hypothesis from Ho et al., 
which was generated using similar methods using drugs with immune liver injury 
evidence. This adds credibility to the proposed model for the important molecular 
features for an immune liver injury reaction. 
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7 CHAPTER 7: DISCUSSION – SIGNAL DETECTION 
7.1 Database selection 
This study utilised population adverse drug reaction data to identify associations between 
drug exposure and adverse events. Sources of data for this study were population data from 
several pharmacovigilance databases such as the Australian Therapeutics Goods 
Administration (TGA), Canadian Therapeutics Product Directorate (TPD) and United States 
(US) Food and Drug Administration (FDA) database.  Database choice depends on a number 
of factors such as database size, database source population; database time period covered 
or database data quality in terms of entry standardization (Table 7.1). From preliminary work 
into various possible databases for this study, it was evident that herb product reporting is 
very low. A pilot search of the TGA and TPD databases revealed 1,616 and 545 case reports 
with any of the study herbs in the entire database, respectively (Table 5.1). Small case 
numbers produce results with poor statistical power, which may not be very useful in 
drawing conclusions about the observed associations [118]. The number of reports was 
therefore determined to be the most important factor in database choice for this study.  
The FDA Adverse Event Reporting System (AERS) was considered the most appropriate 
choice for this study mainly because it contained a greater number of reports with herb 
product intake. The World Health Organization VigiBase is also a very large database. 
However, a greater number of cases with herb intake were identified in the FDA AERS due to 
a lag time in making FDA ADR data available in VigiBase. This is because the US is a major 
contributor to VigiBase and US reports make up 60% of VigiBase entries. FDA AERS was also 
easier to gain access to and therefore it was decided that AERS would form the database for 
this study.  
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Table 7.1   Comparison of pharmacovigilance databases 
Country Date started Size 
(cases) 
ADR 
standardization 
Advantages (+)/ Limitations (-) 
TGA 
Australia 
1971  >200,000 MedDRA + drug entry standardized to drug generic name 
CTP 
Canada 
1965  MedDRA + drug entry standardized to drug generic name 
EMEA 
EU member 
states 
2001 >1 million   + follows ICH E2B guidelines 
- restricted access to database 
FDA 
US 
1969 >3million MedDRA + follows ICH E2B guidelines 
+ publically available 
- time lag in making reports available (3-6 months) 
- drug names inserted ad verbatim  
- case narratives not available except through request, 
which takes months to receive 
VigiBase 
International 
(82 countries)  
1968 >6million COSTART + publically available 
+ good for investigating drugs not marketed in the US 
- regulatory reporting differs in each country and the 
overall quality of the data cannot be stronger than the 
weakest link 
 
The FDA adverse drug reaction reporting system receives voluntary reports from health care 
professionals (doctors, nurses, pharmacists, dentists) and patients or their family members. 
Herbal products are regulated as ‘dietary supplements’ and it is mandatory for 
manufacturers or distributors to report all adverse event reports received to the FDA for any 
product marketed in the US (See section 1.20). The FDA assigns an ‘Individual Safety Report’ 
(ISR) and a ‘case number’ for each case as identifiers. Drug names are entered into the ‘drug 
name’ field as they appear on the report, ad verbatim including misspellings or other errors. 
Adverse drug reactions are coded using MedDRA dictionary. This is advantageous because 
an adverse event may have several descriptions and standardised nomenclature allows for 
standardised and accurate signal detection. Follow up reports may also be received when 
the patient’s condition changes or new information becomes available or cases may have 
multiple reporters leading to duplicate reports in the database.  
The FDA AERS data represents a rich source of drug safety information. Studies have shown 
that the AERS database mirrors well-established drug-adverse event associations such as 
cisplatin and nephrotoxicity [119] or statin and muscular events [120], therefore indicating 
its usefulness.  The rank-order of adverse event rates in the AERS database has also been 
shown to be consistent with published studies [121]and therefore it forms a useful 
comparison. This made the FDA AERS database suitable for use for this study. All 
pharmacovigilance databases have limitations however, and these are discussed in later 
sections.  
 119 
 
Database choice affects the results obtained. In this study, popular herbs in the US market 
were included in the analysis in addition to herbs with previous hepatotoxicity reports. 
Furthermore, the majority of the reports in the FDA AERS database originate in the US. This 
means that the signals observed in this study represent herb hepatotoxicity risks in the way 
herbs are consumed in the US population with US specific predisposing factors. It has been 
shown previously that herbal hepatotoxicity incidence varies widely in different cultural 
contexts because of different herb consumption practices (See section 1.5). Therefore, 
conducting this study on pharmacovigilance databases from different source populations 
may yield different results. 
7.2 Gender in liver injury reports in FDA AERS 
There was no apparent significant difference in liver injury reports between the genders in 
the data, despite the greater number of female reports in the entire database. Therefore, 
this indicates that gender may not be pre-disposing factor in livery injury. This data can be 
compared to a phenotypic analysis of idiosyncratic drug-induced liver injury (DILI) from the 
Spanish registry, which found that DILI peaked in the 40-49 age group and again in the 60-69 
age groups for both genders [122]. Older age did not appear to predispose to idiosyncratic 
DILI; however, older age was associated with cholestatic damage with males predominating. 
There was also no significant gender difference and therefore gender was not a predisposing 
factor to idiosyncratic DILI, however, women exhibited the worst outcomes. The results from 
the study by Luceana et al. (2009) included clinical cases that have been assessed as DILI 
according to three independent expert clinicians and using the CIOMS scale for causality 
assessment. In contrast this study uses cases in which herbal medicine use and a liver injury 
adverse event appear to be associated in the AERS database. Therefore, the results may 
differ slightly. It is also important to note that age or gender risk factors may sometimes be 
drug or herb specific. For example, older age is a predisposing factor for isoniazid liver injury 
and younger age is a predisposing factor for valproate and aspirin liver injury (See section 
1.6)[123]. 
Liver injury reports with and without herb exposure were steady between the years 2004 
and 2010. However, the total number of reports is increasing per year during this time. This 
may be because there is increase in the number of reports with other ADRs not covered in 
this study. 
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7.3 Population data, a source of hepatotoxicity evidence 
Hepatotoxicity concerns may emerge at the pre-clinical phase in early drug development for 
conventional drugs. In pre-clinical testing, raised liver aspartate transaminase and alanine 
transaminase enzyme at two times the upper limit of normal in animal studies hint to a 
hepatotoxicity concern. However, 50% of elevated liver enzyme levels in rodents are not 
predictive of hepatotoxicity in humans and as yet there is no satisfactory test for drug 
hepatotoxicity. In addition, hepatotoxicity testing receives relatively little focus because 
regulation requires pre-clinical data on cardiovascular, respiratory and central nervous 
system side effects, which form the core pharmacological safety testing for drug clinical trial 
approval. Clinical trials recruit at most 3,000 patients, which is not sufficiently large to detect 
rare idiosyncratic drug reactions such as hepatotoxicity, which occurs in 1 in 10,000 to 1 in 
100,000 patients. On the other hand, post-marketing pharmacovigilance allows monitoring 
of drugs at a population level over many years of continued use. Rare idiosyncratic reactions 
such as idiosyncratic hepatotoxicity may appear as a ‘signal’ of disproportionally high report 
numbers with a certain herb exposure-adverse event combination. Therefore, population 
data is a vital source of safety information for drugs with no previous population exposure. 
For herbal medicines, which do not have a formal process to sufficiently assess their safety, 
post marketing surveillance forms a vital source of safety information. Therefore this study 
utilized population data to identify herb-hepatotoxicity associations. 
7.4 Disproportionality analysis 
In signal detection, disproportionality studies are usually considered exploratory [124]and an 
association between an exposure and outcome does not imply causation. However, the 
stronger the association, the more likely it is causal.  
Statistical analysis can be used to determine if exposure to a certain drug is significantly 
associated with the observed adverse event. A statistically significant association between a 
drug and an adverse event is interpreted as a ‘signal’. Reporting odd ratio (ROR), 
proportional reporting ratio (PRR), Chi square, information component (IC) and empirical 
Bayes geometric mean (EBGM) are statistical tools capable of detecting signals. They are 
currently used by regulatory agencies such as in the UK, WHO and FDA. Non-Bayesian 
methods (ROR, Chi square and PRR) are based on a 2x2 contingency table and consider 
particular drug-event combination (Table 7.2). Bayesian techniques (IC and EBGM) are 
appropriate for multiple drug-event combinations [125]. The detection of a signal depends 
on the statistical method used for detection [126]. Each method has slightly different 
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properties and therefore it would be more appropriate to use one over the other in 
particular situations. However, it has been repeatedly shown that the ROR is the most 
sensitive to signals and it is amongst the most frequently used [126]. ROR is suitable because 
it includes all signals that would have been found using other statistical disproportionality 
tools. 
 
Table 7.2  A 2 x 2 contingency table for statistical analysis of herb/drug-adverse event associations 
 With adverse event of interest Without adverse event of interest 
With herb/drug of interest A B 
Without herb/drug of interest C D 
 
A ROR is calculated by dividing the odds of adverse event with herb/drug exposure over the 
odds of the adverse event without the herb/drug exposure (Equation 4). When a certain 
herb/drug is associated with a particular adverse event, this may be reported more 
frequently than expected in comparison to the reporting frequency of other drugs and 
adverse events in the database[127]. Therefore, this is detected as a signal. In this statistical 
analysis, signals of hepatotoxicity are clearer for herbs with a higher level of usage and 
therefore greater number of reports than for herbs with a low number of reports. A ROR 
above 1 shows an increase in risk in adverse event occurrence with exposure to a drug but 
does not quantify the true risk in absolute terms. A significant ROR means that the 
association between the exposure and outcome is important to investigate further and 
additional evidence, such as temporal association, dose-response relationship and biological 
plausibility of the exposure and adverse event, is needed for a meaningful inference of data 
[125]. Investigation could be a cohort study (case-control), randomized controlled trials or 
experimental pharmacology. Evidence for safety from all these methods should be 
considered for evaluating risk from the herb. In some instances however, a significant signal 
on its own may be considered a sufficient basis for regulatory decisions [125]. 
 
     
ROR =      ROR =   (Equation 4) 
      
 
A / B 
C / D 
A x D 
B x C 
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7.5 Safety discussion – the place of pharmacovigilance in herb safety 
Safety information from pharmacovigilance systems is vital in understanding a drug or herb’s 
complete safety profile [127]. During the drug discovery process, pre-clinical studies and 
clinical studies identify common adverse effects of the new drug. Randomised controlled 
trials in phase II and III of drug development are considered small in size, short in duration 
and homogenous in comparison to the size of the population that will be exposed to the 
product. Therefore, these randomised controlled trials are unlikely to detect rare or long-
term adverse effects[128]. Most information on rare adverse effects or long-term harm is 
derived from pharmacovigilance or observational studies[128]. This is more important for 
herbal medicines because they may be approved based on long-standing use and therefore 
may not require pre-clinical and clinical testing like conventional drugs.  
A drug or herb’s safety can be determined via multiple sources: toxicological and 
pharmacological studies, clinical studies and post marketing surveillance. Evidence from all 
of these evidence sources constitutes a complete and comprehensive safety assessment of 
the drug or herb in question. In the case of herbal products, they may have a record of long 
history of use, which can supplement any safety assessment. For example, in order to 
determine the liver safety of green tea the US Dietary Supplement Expert Committee 
gathered evidence from, 1) clinical case reports of green tea and hepatotoxicity from UK, US, 
Canada, Australia, France and Spain, which were critically analysed, 2) reviewed clinical 
pharmacokinetic and safety studies, 3) reviewed animal pharmacological and in vitro 
toxicological reports and 4) considered the historical and current use of green tea[44]. This 
constituted a thorough and complete safety assessment. There are also examples when a 
certain type of evidence, such as in the case of kava where clinical cases reporting 
association between kava and hepatotoxicity, was the primary basis for regulatory decision 
making[129]. It is rare to find thorough and detailed herb hepatotoxicity assessments, like 
the one for green tea, in the literature. In addition, herbal remedies frequently have 
incomplete safety information in each of these categories and careful consideration is 
needed prior to a final decision on safety status of the herb. In addition, each type of safety 
or toxicity evidence has its limitations. For example, traditional use may not compare with 
current use and in vivo or in vitro studies may not completely represent toxicity in a human.  
Therefore, in this study significant signals are interpreted after considering all of the safety 
evidence available for that particular herb and with consideration of the limitations of each 
data source. 
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7.6 Herb hepatotoxicity signals identified in this study 
Investigation of herb hepatotoxicity at the population level has not been studied before and 
this study was the first to investigate herbal hepatotoxicity associations from 
pharmacovigilance data.  A total of 15 herbs showed a signal (significant ROR and lower 
confidence limit above one) and this section assesses each signal individually to determine 
what new safety or toxicity information the signal provides. As stated previously, a 
significant signal for hepatotoxicity warrants further investigation. Furthermore, a herbal 
medicine’s overall safety is based on all types of safety/toxicity evidence, part of which is 
population safety. Therefore, each signal is considered individually with all other safety or 
toxicity evidence available for the herb to determine if the new information in this study 
alters the herb risk-benefit ratio.  
7.7 Kava 
Kava appeared 20 times in the database with 7 reports being associated with hepatotoxicity. 
This formed a significant signal and the highest of all herbs (ROR 6.813, 95% CI 2.831 – 
16.498). As a significant signal, this suggests kava has an association with hepatotoxicity and 
its potential harm may outweigh its benefit at a population level. However, this signal may 
have been affected by several factors: 
1. Kava use has declined after a hepatotoxicity warning was issued in the US, thereby 
reducing intake and potential for adverse events to occur and be reported in the 
database 
2. Kava was banned in 2002 in several countries and its hepatotoxicity has been hotly 
debated in the literature since the ban. Therefore kava received extra media 
attention, increasing awareness and reporting of liver injury events associated with 
kava exposure 
3. Peak kava use was in late  0’s and reports during that time were not included in the 
search, which contained data from only 2004 to 2011. Reports prior to 1998, before 
kava hepatotoxicity awareness and media attention, may reveal new information 
The sections below discuss evidence for kava’s toxicity or safety and interpretation of the 
observed signal in this study. 
7.7.1 Historic use 
Kava root (Piper methysticum rhizoma) is native to the South Sea Islands, Hawaii, Polynesia 
and Fiji and was cultivated approximately 3,000 years ago. Traditionally, an aqueous extract 
of kava lateral root is used as a beverage to mark important social events, promote friendly 
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discussions and for its medicinal properties [23].  Traditional use and preparation contrasts 
to that in western countries where kava is marketed for anxiety, depression and as a 
sleeping aid and considered to be an alternative to anti-anxiety drugs [4, 23, 55]. Western 
kava preparations are in the form of pills and are prepared using an organic extraction 
process and the extract is standardized to specific kavalactone concentrations.  
Kava has been used safely in the South Pacific for thousands of years and was most popular 
in western countries in the 1  0’s with huge exports mostly to Germany and the US peaking 
in 1998 [130]. At the peak of its popularity, reports of toxicity emerged in Europe and kava 
products were subsequently banned in Germany and Switzerland in 2002, followed by other 
countries like the United Kingdom and France [55] . The US Food and Drug Administration 
(FDA) issued a customer advisory warning regarding the risks of kava. In Germany, 
Commission E, which works closely with The Federal Institute for Drugs and Medical Devices 
(BfArM) as an expert advisory group on herbal medicines, opposed BfArM’s decision. 
Academic and industry experts in commission E stated that BfArM had assigned causality 
beyond what the evidence supported, that the risk-benefit assessment of kava is favourable 
and new kava regulation as a prescription only herbal medicine would be sufficient for risk 
management. Many other academics have shared a similar point of view [130, 131]. 
Studies examining kava hepatotoxicity fall in to two main categories – a clinical causality 
assessment of hepatotoxicity cases with exposure to kava and a toxicological assessment of 
the kava product in vivo and in vitro. Conclusions from these studies are discussed in more 
detail below.  
7.7.2 Clinical safety evidence 
In a study conducted by Stickel et al. in 2003 [65], 7 published cases of kava toxicity were 
analysed with an additional 29 unpublished cases. Each case was assessed systematically for 
drug-induced liver injury. The results showed variable latency and cumulative doses. Nine 
patients developed fulminant liver failure and eight of the patients needed liver 
transplantation. Three patients died and all other patients recovered after kava withdrawal 
[65]. In many of these patients, the recommended dose of 120mg per day was exceeded 
several times and this suggests that the observed toxicity was of a metabolic idiosyncratic 
nature. Two individuals who experienced kava toxicity were found to have a poor-
metabolizer phenotype via CYP450 2D6 possibly predisposing them to kava-induced liver 
toxicity [132]. Several theories have been put forward to explain mechanisms of kava 
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hepatotoxicity and the available data point to an idiosyncratic, immunologic mechanism, 
with a genetic CYP450 2D6 deficiency being a precipitating factor.  
Teschke et al. conducted a study in 2009, to assess the 20 cases declared by BfArM as 
causally related to kava products [133]. The cases were obtained from the regulatory agency 
and where data was incomplete, additional data was requested from reporters, authors and 
pharmaceutical companies. Cases were assessed on the CIOMS causality assessment scale 
and were compared to their respective assessments by the BfArM, MCA (Medicines Control 
Agency, Britain) and EMEA. It was found that causality assessments by the different 
regulatory agencies varied greatly, with weaker causality being found by MCA and EMEA 
compared to BfArM even though the cases were identical. For example, in BfArM’s 
assessment, causality was probable, possible or certain in all the 20 patients, whereas MCA 
assigned 7 cases unassessable, 1 case unlikely and none as certain. This is also different to 
EMEA’s assessment, which assigned 6 cases as unassesable 1 case unlikely and none were 
certain. All three agencies agreed on the assessment of only 2 patients, their assignments for 
the remaining were different. The high variability in causality assessment questions the 
validity of the process used in assessing the risks of kava. Based on the same case 
information, applying the CIOMS scale by the authors excludes 6 cases, 11 cases are unlikely 
and 2 are possible. Repeating the assessment with the supplementary information increased 
the causality assignment to a higher grade. The study concluded that the data used by the 
regulatory agencies was insufficient and lacking in quality, that ad hoc assessment is 
unreliable and a structured tool such as the CIOMS scale should be used. The authors also 
called for a formal re-assessment of kava causality in hepatotoxicity.  
In another study examining the clinical evidence, [131] the 20 cases were closely scrutinized.  
There is only one well-documented case with clear association between kava intake and 
hepatotoxicity, with a positive re-exposure. However, it is also important to note other 
predisposing factors in this patient, such as oral contraceptive intake and previous long term 
paroxetine treatment. Both have hepatotoxic potential and may predispose to kava 
hepatotoxicity. Paroxetine is also an inhibitor of CYP450 2D6 and the patient had also taken 
St John’s Wort, which is a known enzyme inducer. It is therefore possible that a 
pharmacokinetic interaction may have played a role in triggering the toxicity. Other cases 
had missing information such as the latency period, kava product used and exclusion other 
possible causes. In one patient, the latency period of 24 months was considered too long 
and not observed in other cases. In another with a latency of 12 months and an extreme 
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overdose with kava lactones (480mg/day) other causes of liver toxicity were not investigated 
and ruled out. The study concluded that kava toxicity was very probable in only one patient, 
possible in another and excluded or not probable in 5. For the remaining cases, further 
information was needed. This low toxicity rate means that kava hepatotoxicity is real but it 
compares well with other registered drugs and herbal medications. Numerous other studies 
have been conducted to clinically re-assess the cases associated with kava [134, 135] and 
arrived at similar conclusions. 
7.7.3 Pharmacological safety assessment 
Despite the decreasing popularity of kava in western markets, in vivo and in vitro studies do 
not provide straightforward evidence for its toxicity or safety. Kava is a well-studied and well 
chemically characterized herb and the toxicological studies carried out follow the same 
national and international guidelines on toxicity of chemically defined substances regardless 
of their herbal or synthetic origin. They reveal low acute toxicity with LD50 values between 
1.5 and 980 mg/kg for individual constituents (mice, oral)[136]. Chronic dihydrokavain 
administration at 50mg/kg/day for three months in rats did not reveal any toxicity and it has 
so far not been possible to induce hepatotoxicity in rats using kavalactones [136][137].  Kava 
organic and aqueous extracts have also been administered to rats with no evidence of 
hepatotoxicity up to 1g/kg/day kavalactones. On the other hand, in vitro studies have shown 
evidence of toxicity [138]. In one study, isolated rat livers were perfused with kawain 
solution (10 μg mL) for two hours and light and electron microscopy examination revealed 
severe vascular and endothelial damage[139]. This effect may be due to kawain’s direct 
effect on endothelial lining or through activation of the liver associated macrophage 
population (Kupffer cells), which in turn release cytotoxic substances leading to tissue 
damage[139]. A follow up study administered kava lactones to perfused rat livers pre-
treated with gadolinium chloride, which depletes liver macrophages [140]. Electron 
microscopy results showed significant damage to sinusoidal endothelial cells with 
kavalactone administration. Liver pre-treated with gadolinium chloride did not show 
statistically significant difference to control in sinusoidal cell damage[140]. Therefore, this 
study shows that liver macrophages play a role in kava-induced liver injury. In an in vivo 
study, administration of kava extracts at five dose levels between 0.125 and 2 g/kg/day to 
rats resulted in increases in GGT, hepatic hypertrophy and changes to CYP enzyme levels 
within the 14-day treatment period [137]. Further studies are required to investigate how in 
vitro and in vivo results apply to humans and to further investigate long term effects of kava 
exposure. Olsen et al. concluded that in order to induce hepatotoxicity in rats, it would 
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require an administration of 0.5-1g of kava lactones per kg per day for 1 to 3 months [141]. 
Other authors conclude from the same or similar data that kava appears to be safe under 
normal experimental conditions [131].  
7.7.4 Pharmacovigilance safety evidence 
Many researchers agree that the risk-benefit balance for kava is favourable[130]. According 
to sales figures in Germany, it can be calculated that approximately 250 million daily doses 
were sold between 1990 and 2000 [134]. If all the German and Swiss cases were considered 
to be certainly caused by kava, then kava hepatotoxicity would have an incidence of 0.24 
cases per 1 million patients. The real incidence would be much smaller than this of course, 
given that not all cases are caused by kava. Other sources calculate 0.008 cases per million 
daily doses[137]. In comparison to other drugs, such as benzodiazepines (between 0.9 and 
2.12 per million daily doses), which have similar indications to kava, kava has a low 
hepatotoxicity incidence [134, 142, 143]. Kava market restriction means that users would 
resort to alternative medication with a significantly higher hepatotoxicity risk. Both of the 
kava and benzodiazepine daily doses are calculated with the assumption that ‘sold’ doses 
are consumed. 
7.7.5 Overall safety 
Although kava hepatotoxicity has received negative media attention and some regulatory 
bodies have banned kava use, a thorough analysis of all the evidence draws different 
conclusions about kava’s risk benefit ratio.  Epidemiological and toxicological evidence show 
that kava appears to be safe when consumed at recommended doses and the possibility of 
hepatotoxic reactions is lower than that for registered drugs. In addition, kava appears to be 
safe when consumed in the traditional way. Regulatory bodies post marketing assessments 
mostly used clinical case reports, which lacked essential information and were generally 
poorly documented reports. It is possible that the signal observed in this study was 
confounded to some degree by the factors mentioned earlier. Although the signal may not 
change the balance of evidence toward hepatotoxicity, it is a significant signal and requires 
further investigation to ascertain causality.  
7.8 Valerian 
7.8.1 Historic use 
Valerian (Valeriana officinalis) is native to Europe and parts of Asia and its use dates back to 
ancient Greece and Rome [136, 144]. It is traditionally used for insomnia, anxiety, digestive 
and urinary problems [67].  
 128 
 
7.8.2 Clinical safety assessment 
Evidence for valerian-induced hepatotoxicity is derived from a clinical analysis of case 
reports. Four cases were reported in 1989 with Neurolax® or Kalms® intake, which are 
believed to contain valerian and/or skullcap [145]. Other reports are similar [146-149] with 
patients reporting long-term valerian consumption often in combination with other herbs. 
To date, there has been no formal systematic causality assessment of all the valerian 
hepatotoxicity case reports and no other direct evidence of hepatotoxicity.  
Meta-analyses and randomised controlled trials have differed on how effective valerian is in 
treating insomnia and anxiety but have all concluded that valerian is safe [67]. Its safety is 
superior to that of alternative treatments such as benzodiazepines and other 
hypnotics[150].  
7.8.3 Pharmacological safety assessment 
Toxicological studies challenge the inferred valerian hepatotoxicity. Animal studies show 
unremarkable acute toxicity with large doses of valerian extract (600mg/kg/day) over 30 
days [151], an LD50 of 3.3g/kg for valerian extract and no significant toxicity with chronic 
exposure [152]. In fact, Tabach et al. suggests that valerian may be considered atoxic 
because the LD50 of the extract is above 5g/kg [153]. Human trials also challenge valerian 
hepatotoxicity [154].  
In vivo studies using valerian extract in rats reveal no signs of toxicity. In a study by Vo et al. 
(2003), chronic valerian administration in rats revealed no signs of liver toxicity (no changes 
in bilirubin, ALT, GGT or ALP and in bile flow). The results of this study do not rule out 
hepatotoxicity by valerian. It is possible that herb-herb or herb-drug interactions in the 
reported clinical cases led to the toxicity and it is also possible that due to species 
differences, the human liver is more susceptible to valerian hepatotoxicity.  
7.8.4 Overall safety 
In light of the case reports as evidence for valerian hepatotoxicity, it seems that there may 
be a possible association. Although animal safety and toxicological studies show valerian is 
safe, idiosyncratic hepatotoxicity is rare and may be detected in a population of 10,000 or 
more consumers. This means that it is unlikely to have been detected in toxicological tests or 
randomised controlled trials. The results of this study, with a significant signal for 
hepatotoxicity (ROR 3.618, 95% CI 2.489 – 5.261), which significantly associates with 
immune features, adds further evidence to the theoretical association. Valerian is a widely 
used herb and present in numerous over the counter sleep and relaxation products[155]. 
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Given its widespread use and possible hepatotoxicity association, its liver safety requires 
further investigation.  
7.9 Herbalife ® 
7.9.1 Historic use 
Herbalife® is the name of a company that sells nutrition, weight management and skin care 
products. Herbalife® markets a wide range of products in the form of protein shakes, protein 
snacks, nutrition, energy supplements and topical personal care products in 91 countries 
through 3.2 million independent distributors[156].   
In this study, cases with Herbalife® exposure were identified as any case with the word 
‘Herbalife’ contained in the drug name field. The signal observed in this study (ROR 3.4 3, 
95% CI 1.503 – 8.118) therefore included any Herbalife® product identified as such with no 
differentiation between specific products.  This was due to the inherent ambiguity and 
inaccuracy in the ‘drug name’ fields making accurate product searching a challenge. Instead, 
a frequency of the terms used was collected (See section 5.9). It is interesting to note that 
although Herbalife® sells numerous products with different compositions; suspected toxicity 
cases in the literature have considered Herbalife® products as one group. 
7.9.2 Clinical safety assessment 
Evidence for Herbalife toxicity has so far only been derived from a handful of case reports. 
Herbalife® products have been popular since their launch in 1980. The first cases of 
hepatotoxicity were only noted in 2004 in Hadassa medical centre, Israel when 4 patients 
experienced unexplained liver injury and had consumed Herbalife® products [157]. This 
sparked a joint investigation by the Israeli Ministry of Health and a total of 12 cases of 
unexplained hepatotoxicity were identified associated with Herbalife® consumption. All 
patients had consumed at least five different Herbalife® products and two developed 
fulminant hepatic failure. Using the WHO causality scale, causality was certain in 3 cases, 
probable in 6 and possible in 3. Liver enzyme levels normalised in all patients when 
Herbalife® product(s) were withdrawn except for one deceased patient.  
About the same time, another group of 10 hepatotoxicity cases were picked up in 
Switzerland, which implicated Herbalife® product intake [56]. Data was obtained from 
hospitals, departments of pathology and the Swiss pharmacovigilance database in a 
retrospective analysis. The WHO scale was used to ascertain causality and was found to be 
certain in 2 cases, probable in 7 and possible in 1. The authors evaluated the evidence as 
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substantial for Herbalife® hepatotoxicity. However, the estimated incidence was low 
(1.8/106/year) and therefore Herbalife® products were not considered a threat to public 
health. The calculation is based on 10 cases identified in a 7-year period in a population of 
approximately 80,000 Herbalife® consumers. In addition, another two studies from Sweden 
and Spain also identified 10 cases each [46]. 
Although the above two studies present seemingly convincing Herbalife®-hepatotoxicity 
associations, the clinical assessment of the cases is limited in important ways: 
 Unclear product identification. The patients in the reports had consumed multiple 
dietary supplements (between 3 to 12 products taken concurrently) and it is 
unknown which product is the primary suspect. 
 Unknown product ingredient(s)/composition. The company has not revealed the 
ingredients used and researchers can only speculate that Camellia sinensis, Ephedra 
sinica, N-nitroso-fenfluramine or Paullinia cupana caused the toxicity. Unknown 
product composition severely limits causality assessment and can only allow general 
assumptions to be made.  It is also unknown what extraction processes or plant 
parts were used. 
 Questionable dietary supplement intake information. Patients’ did not report dietary 
supplement intake unless insistent questioning was used and some patients were 
unsure or vague about their intake and its time. This severely limits the validity of 
the specific cases involved.  
 Missing essential information for causality assessment: 
o Patient pre-existing health status was inadequately described. Indications 
for dietary supplements are only briefly mentioned in Elinavet al.[157]and 
not mentioned in Schoepfer et al[56].  
o Doses consumed by patients were not mentioned – it may be that overdoses 
or cumulative doses that contribute to toxicity. 
o Start and stop dates for dietary supplement intake, symptom onset date – 
liver disease emerging 2.5 months to 2 years after cessation may rule out 
this dietary supplement in the causation [30] 
o Liver injury criteria not mentioned in Elinav et al.[157] 
 Presence of confounding factors: 
o Underlying liver disease in some patients  
o Recurrent liver enzyme elevation despite dietary supplement cessation  
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 Liver injury criteria were not defined by the authors in Elinav et al. 
Eight patients have been reported to have positive re-exposure with Herblife®. Positive re-
exposure is usually regarded a gold standard in causality assessment. However, cases must 
meet certain requirements for a valid reliable conclusion to be drawn, for example, baseline 
liver enzyme levels prior to re-exposure are required. Only one case was found to contain 
sufficient detail for a reliable positive re-exposure. One case was classified as negative and 
the remaining seven cases were uninterpretable due to missing crucial information [62].  In 
addition, a re-evaluation using liver specific CIOMS criteria resulted in lower causality scores 
for each case. Therefore, the strength of causality in Herbalife cases had to be downgraded. 
7.9.3 Pharmacological safety assessment 
No pharmacological or toxicological evidence are available. 
7.9.4 Overall safety 
All the currently known evidence for Herbalife® hepatotoxicity has been derived from clinical 
analysis of case reports of variable quality. These cases form weak evidence for Herbalife-
hepatotoxicity association. The observed significant signal in this study adds evidence for 
suspected Herbalife- hepatotoxicity associations. The signal was also significantly associated 
with immune features, which warrants further investigation. However, it is important to 
note media attention may have affected this signal, for example when an affected patient in 
Israel sued Herbalife®[158]. Further epidemiological and toxicological studies are required to 
investigate a definite causal relationship and its possible mechanisms.  
7.10 Chinese medicine 
It was observed in the study that numerous entries referring to Chinese medicine, simply 
reported drug exposure as ‘Chinese medicine’. ‘Chinese medicine’ encompasses a very wide 
range of herb and animal derived remedies. Further investigation into specific Chinese herbs 
is required to infer a meaningful conclusion on the individual herbs association with liver 
injury. Although a number of entries contained specific Chinese herbs in the database, there 
were several limitations in searching for Chinese herbs that prevented further analysis: 
1. Spelling. Chinese herbs may be reported in many different English spellings. For 
example, Dai Saiko To and Daisaikoto. 
2. Japanese vs. Chinese names. Some Chinese herbs are reported with their Japanese 
name written in English. For example, Onshido and Chaso. 
 132 
 
3. Multiple names for one Chinese herb. For example, He Sho Wu and Ho Sho Wu or 
Boh Gol Zhee and Bu Ku Zi. 
Compiling a list of possible misspellings, multiple names in Chinese and multiple names in 
different Asian languages for Chinese herbs was considered outside the scope of this project. 
Therefore it was not possible to detect herb specific signals for Chinese herbs.  
The signal from this study for Chinese herbs in general confirms the association previously 
known in the literature between specific Chinese herbs and liver injury. Herbs such as Ba Jiao 
Lian, Bai Fang, Boh Gol Zhee, Chaso, Chi R Yun, Ho Shou Wu, Dai Saiko To, Shenmin, Sho 
Saiko To, Shou Wu Pian, Shu Ling and Xiao Chai Hu Tang have been previously associated 
with liver injury[144].The level of evidence for each herb varies from anecdotal evidence to 
well documented clinical case reports. In either case, it is important to note the context in 
which traditional Chinese medicines are used to understand their signals in general. Herbal 
medicines comprise a large part of Traditional Chinese Medicine (TCM), which also uses 
acupuncture and massage. There are over 100,000 herbal formulae and the composition is 
usually of four herbs: the Emperor, the Minister, the Assistant and the Envoy depending on 
their role in the mixture. The emperor herb gives the main therapeutic effect, the minister 
enhances this effect, the assistant may either enhance the effect of the emperor or minister 
or reduce unwanted effects and the envoy guides all the herbs to the treatment site[159]. 
The selection of a herbal formula depends on the patient’s pattern of disharmony between 
entities in the body or between the body and the environment and this pattern 
differentiation is therefore the most crucial aspect in TCM. Restoring the harmony or 
balance is the aim of TCM. It is also patient specific and two patients who present with the 
same disease but different patterns of disharmony and therefore receive different 
treatments or two patients with different diseases are treated with the same treatment 
[159]. In addition to patient-specific treatment, herbal formulae only work in the 
combinations selected and not in isolation. This is because the overall therapeutic effect is a 
combination of numerous low-potency herb chemical constituents[159].  In this framework, 
evidence for hepatotoxicity for a single ingredient in TCM herb may be out of context, 
misleading or incomplete. In addition, TCM herbals consumed via non-traditional methods 
may have different effects and these factors must be taken into account in TCM safety 
assessment.  The significant signal in this study is non-specific and not all TCM herbal 
medicines are hepatotoxic. Further research is required for product-specific associations in 
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population data. Furthermore, research is required into combination or multi-ingredient 
traditional remedies because that reflects the way in which these are consumed.  
7.11 Unspecified herb 
It was observed that herbal remedy entries were often reported as ‘herb’, ‘plant extract’ and 
‘botanical remedy’. It is evident from this signal that herbal remedies may be significantly 
associated with liver injury. Herbal remedies are a very large group of very diverse herbs and 
it is difficult to make further conclusions from this signal (See section 7.20). The number of 
non-specific entries for herbs exceeds herb-specific entries in many instances and this 
illustrates the poor reporting quality for herbal medicines. 
7.12 Ginseng 
The results of this study showed a significant signal for ginseng (ROR 1.826, 95% CI 1.175 – 
2.837), which was also significant for immune features.  
7.12.1 Historic use 
Ginseng is a popular herbal remedy in Eastern and Western populations, including the US, 
being the fourth highest selling herb in 2002 [160]. Ginseng is native to eastern Asia, mostly 
Korea and China and has been in use for at least 2000 years [161]. Plants belonging to the 
Panax genus are considered true ginseng. Although American ginseng, Japanese ginseng and 
Siberian ginseng are also called ginseng, they have distinctly different functions. Ginseng is 
highly prized in Traditional Chinese Medicine. It is considered a panacea remedy and used in 
various conditions including hypodynamia, anorexia, shortness of breath, palpitation, 
insomnia, impotence, haemorrhage and diabetes [161]. It is important to understand 
traditional use of ginseng in the context of Traditional Chinese Medicine practices in which a 
herbal remedy is administered in a way to restore the balance in the body with emphasis on 
patient-specific treatment (See section 7.10). Modern techniques have revealed that 
ginsenosides, which are the bioactive constituents, also have anti-oxidant, anti-
inﬂammatory, anti-apoptotic and immunostimulant properties. Ginseng, in the form of 
tablets and capsules, has been marketed in the Western world for these properties.  
7.12.2 Clinical safety assessment 
There are two reports of hepatotoxicity involving ginseng and other medications. One 
patient experienced liver enzyme elevations, jaundice and significant weight loss 39 days 
after starting Panax ginseng lozenges [49]. The patient was HIV positive, had long-term 
hepatitis C and was on raltegravir, lopinavir, ritonavir, aspirin and esomeprazole. Ginseng’s 
 134 
 
association with the liver injury was assessed as ‘probable’ on the RUCAM scale and was 
attributed to ginseng-raltegravir interaction. Ginseng is a known CYP3A4 inhibitor and may 
have therefore increased plasma concentrations of raltegravir. The second patient 
experienced right upper quadrant pain after three months of taking an energy drink 
containing Panax ginseng daily [162]. The patient was also on imatinib for the past 7 years. 
Liver enzymes were found to be elevated, liver biopsy showed lobular hepatitis and the 
patient was diagnosed with imatinib-induced hepatotoxicity. The case resolved with both 
ginseng and imatinib cessation and corticosteroid treatment. Imatinib was then restarted 
with no further liver enzyme elevations. This reaction was also attributed to a herb-drug 
interaction mediated via CYP3A4.  There are no other clinical reports in the literature on 
ginseng hepatotoxicity. In ruling out the possible causes of the hepatotoxicity, the authors 
relied on the fact that there are no reports in the literature of ginseng hepatotoxicity. 
Although absences of previous toxicity reports diminish suspicions of association, ginseng-
associated toxicity in a susceptible individual still remains a possibility. It is also possible that 
ingredients other than ginseng in the energy drink consumed in the second case contributed 
to the toxicity, this was not excluded by the authors. 
7.12.3 Pharmacological safety assessment 
Numerous studies have been conducted to examine the hepatoprotective effects of several 
ginseng varieties and extracts. In these studies similar exposure scenarios were used in 
which ginseng is administered to rat or mice prior to inducing liver injury with carbon 
tetrachloride, alcohol or acetaminophen [163-167]. Hepatoprotection was evident as 
significantly reduced liver enzyme levels and reduced hepatic necrosis in histology samples 
in the ginseng treatment group compared to control. These effects were attributed to 
ginseng scavenging of reactive free radicals, up regulating anti-oxidant enzymes (superoxide 
dismutase, glutahione peroxidase and catalase), restoration of hepatic glutathione and down 
regulation of the inflammatory response [164, 167].  
There is only one study identified in the literature that examined the effects of ginseng on 
the liver and other body organs from a neutral perspective[168]. Beagle dogs were given 
intravenous administration of compound K, which is the main metabolite of the 
protopanaxadiol type ginseng saponins. Therefore, when ginseng is consumed, gingenosides 
such as Rb2, Rb3, Rc, Rb and Rb1 are transformed mainly into compound K by intestinal flora 
and it is one of the main compounds absorbed. Hepatoprotective, anti-inflammatory and 
anti-cancer properties of ginseng have been shown to be mediated by this compound. Over 
the 90-day treatment period, the dogs showed significantly increased liver enzymes (alanine 
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aminotransferase, gamma gluamyltranspeptidase and alkaline phosphatase) and slight liver 
histology changes. These results indicate possible hepatotoxicity potential of ginseng 
metabolite, compound K.  
It is apparent from the available literature that far greater effort has been spent in 
investigating hepatoprotective effects of ginseng than investigating its safety from a neutral 
perspective. They also highlight two important points. Firstly, hepatoprotective and 
hepatotoxic effects may both be properties of one herb and the observed effect depends on 
the exposure scenario. For example, some herbs exhibit hepatoprotective effects when 
administered prior to induced liver injury and aggravate liver injury when administered 
afterwards[169, 170]. Second, ginseng administration as a whole herbal extract and isolated 
extracts may also lead to different effects. Therefore, from the available information on 
ginseng in vivo safety, it may be concluded that further information is required to uncover 
ginseng’s effects on the liver under different exposure scenarios.  
7.12.4 Overall safety 
Although no clinical reports on ginseng hepatotoxicity have been reported, ginseng is 
significantly associated with liver injury in this study. Ginseng is not indicated in liver damage 
as part of its traditional use and therefore this is an unlikely confounder for this signal. 
Therefore, the signal in this study adds evidence to the possible association between ginseng 
and liver injury and warrants further investigation.  
7.13 Senna 
7.13.1 Historic use 
The use of senna (Cassia acutifolio, C. angustifolio, Senna alexandrina) dates back to the 9th 
century in the Middle East and is also used in traditional Chinese and Indian medicine [171] . 
Traditionally, the leaves are brewed in a tea and consumed to treat constipation and 
topically for infections. Laxative activity has been attributed to sennosides, which act as a 
local irritant in the colon and stimulates peristalsis and evacuation. Adverse effects are 
generally mild and include diarrhoea and abdominal cramps. Less commonly, senna can also 
cause hepatotoxicity. Senna is not usually included in herbal hepatotoxicity reviews [4, 55, 
66] and briefly cited in others [1, 74] but is very widely consumed product with easy access 
over-the-counter and with known hepatotoxic components.  
Sennosides, being hydroxyanthracene glycosides, are anthraquinone derivatives. In the gut, 
they are split into rhein anthrone by E. Coli and other gut bacteria, which may be absorbed 
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and then undergo hepatic metabolism and clearance via glucuronidation and sulphation [52, 
74, 172]. Rhein anthrones, being hepatotoxins, are structurally similar to danthron, which is 
a well-known hepatotoxic laxative. In addition, anthraquinones in rhubarb, aloe and cascara 
have also been implicated in liver disease. Mitoxantrone, an anti-neoplastic drug used in the 
treatment of metastatic breast cancer and other cancers, is an anthraquinone derivative 
similar in structure to rhein anthrone and known to cause liver enzyme elevation and liver 
impairment [173]. Exifone, used in the treatment of cognitive memory problems in the 
elderly, is also structurally similar to anthraquinones and has been withdrawn from the 
market due to cytolytic hepatitis [173].  
7.13.2 Clinical safety assessment 
Despite senna’s common use, there have only been 4 reports of hepatotoxicity described in 
the literature [47, 172, 174, 175]. Beuers 1991 described a 26-year-old lady who had 
consumed ten times the recommended senna dose in a laxative tea. Symptoms returned on 
re-exposure. Vanderperren et al.[174] described in comprehensive detail the case of a 52 
year old woman who had taken senna herbal tea for over 3 years with no other medications 
who developed acute hepatic failure and required intensive care. No other possible causes 
for the liver toxicity were found. Laboratory analysis showed the senna product used 
complied with European Pharmacopoeia. However, high cadmium levels in urine suggested 
metal contamination. The water used to make the tea contained similar cadmium levels and 
although suitable for drinking (WHO standards) it could have contributed to the toxicity. 
Senna was a possible cause of the toxicity (Naranjo scale) and the study concluded that 
chronic senna use exposing individuals to large doses may lead to hepatotoxicity. It is 
interesting to note that while human cases are limited in the literature, there are numerous 
reports of farm animal liver toxicity due to senna ingestion. The senna species concerned 
(occidentalis) also contains anthraquinones as their major substance, similar to senna 
alexandrina, which is used for medical purposes [176]. Currently there are no marketing 
restrictions on senna products and it may be purchased over-the counter. Consumer and 
health professional information sheets highlight hepatotoxicity risks in registered products.  
7.13.3 Pharmacological safety assessment 
There are no pharmacological or toxicological studies examining senna’s hepatotoxicity. 
7.13.4 Overall safety 
The cases described in the literature provide weak evidence for hepatotoxicity because of 
their very small number and lack of detailed information for a thorough causality 
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assessment, except for the one detailed case described above. In addition, further 
pharmacological and toxicological investigations are required. The signal in this study adds 
further evidence to senna’s hepatotoxicity and this warrants further investigation. 
7.14 Gingko 
In this study, a significant signal was observed for ginkgo (ROR 1.400, 95% CI 1.141 – 1.716). 
This may interpreted in light of the literature evidence below. 
7.14.1 Historic use 
Ginkgo is native to central China and has been used for thousands of years for a wide variety 
of illnesses. The current use of ginkgo is mainly for neuroprotection such as in dementia, 
memory loss and Alzheimer’s disease. It is also used for tinnitus, macular degeneration and 
glaucoma [67, 110]. 
7.14.2 Clinical safety assessment 
There are no reports in the literature for liver injury associated with ginkgo intake.  
7.14.3 Pharmacological safety assessment 
Several in vivo studies have shown the protective effect of ginkgo extract on rat or mouse 
liver. Yao et al. (2007) showed that administration of ginkgo biloba extract to rats protected 
against alcohol-induced hepatotoxicity over a 90-day exposure period[177]. Further 
investigation into the mechanisms revealed that ginkgo extract induced expression of 
haemeoxygenase-1, which is involved in cellular stress-damage resistance. 
Haemeoxygenase-1 up regulation enhances cellular antioxidant capacity and thus attenuates 
alcohol-induced liver injury. Yang et al. (2011) found similar hepatoprotective results when 
ginkgo extract was administered to rats prior to carbon tetrachloride-induced liver injury 
[178]. The hepatoprotective effects were attributed to ginkgo’s ability to scavenge free 
radicals and augment glutathione and superoxide dismutase, which form part of the cellular 
antioxidant defence. Another study also demonstrated hepatoprotective effects of ginkgo 
extract in guinea pigs [179]. Ginkgo extract decreased liver lipid peroxidation and serum liver 
enzyme levels to the same extent as silymarin therefore implying the same level of 
hepatoprotection. Ginkgo’s hepatoprotective mechanism may be by supporting the cellular 
antioxidant defence system, which is composed of glutathione, superoxide dismutase and 
catalyse [179, 180].  
On the other hand, in vitro studies have shown opposite effects. Ginkgo pre-treatment in 
cultured hepatocytes with acetaminophen aggravated the cytotoxicity [181]. Constituent 
 138 
 
specific analysis revealed that ginkgolide A induced this effect by inducing CYP3A4. 
Ginkgolide B, ginkgolide C, gingkolide J, quercetin, kaempferol, isorhamnetin and 
isorhamnetin-3-O-rutinoside however, did not aggravate acetaminophen toxicity.  
The results of the above studies lead to tremendously different conclusions regarding ginkgo 
hepatotoxicity. The contradicting results can be partly explained by the different ginkgo 
product/extract used. For example, Rajaraman et al. (2006) used ginkgo extracts with 
quantified ginkgolide A, whereas Yao et al. (2007) and Yang et al. (2011) purchased standard 
ginkgo extract and specific constituent amounts are not reported. Pimaroo et al. (2014) used 
gingko extract containing ginkgolide B, C, bilobalide and traces of ginkgolide A and J. It may 
be possible that ginkgolide A in high quantities is hepatotoxic and other ginkgo components 
are hepatoprotective. It is important to note again these studies represent one exposure 
scenario and therefore cannot serve as evidence for absolute hepatoprotective or 
hepatotoxic attributes of ginkgo.  
7.14.4 Overall safety 
There is no convincing evidence of gingko’s hepatotoxicity or hepatoprotection. There are no 
clinical cases with suspected ginkgo involvement. However, ginkgo is a widely consumed 
herb and the signal in this study suggests that there is a significant association that warrants 
further investigation. The signal in this study was also significant for jaundice, cholestasis 
and hepatic cirrhosis, which provides information on the nature of ginkgo-associated 
hepatotoxicity. 
7.15 Hoodia 
Hoodia showed a strong signal relative to other herbs searched in the database (ROR 7.195, 
95% CI 2.538 – 20.396) which was significant for liver injury, steatosis and jaundice.    
7.15.1 Historic use 
Hoodia has been used for thousands of years by the San tribes of the Kalahari Desert in 
Southern Africa. Hoodia fresh stems are consumed as a food, appetite suppressant in long 
hunting trips and thirst quencher with no preparation prior to consumption [182, 183]. 
Hoodia may also be used for indigestion and minor infections. Traditional use and 
preparation are very different in the traditional use population as compared to the Western 
population, who receive hoodia in the form of extract in a tablet or capsule. There are no 
reports of hepatotoxicity in the traditional population. 
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7.15.2 Clinical safety assessment 
There are no reports of liver toxicity associated with hoodia intake in the literature. In a 
small clinical trial investigating hoodia weight loss efficacy and safety, there were no serious 
adverse events [63]. However, treatment with hoodia gordonii purified extract showed 
minor but significant increases in alkaline phosphatase and bilirubin at the end of the 15-day 
trial. The clinical significance of this is unclear because there were no other elevations in 
liver enzymes and no haemolysis [63].  
7.15.3 Pharmacological safety assessment 
There are no published articles on hoodia hepatotoxicity in vivo or in vitro. However, there 
are a few studies on hoodia pharmacokinetics and tissue distribution, which may be used to 
gain some context for the observed hepatotoxicity signal in this study. A pharmacokinetic 
study examining tissue distribution was conducted on P57AS3 (P57), which is an 
oxypregnane steroidal glycoside in hoodia and the only known constituent with anorexigenic 
activity, showed that P57 was present in highest amounts in kidney than in liver tissue in 
mice [184]. A pharmacokinetic study investigating phase I and phase II metabolism showed 
P57 was extensively metabolised by liver microsomes (>70% metabolised in 60 minutes) and 
was found to inhibit CYP3A4. Therefore, hoodia may interact with other drugs metabolised 
by CYP3A4 and alter their efficacy or toxicity [185].  
7.15.4 Overall safety 
Hoodia is not considered as a plant with possible hepatotoxicity association in the literature 
and there is very little evidence for this. The observed signal in this study draws attention to 
the possibility of hoodia intake being linked with liver injury and therefore warrants further 
investigation.  
7.16 Black cohosh 
7.16.1 Historic use 
Black cohosh (Actaea racemosa/Cimicifuga racemosa) plant is found in eastern USA and in 
Canada. It is mainly used for menopausal symptoms and also for joint pain, myalgia, 
bronchitis and weight loss.  
7.16.2 Clinical safety assessment 
By 2007 there were three reports of Black cohosh hepatotoxicity [186-188] that formed the 
basis of what was known of Black cohosh hepatotoxicity. Although the toxicity required liver 
transplant in two cases, the association was only probable and hepatotoxicity was therefore 
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considered a rare event [55]. Since that time however, 82 additional cases have been 
reported [189]but reviewers have disputed Black cohosh causality. Teschke et al., reviewed 
69 of the reports available before the time of publication and applied the Council for 
International Organizations of Medical Sciences (CIOMS) scale to assess causality in each 
case [190]. The study concluded that one patient had a possible causality for Black cohosh 
and the remaining 68 cases were either excluded, unrelated, unassessable or unlikely to be 
causal. The authors draw attention to the numerous confounding factors encountered, 
among them were failure to identify the Black cohosh product, use of herbal mixtures with 
multiple herbal ingredients or co-medication with other herbal products, missing temporal 
association, pre-existing liver disease and insufficient exclusion of other pre-existing liver 
disease. Many cases suffered from poor documentation that hindered causality assessment, 
for example, cases omitted information about the doses consumed and duration of herb 
exposure. These factors illustrate the current limitations of herbal safety assessment. In 
another study, Naser et al. conducted a meta-analysis of randomized controlled trials that 
included a total of 1,117 patients to assess Black cohosh effect on liver function. The study 
found no evidence of hepatic injury [191]. It must also be noted however, with regard to the 
study by Teschke et al, that the CIOMS scale for causality assessment is not yet a universally 
accepted method to determine drug-induced liver injury and it comes with limitations [45, 
192, 193]. In addition to this, the number of toxicity reports that may be associated with 
Black cohosh are increasing and regulatory authorities have concluded that a signal of safety 
concern is emerging. Such signals may not be visible in studies of 10,000 or less patients. In a 
US Pharmacopoeia review by Mahady et al., 30 case reports of black cohosh hepatotoxicity 
were assessed. The study used the Naranjo scale for assessment and found that all the 
reports were of possible causality and none were probable or certain [24]. The study 
concluded that based on the results, the Dietary Supplement Information Expert Committee 
would now require all Black cohosh products to be labelled with a cautionary statement. 
These conclusions are in line with assessments by government agencies in Britain, Canada 
and Australia [194-196] that have also issued warnings or cautionary labelling.  
7.16.3 Overall safety 
The case reports form most of the clinical evidence for black cohosh hepatotoxicity. The 
significant signal adds evidence for association. Further studies are required to ascertain 
causality and identify mechanisms of hepatotoxicity.  
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7.17 Green tea 
The results of this study show a clear significant signal for green tea (ROR 1.838, 95% CI 
1.103 – 3.063) and this signal may supplement safety information already known about 
green tea, discussed below.  
Green tea is also a component of numerous products including Hydroxycut® and Herbalife® 
products. The evidence for their toxicity is considered separately.  
7.17.1 Historic use 
Green tea (Camellia sinensis) has been widely consumed for over 50 centuries and 
considered a health beverage since ancient times. In Traditional Chinese Medicine, green tea 
is recommended for headaches, body aches, digestion, detoxification, energizing the body 
and to prolong life[169]. Popularity and widespread use have expanded from the Middle 
East and Asia to Europe and the US and now considered the mostly widely consumed 
beverage worldwide after water. This popularity was partly stimulated by scientific evidence 
for the claimed health benefits in reducing cholesterol, reduced risk for some cancers and 
promoting healthy body weight[197]. Numerous weight control products in the form of 
capsules and tablets now contain the main catechin component of green tea extract, 
epigallocatechin-3-gallate (EGCG) [169]which is responsible for weigh loss effects [198].  
7.17.2 Clinical safety assessment 
Safety concerns arouse from a number of hepatotoxicity reports between 2002 and 2005 
[199]. In a literature review of the clinical cases, 34 cases were identified between 1999 and 
October 2008 with green tea consumption and hepatotoxicity, seven who experienced 
positive rechallenge[43]. Possible confounders were identified in some cases, including 
concomitant medication (paracetamol, diclofenac, progestogens) and adulteration (with n-
nitrosofenfluramine). Excluding cases with confounders, there were 27 cases with 
hepatotoxicity associated principally with green tea consumption. The authors concluded 
that this formed sufficient evidence for a causal relationship between green tea 
consumption and hepatotoxicity. It must be noted however, that this review does not 
present a critical analysis of the information required for each case to be valid evidence for 
toxicity. Data on indications for herb use, doses consumed, chemical analysis of implicated 
products and adequate differential diagnosis were not presented. This information is 
essential for acceptable causality assessment and therefore it is not possible to reliably 
conclude that these cases form sufficient evidence for green tea hepatotoxicity. A careful re-
assessment, taking into account the vital missing information, frequently reduced the 
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causality assessment score[30, 54]. In addition, the article does not mention criteria required 
for a positive re-challenge.  Re-assessment of positive re-exposure cases with clear criteria 
also reveals that the data suggests a lower level of causality than previously suggested[54]. 
Further case report evidence for green tea extract and liver injury is present in other 
publications [40, 199]. In addition, the US Pharmacopoeia conducted a review of green tea 
safety in response to Exolise® withdrawal in Spain and France due to hepatotoxicity cases 
[43, 44, 144]. The study was a thorough literature search for published reports plus reports 
from US Medwatch, USP MEDMARX, Australian Therapeutic Goods Administration, UK 
Medicines and Healthcare products Regulatory Agency, Canadian Adverse Drug Reaction 
Monitoring Programme and French and Spanish reports. Causality was determined to be 
‘possible’ in 27 cases and ‘probable’ in the remaining 7 cases using the Naranjo scale (total of 
34 liver injury cases with green tea consumption). Confounders, such as poly-herbal 
formulations and concomitant drugs, and limited information in the reports made causality 
assessment difficult. The Dietary Supplement Safety Committee concluded that individual 
case reports for green tea hepatotoxicity were weak, however considering pharmacokinetic 
and toxicological data, the total body of evidence points to potential risk. Therefore, green 
tea extracts were reclassified as ‘Class 2’ dietary supplement and required a warning label 
for all products, which alerts consumers to livery injury symptoms and to seek medical 
advice in such a case.   
Gallo et al. (2013) presents a case of liver injury in which predisposing factors were 
identified. The patient was diagnosed with autoimmune hepatitis triggered by an acute toxic 
damage. The patient was taking oral contraceptives, irbesartan and high concentration 
green tea infusion and was found to have genotypes for reduced glutathione-related 
detoxification pathways[200]. Therefore, predisposing factors included female gender, 
genetic predisposition toward oxidative damage, herb-drug interactions and high dose 
resulting in an abnormal response to mild toxins.  
7.17.3 Pharmacological safety assessment 
EGCG is a catechin, which is a flavan-3-ol and a subtype of polyphenol (Figure 7.1). 
Polyphenols and flavan-3-ols are known for their antioxidant properties. However, it is also 
becoming apparent that polyphenols have pro-oxidant properties. 
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Figure 7.1 EGCG chemical classification 
Many experiments were undertaken to investigate EGCG hepatotoxicity in vivo and in vitro. 
In a study by Saleh et al. (2013) EGCG was administered to mice with and without 
lipopolysaccharide (LPS) [169]. LPS is a known inflammogen that induces fever and therefore 
represented health-compromised mice with a predisposing factor for liver injury. This was 
the first study of its kind to examine idiosyncratic herb induced liver injury with a 
predisposing factor. The results showed that low EGCG (750 mg/kg IG) with LPS (6mg/kg IP) 
resulted in mild liver enzyme elevations and a high EGCG dose (1,500 mg/kg IG) with LPS 
showed clear acute liver damage with an 8 times greater increase in ALT, sinusoidal 
congestion, increase in degenerated hepatocytes, prominence of Kupffer cells and 
inflammatory cell infiltration.  In addition this study showed that green tea hot water extract 
did not result in liver injury in the mice. This therefore means that green tea consumed as a 
whole extract cannot be implicated in liver injury. However, consumption of high doses of 
isolated green tea extracts such as EGCG under compromised health conditions produced 
exaggerated liver injury. In another study by Salminen et al. (2012) it was shown that green 
tea extract administered to mice prior to acetaminophen-induced hepatotoxicity showed 
hepatoprotective effects whereas its administration of the extract after inducing toxicity 
potentiated the toxicity further [170].  This paradox could be explained by green tea extract 
further depleting glutathione, which is essential for acetaminophen metabolism. Therefore 
this study illustrates the importance of drug-dietary supplement interaction and importance 
of multiple exposure scenarios to model toxicity. Other pharmacological studies include Xu 
et al. (2012), Xu et al.(2007) and Tsai et al. (2012) who demonstrate hepatoprotective effects 
of green tea extract in mice when administered prior to liver injury inducing agent[201-203]. 
In contrast, Kapetanovic et al. (2009) found hepatotoxic effects of green tea extract in a 
chronic 9 month administration to dogs, which was worse in dogs administered green tea in 
the fasted state[204].  
Polyphenols 
Flavanoids 
Other groups 
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Catechins 
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7.17.4 Overall safety 
It is therefore evident from the pharmacological studies above that green tea water extract 
consumed at regular doses poses no detectable hepatotoxicity risk and high concentration 
of green tea extracts in compromised individuals or those taking multiple pharmaceutical 
products poses a hepatotoxicity risk. Moderate green tea consumption is not a cause for 
concern, but pure EGCG extract presented in tablets or capsules is a cause for concern.   
Green tea extract is frequently used in weight loss products, which have frequently been 
found to contain adulterants [199]. Clinical cases therefore need to provide a chemical 
analysis for their products for a valid conclusion to be made regarding green tea 
hepatotoxicity. For example, Wai et al. (2007)found a significant proportion of herbal 
products adulterated with prescription medicines in HILI cases[31]. However, 
pharmacological and toxicological evidence in vivo points to possible toxicity in certain 
exposure scenarios. The signal from this study does not differentiate between green tea 
consumed as a whole extract and consumption of specific extracts alone. However, it points 
to a possible risk for the population to be exposed to unregulated green tea extracts.  
7.18 Noni 
The results of this study show a significant signal for noni (ROR 1.155, 95% CI 1.027 – 1.299). 
This signal may be interpreted in line with other safety evidence, below.  
7.18.1 Historic use 
Noni berry is a fruit that has been used for over 2000 years in Polynesia as a herbal remedy. 
It became popular in the US from 1996 when it was marketed for a wide and varied number 
of ailments including cancer, diabetes, HIV/AIDS, gastric ulcers, hypertension, infections, 
depression, and chronic fatigue. No evidence was found in the literature for the presence or 
absence of liver injury due to noni in the traditional population.  
7.18.2 Clinical safety assessment 
Seven case reports in the literature report hepatotoxicity with noni consumption [205]. As 
with other herb case reports, most reports fail to report essential information for valid and 
reliable causality assessment. For example, the seventh case does not mention causality 
assessment methods such as RUCAM and does not sufficiently rule out other causes of 
hepatotoxicity. The patient had consumed ‘Mind®’, a herbal mixture containing aloe vera, 
acai berry, muscadine grape, mangosteen, noni berry, gogi berry, pomegranate, blueberry, 
green tea extract, and plant-derived vitamins and minerals. Aloe vera and green tea have 
previous reports in the literature for hepatotoxicity [105], however, the study did not 
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provide a valid reason for not considering these ingredients as possible culprits [205]. West 
(2011) [206]conducted a phytochemical analysis of the implicated noni product and found 
the product contained less than 1% noni juice and no detectable anthraquinones, which 
were assumed to be the toxic constituents. It must be noted however, that the author of the 
phytochemical study is from the Research and Development department of Tahitian Noni 
International and there are no other sources refuting noni hepatotoxicity evidence [207-
209]. Another case report, for example, involving a 45-year old patient, does not report a 
causality assessment method, herbal product details or accurate time to toxicity onset 
following herbal exposure [210]. Yuce et al. (2006)[211] presents an interesting case where 
the patient developed symptoms of liver injury after interferon beta 1a treatment was 
initiated, but failed to recover when it was withdrawn. The patient returned to normal only 
after noni consumption was stopped. Therefore this case represents a situation where noni 
consumption led to a worsening of interferon beta 1a induced liver injury and highlights the 
importance of patient-specific risk factors predisposing to idiosyncratic toxicity. In summary, 
the seven case reports represent weak evidence for noni being the causal factor in the 
observed hepatotoxicity because essential information required for reliable causality 
assessment is missing.  
7.18.3 Pharmacological safety assessment 
Several in vivo and in vitro studies have been conducted to examine noni effects on the liver. 
In one study, in vitro hepatotoxicity was investigated using human HepG2 cells incubated 
with freeze-dried filtered noni puree. Treated cells showed good viability with an IC50 above 
150 μg/ml [208].    A sub-chronic toxicity test using 80 rats was also conducted by the same 
research group using doses of freeze-dried noni puree between 1.72 and 6.86 g/kg. The high 
dose is equivalent to 90 mL of noni juice per kg body weight and is 10 mL greater than the 
previously established no-observed-adverse-effect-level dose. No significant differences in 
liver enzymes were observed between the control and treatment groups and no statistically 
significant dose effects were observed[208]. Furthermore, a human clinical study was 
conducted in 96 subjects at three dose levels (750 mL/day was the maximum dose) and 
controlled with a placebo group for 28 days. No significant findings of liver injury were found 
[209]. These studies were conducted by the Research and Development department in 
Tahitian Noni International and therefore may be biased.  
 
Two other studies were identified in the literature that investigated noni effects on the liver. 
Both examined the effect of oral noni administration in rats prior to carbon-tetrachloride-
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induced liver injury. Both studies show a significant hepatoprotective effect in liver with 
markedly lower liver enzyme levels in noni treatment groups compared to placebo [212, 
213]. In a relatively similar study, noni was also found to be hepatoprotective in diabetes-
induced rats as measured by fatty hepatic degeneration using liver histology samples [214].  
Hepatoprotective effects are in line with the traditional use of noni in liver ailments. 
However, administration of noni prior to inducing liver injury represents only one exposure 
scenario. Other scenarios investigating noni’s effect on the liver alone, with stress factors 
such as LPS or after induced liver injury may reveal different effects.  
7.18.4 Overall safety 
Clinical case reports are very weak individually and present poor level of causality 
assessment given the missing essential information. Toxicological assessments do not reveal 
hepatotoxicity potential. However, in this study, a large number of noni exposure reports 
were associated with liver injury suggesting that there are more possible cases where noni 
may have contributed to the toxicity than had been identified. This is can be contrasted with 
kava reports (only 20 and 7 with hepatotoxicity, the published reports exceeds this greatly). 
It is also possible that the cases are confounded by an indication given that noni may be 
used to treat liver symptoms according to traditional healing practices. However, noni has 
numerous uses and generally marketed for cardiovascular diseases, cancer and to improve 
immune function [67]. It is also not possible to determine the nature of the indication in the 
database. Therefore, it can be concluded that the signal observed in this study warrants 
further investigation for a possible association between noni juice exposure and 
hepatotoxicity. It also adds further information to the nature of the possible noni 
hepatotoxicity in that case reports were significant for ‘jaundice’, ‘hepatic failure’ and 
‘cholestasis’ with no immune features. Investigation is also required in the traditional use 
population because that has not been reported. It is also important to investigate why such 
a serious reaction was only identified in 2005 when the product had been popular since 
1996 in Western markets and used for over 2000 years in the traditional population. 
7.19 Missing expected signals 
Several herbs that have been known to cause hepatotoxicity did not appear to have signals 
in this study. These herbs include cascara sagrada, chaparral, germander, comfrey, 
crotalaria, heliotropium senecio longilobus and mistletoe. For most, signals were not evident 
because there are no reports present in the database. Others have too few reports for a 
signal to be detected. In order to ensure that the results were valid, the search terms for 
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these herbs were reviewed to ensure any possible entry was included and herbs were cross-
checked with the US dietary supplement label database to investigate their availability in the 
US market. 
Since all possible search terms have been included and these herbs were not found in the US 
dietary supplement database, it is reasonable that they may be considered in rare use in the 
US or that they are included in multi-ingredient formulations that have not been reported at 
that level of detail in the database. 
7.20 Pharmacovigilance limitations 
The FDA spontaneous reporting system is voluntary and a passive system that collects 
reports of adverse events possibly associated with a drug’s or herb’s exposure from health 
professionals, patients and manufacturers. The AERS database has strengths including 
comprehensive coverage of all drug products marketed in the US, it is simple and low cost 
relative to active surveillance systems. It is also well configured to detect rare events such as 
liver failure or aplastic anaemia, which occur rarely (few cases per million) yet are 
considered a safety concern [215]. Limitations of pharmacovigilance databases are 
summarised below. These limitations have impact on data analysis and interpretation of 
results: 
 Under-reporting. It is estimated that between 62-99% of adverse reactions are not 
reported [215]and that the FDA receives less than 1% of adverse reactions 
associated with dietary supplements[216]. An important factor in under-reporting is 
knowledge and attitude of the health care provider and educational interventions 
have shown greatly improved reporting [217]. In addition, encouraging patient self-
reporting is beneficial[127]. Although reporting has increased in recent years (Figure 
5.4), it is not possible to estimate adverse event incidence rates in the population 
from pharmacovigilance data due to the lack of a denominator.  
Several countries, such as France, Canada, US and EU, are working toward an active 
surveillance system that utilises health care data for epidemiological analysis. This 
would allow earlier detection of signals and overcome the low reporting rate with 
current passive surveillance systems. Early signal detection is important for human 
safety, for example, while 200,000 digoxin-related hospitalizations occurred over 
seven years, only 82 adverse reactions reports were received annually to the FDA 
[218]. In addition, the International Conference on Harmonization (ICH) has 
developed standards for active pharmacovigilance.  
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 Uneven reporting. Reporting is influenced by several factors. The number of reports 
is high in the first two years in the market and may fluctuate after that for several 
years and this may apply to some herbs. Reporting also increases when a particular 
drug-event association is highlighted in the literature or media. Also, well-known 
adverse effects of one drug may increase reports for other drugs in the same class. It 
is therefore important to consider the time frame of the data used to determine 
signals and the effect of publicity on the signal. 
 Masked signals. Large number of reports for a certain adverse event which are 
associated with other drugs will in effect make a signal invisible for the drug under 
investigation [125]. Reporting over time graphs may be used to reveal such signals 
[127]. 
 Variable reporting quality. Reports may be of uneven quality, or contain missing or 
incorrect information.  
 Reports represent an association between an exposure and event and no causal 
links are required for a case to be reported. 
 There is no control group to compare drug-associated adverse events. Some adverse 
events are disease-related, though they may appear as drug-associated events. 
 Confounding drugs. A drug event association may be explained by the presence of a 
co-administered drug. Including confounders in the analysis may minimize this 
effect.  
 Drug-drug or herb-drug interactions may explain the hepatotoxicity. However, these 
interactions are not evident from spontaneous reporting data.  
 Disproportionality analyses consider bivariate relationships. It may be possible 
though that an adverse event occurs when exposure is to a combination of two or 
more drugs taken concurrently. These relationships indicate drug-drug interactions 
or may represent pre-disposing factors for an adverse reaction. It may also be that 
exposure to the group of drugs leads to multiple adverse events. It may be possible 
to investigate the effects of a combination of drugs using pattern analysis. 
7.21 Herb pharmacovigilance 
There are additional limitations in investigating herbal exposure - adverse event associations 
in pharmacovigilance databases: 
 Under-reporting of herbal product use. Herbal medicines have a lower reporting rate 
than the low reporting rate for conventional drugs[14]. Patients frequently view 
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herbal medicines as ‘natural’ and therefore free of harm and may not report their 
use to doctors. Doctors frequently do not enquire about herbal medicines use[219].  
  Non-standard nomenclature. Herbal products are reported in many ways, for 
example, their common name(s), botanical name or brand name(s). Plant parts used 
or plant species are not usually reported[14, 220]. When multi-component brand 
names are included, their herbal ingredients are not reported. It is very common for 
reports to contain very non-specific reference to herbal medicine use, for example 
‘herbal product’ or ‘plant extract’ or ‘Indian medicine’. The World Health 
Organization has compiled a Herbal Dictionary as an international reference to code 
herbal product entries in spontaneous reporting systems[221], however, this is not 
yet universally implemented. In addition, manufacturers change the herbal 
constituents in their multi-component products, which may not be detectable when 
herbal products are reported in the brand name. 
 Herbal medicinal product quality. Herbal material used may be of poor quality, 
incorrect or misidentified, adulterated or incorrectly processed and these issues 
have frequently confounded herbal-hepatotoxicity cases[31]. The FDA frequently 
identifies industry sites with non-compliant Good Manufacturing Practices in routine 
inspection; however, many herbal remedies may be obtained online via non-
registered manufacturers that have different regulations and manufacturing 
standards. Therefore, these factors are confounders that cannot be excluded in a 
retrospective analysis (See section 1.11). 
 Natural variation in herbal product despite standardisation. Herbs are rarely 
standardised against the active constituent(s) because they are often unknown. Due 
to their natural origin, herb active constituent concentrations will vary from batch to 
batch due to several factors such as soil conditions, climate, harvesting time and 
geographical origin[14, 220]. In addition, different manufacturers using the same 
herbal source may have non-bioequivalent final products due to different plant 
parts, storage conditions, processing and extraction conditions.  
 Herbal products may be prepared and consumed according to traditional practices. 
This is not possible to detect or quantify in retrospective analysis of spontaneous 
reporting data. The quality and identity of the consumed product needs to be 
confirmed and the product may not be comparable to manufactured herbal 
medicines using the same plants. 
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 Herbal products are complex mixtures of a large number of chemical constituents. 
Some constituents mitigate the harmful effects of other constituents in the same 
plant, which also have beneficial effects. Therefore the plant has beneficial effects 
overall when consumed whole. Plant extracts containing specific ‘active’ compounds 
may therefore have different effects to a product using all constituents in a plant. 
For example, in green tea, the flavanoids increase gastric motility while the tannins 
decrease the gastric motility therefore delivering a fine balance to keep gastric 
motility normal while delivering favourable effects without the undesired side 
effects[169].There is no differentiation between products using all of the plants 
constituents and single extract products, which may be reported in a similar manner.   
 A herbal product may have both hepatotoxic and hepatoprotective effects. The 
effect experienced may depend on the exposure scenario (See section 7.17).   
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8 CHAPTER 8 DISCUSSION– PHARMACOPHORE DETERMINATION 
8.1 Method suitability 
In silico pharmacophore modelling was an ideal method in this study to find clues for toxicity 
mechanisms. In vivo and in vitro studies have so far been narrow and specific in their 
approach by their nature because they consider only one herb at a time and investigate a 
relatively small number of phytoconstituents. In this study however, a wide approach was 
used by investigating a large set of phytoconstituents derived from seven herbs, which 
shared the same hepatotoxicity features.  
A group of herbs that cause liver injury with the same or similar features, patterns or type of 
liver injury may be doing so via the same pathways. These herbs may therefore have in 
common the constituents that interact with the same proteins in pathways leading to 
toxicity.  Pharmacophore modelling aims to reveal the structural features important to the 
ligand-protein interaction that is part of the toxicity pathway, which the herb 
phytoconstituents would be expected to share. Signal detection in the first part of the study, 
together with literature reports, provided the evidence for selecting herbs with shared 
hepatotoxicity features. This approach, namely using population data in order to gain insight 
into molecular features essential for interaction, is a valuable approach in studying rare 
events.  
8.2 Ligand structural variability 
It was found in this study that the number of matching ligands was consistently less than 
60% in all the strategies used. The ligands themselves had high molecular structural 
variability, which contributed to this. For example, ligands belonging to the alkaloid group 
from all herbs have diverse chemical structures and ligands belonging to ‘senna’ had diverse 
chemical structures (Figure 8.1 and Figure 8.2). In contrast, molecules belonging to 
‘flavanoids’ shared a backbone structure, relatively low variability and high matching rate for 
pharmacophore hypotheses within the group. Likewise, herbs that had a small selection of 
phytoconstituents such as ginkgo, which had 5 constituents meeting the inclusion criteria 
and all were diterpenes, had a relatively low variability and high matching rate within the 
herb group. When matches are required between different groups of chemicals or herbs 
however, the molecular structural variability has a significant effect on the ligand match rate 
for the generated pharmacophore hypotheses. In order to overcome this limitation for this 
work, two steps were taken: 
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1. Training set selection was based on grouping of the numerous phytoconstituents to 
determine shared groups that would be most appropriate for analysis 
2. Several search strategies were used to identify pharmacophore hypotheses that 
would otherwise not have been identified in order to find a strategy with optimal 
results 
 
 
 
 
Cytisine N-methyl cytosine Cimipronidine methyle ester 
 
 
 
Cyclocimipronidine Actinidine Valerianine 
   
n-(p-hydroxyphenethyl) 
actinidine 
2-acetylpyrrole 3-acetyl-2,7-paphthyridine 
 
 
 
Cimipronidin Dopargine 
Figure 8.1 Chemical structures of ligands in the ‘alkaloid’ group 
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Isorhamnetin 6-O-methylapigenin Sennidin A 
 
 
 
 
Aloe-emodin Chrysophanol Rhein 
Figure 8.2 Chemical structures of ligands belonging to senna. 
8.3 Training set selection 
The appropriate selection of a training set is crucial for building a reliable pharmacophore 
model. In this study, ligand selection for the training set was based on using the most 
appropriate phytoconstituents that belong to chemical classes shared among the included 
herbs. Herbs contain a large number of known constituents (see Appendix D. Chemical 
constituents of herbs considered for  pharmacophore analysis) and in order to compare herb 
constituents with other herbs, the constituents were grouped according to their chemical 
class. Constituents under one chemical class share similar chemical features and are usually 
based on a primary structure or backbone, therefore it would be appropriate to use 
chemical class grouping in order to determine constituents that would be shared among 
different herbs. Hence, one criterion for training set ligand selection was that they belonged 
to a chemical class that was common to at least four other herbs.  
Ideally, ligands in the training set would adequately represent molecules that act on the 
unknown target with sufficient coverage of chemical and biological space. Therefore, 
chemical diversity in the training set is favourable to an extent because inclusion of 
chemically similar compounds would produce models biased toward these structures.  The 
training set in this study was diverse in that it included structurally different molecules from 
different chemical groups for each herb. However, it would have been preferable for each 
herb group in the study to contribute an equal number of ligands to the training set. Some 
herbs in this study, such as black cohosh, kava and senna have a greater number of 
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identified constituents than herbs such as Jin Bu Juan, ephedra, primrose and Sho Wu Pian. 
In addition, some herbs had a relatively large number of identified constituents with similar 
chemical structures, which belong to the same chemical group. Therefore, the herbs and 
chemical groups with the larger number of constituents had a greater contribution to the 
pharmacophore models generated. In future studies it may be beneficial to apply a sampling 
method, such as stratified sampling where each herb group is a strata, to obtain a training 
set with a more balanced ligand contribution from each herb and from each chemical class. 
Alternatively, herbs with a small number of known constituents could be either further 
investigated for additional constituents or excluded from the analysis (See section 8.8).   
8.4 Search strategies 
Several strategies were used to search for possible pharmacophore hypotheses. The ‘tree’ 
strategy was designed in order to find hypotheses not previously evident through the ‘forest’ 
strategy that would have increased ligand match rate. The theory behind this strategy is that 
shared pharmacophore hypotheses may not always be high scoring and therefore may be 
overlooked in the ‘forest’ strategy. In the tree strategy, there was a relatively high number of 
matching ligands for individual chemical groups, however, a low match rate over all. 
Attempts to improve the search method did not show significantly increased improvement 
in outcomes, however, ligand selection could be changed to investigate different 
phytoconstituent inclusion criteria in future studies.  
8.5 Validation 
Pharmacophore model validation is important to determine the specificity and accuracy of a 
hypothesis in reliably differentiating active molecules from inactives. In addition, the target 
receptor site is unknown and it is unexpected that a single pharmacophore hypothesis would 
produce a correct model. Therefore, several hypotheses were selected for validation. Two 
methods were used in this study: a test set of active compounds to test how well the 
pharmacophore hypothesis can identify active compounds, measured as sensitivity, and a 
decoy set of active and inactive compounds to test how well the hypothesis can differentiate 
the actives from the inactives, measured as selectivity. Both of these validation methods are 
very commonly used in pharmacophore validation [222]. High selectivity and sensitivity 
scores mean that the hypothesis has high predictive power and therefore likely to represent 
the features required for the ligand-target interaction. Ideally, the test and decoy set would 
be derived using inclusion and exclusion criteria equivalent to that used for the ligand 
training set. In that case, the active compounds would be defined as phytoconstituents 
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belonging to the chemical groups used in this study known to elicit immune mediated liver 
injury, which were not used in the training set. In order to conduct validation in this way, it 
would have been necessary to exclude some herbs from the training set and retain them for 
the test set. The training set was considered small in number to allow for further reduction 
and therefore all the training set ligands were retained to form pharmacophore hypotheses. 
Therefore, in this study actives were drug molecules with known immune liver injury. It is 
also possible to exclude phytoconstituents from the training set and test hypotheses if they 
re-identify them as actives. This additional validation step could be carried out in future 
studies. As for the inactives, they would ideally be defined as phytoconstituents that belong 
to herbs with no known immune liver injury. Evidence for their liver safety would also be 
derived from a literature search and absence of a signal in the FDA AERS data. This would 
require a thorough search similar to the one conducted in signal detection work in the first 
half of this study and can be suggestion for future studies.  
8.6 Clues to toxicity mechanisms 
The results of the pharmacophore modelling reveal two hypotheses shared among the 
constituents, which were tested to be valid. These pharmacophore hypotheses may 
represent important structural features for a phytoconstituent to illicit an immune liver 
injury.  
There are several hypotheses for immune mediated DILI mechanisms, which may explain 
how a phytoconstituent interacts with proteins causing immune liver injury. A 
phytoconstituent can induce an immune response by [223]: 
1. Formation of reactive metabolites with active antigen presenting cells (APCs). For 
example, reactive metabolites may be formed via cytochrome P450 (CYP) enzymes 
that are abundant in the liver or by myeloperoxidase system present in APCs. 
2. Acting as a hapten. The phytoconstituent or its metabolite can bind a protein thus 
forming a neoantigen, which can start an immune response. For example, a 
phytoconstituent or its metabolite bound to a protein may be recognized by an 
antibody as foreign.  
3. Causing a ‘danger’ signal. In this hypothesis, two signals are required. The 
phytochemical would cause up-regulation of co-stimulatory molecules such as CD40 
on APCs, which would interact with T-cell receptors and generate signal 2. Signal 1 is 
generated when T-helper cells recognize the antigen, which is a phytoconstituent-
modified protein, presented by APCs. Both signals 1 and 2 are required to activate T 
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helper cells and T helper cells are required for an adaptive immune response, 
otherwise the response would be immune tolerance.  
4. Other mechanisms such as the pharmacological interaction hypothesis or 
involvement of epigenetic factors. 
It is not possible to derive information about the herb-induced liver injury mechanisms from 
this study and any of the above mechanisms may be involved in the toxicity. 
Pharmacophore modelling is an iterative process with constant refinement. Further work is 
required in generating alternative hypotheses to explore alternate binding modes. Alternate 
binding modes are possible when active ligands bind the same receptor via different 
interactions. In addition, further in silico docking of active ligands with possible target 
proteins such as toll like receptors, which are present on APCs to detect pathogens, may 
reveal new information. In vitro experiments may be also used to validate the hypotheses.  
Several assumptions were made in order to generate the pharmacophore hypotheses. These 
need to be taken into account when interpreting the results and in further exploration of 
possible mechanisms. These are: 
1. Phytoconstituents cause biological effects independently. However, in many 
instances phytoconstituents interact with each other resulting in a net effect on an 
organism. Therefore, a beneficial effect in an organism is due to the action of all the 
constituents, some being primarily responsible for the effects while others further 
enhance it or mitigate toxic effects. These interactions are not taken into 
consideration in a pharmacophore model. It may be possible that a set of 
pharmacophores in a group of phytoconstituents is required for immune mediated 
liver injury. 
2. The active molecules act on the same receptor. It is possible that different herbs 
elicit the same immune liver injury via different pathways. 
3. The active molecules interact with the receptor in the same or similar way. 
4. The active molecules cross biological barriers to make it to the receptor in sufficient 
numbers. 
8.7 Flavanoid safety and toxicity 
Flavanoids are a class of plant secondary metabolites that share the flavone backbone 
(Figure 8.3). They are found ubiquitously in plants and are present in relatively high amounts 
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in parsley, green tea, berries, bananas and citrus fruit. Flavonols, flavones and flavanones are 
subgroups of flavanoids, which differ in their chemical structures (Figure 8.3).  
  
Flavone chemical structure  Flavanol chemical structure (example shows 
flavon-3-ol)  
 
 
Flavonone chemical structure  
Figure 8.3 Flavanoid chemical structures. 
 
In this study, many ligands of the flavanoid class were hits for high scoring hypotheses. In the 
two hypotheses, AAR.532 and AAR.66, 39% and 49% of matching ligands were flavanoids 
respectively (See Appendix I. Ligands possessing structural features matching 
pharmacophore hypothesis). In addition, the matching flavanoid ligands had high alignment 
scores to the hypotheses. This may seem a contradiction given that flavanoids are frequently 
researched for their health promoting properties such as hepatoprotection, anti-oxidant and 
anti-cancer properties. However, although most research investigates beneficial properties, 
flavanoids also have evidence of toxicity (Table 8.1). Studies such as Tsuji et al. (2008) and 
Valdemeri et al. (2010) found flavanoids studied show cytotoxic effects in liver cells. Tsuji et 
al. (2008) proposes that the toxicity pathway involves myeloperoxidase, which is most 
abundantly expressed in neutrophils, that oxidizes flavones to toxic species. Glutathione 
addition was found to halt this process. Valdameri et al. (2010)investigated a mitochondrial 
pathway and suggests that the toxicity is caused by slight uncoupling in oxidative 
phorphorylation that may have reduced hydrogen peroxide levels[224]. This toxicity is 
attributed to the flavone core structure and therefore applicable to the flavone subgroup. 
Studies differ in their conclusions regarding flavanoid hepatoprotective and hepatotoxic 
effects and this may be because of differences in methodologies used. For example, studies 
use different subgroups and different compounds of the flavanoid class, flavanoid 
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administration is before hepatic injury in some studies and after hepatic injury in others, 
differences in doses used and outcomes measured. In conclusion, flavanoids can have toxic 
or protective effects depending on the exposure scenario, their concentration and host 
factors. In herbal medicinal products, the net effect of flavanoid compounds on a biological 
organism may be affected by other constituents in the plant. 
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Table 8.1  Summary of studies that examine the hepatotoxic/hepatoprotective effect of flavanoids 
Study Findings  Methods 
De Freitas 2013.  
[225] 
 
Flavonoids* and phenolics in plant extract did not affect liver function (AST, ALT) and no 
morphological effects on hepatocytes observed. 
Rats were fed plant extract for 30 days at three doses. 
Flavonoids and phenolics were quantified by HPLC. 
Tsuji 2008. 
[226] 
Hydroxylated flavones show cytotoxicity at small doses, methylated flavones showed no signs 
of toxicity. 
Toxicity at low doses (2 uM) is 25 times less than dose for antiproliferative effects 
Low doses of flavonoids like those present in the diet may be safe, but flavonoid levels are 
high in supplements. E.g. chrysin used by body builders at relatively high doses and may not 
be as safe as previously thought. 
Cultured trout hepatocytes were exposed to flavonoids (chrysin, 
apigenin, luteolin, quercetin, 5’,7’DMF and 3’,4’DMF). Results 
measured growth, cell proliferation and myeloperoxidase activity 
in the cells.  
 
Lekic 2013. 
[227] 
 
Quercetin reduced impact of d-galN/LPS induced toxicity (reduced AST and ALT)  it is 
hepatoprotective. Also increased expression of potent antioxidant enzyme HO-1 and NOS-2 
under hepatotoxic conditions  ameliorates hepatic disease. No hepatoprotective effects 
under physiological conditions.  Hepatoprotective effects could be through NOS-2 and HO-1. 
Also could be due to SIRT1 activation.  
Quercetin may cause toxicity (e.g. inhibit topoisomerase II leading to secondary leukemia’s) 
so interpret benefit with caution. 
Rats received injection of d-galN+LPS followed by injection of 
quercetin (50mg/kg). Animals were sacrificed after 24 hours. 
Compared with a quercetin only control group, liver injury only 
control group and a group with neither (blank control). 
Davila 1989.  
[228] 
 
Catechin and silybin protect hepatocytes against cell injury, measured as decreased AST and 
ALT levels. 
Hepatocyte cultures were exposed to toxins (erythromycin, 
amitriptyline, nortripyline and tert-butylhydroperoxide) for two 
hours. 
 
Onoue 2013.  
[229] 
 
Nobiletin has hepatoprotective activity (reduced AST, ALT levels in rats with liver injury). 
CCl4 was used to induce liver injury in rats. Four blood samples 
taken up to 24 hours, rats then sacrificed. ALT, AST and 
pharmacokinetics measured. 
Green 2012. 
[230] 
 
Flavones reduced AST and ALT levels  flavone modulates organ injury associated with 
hypercholesterolemia. Note: studies show hypercholesterolemia is a common feature of 
primary biliary cirrhosis and other forms of Cholestatic liver disease. 
Rats were fed high cholesterol diet for 49 days. Treatment group 
received the flavonoid.  
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Table 8.1  Summary of studies that examine the hepatotoxic/hepatoprotective effect of flavanoids 
Study Findings  Methods 
Barsalani R. 2013. 
[231] 
Isoflavone supplementation shows some benefit in reducing risk of developing non-alcoholic 
hepatic steatosis when combined with exercise (AST ALT and other enzyme levels decreased) 
though it was exercise that had most benefit. 
Postmenopausal women (n=54) were allocated to treatment 
with exercise with or without isoflavanoid supplementation in a 
double blind randomized controlled trial. Outcomes measured 
were plasma liver enzyme levels. 
Valdameri 2010. 
[224] 
Flavones altered membrane properties of mitochondria isolated from rat liver. They inhibited 
enzymes in the respiratory chain (between complex I and III) as well. These may partly explain 
their cytotoxic effects. Study uses flavone core structure. Other studies attribute activity to 
hydroxyl or methyl groups but the core structure also has biological effect.  
 
Polarographic experimentation conducted on mitochondria 
isolated from rat liver using flavone, glutamate and succinate. 
Analyzed enzymatic activity in respiratory chain, measured 
membrane electric potential and swelling. 
Lv Y. 2013. 
[232] 
Naringenin (flavone) exposed mice showed a dose dependent reduction in liver enzyme 
levels. Naringenin can reverse paracetamol induced hepatotoxic damage. 
Mice were fed naringenin for four days prior to paracetamol 
exposure. Liver enzymes were measured as indicators of toxicity. 
Huang Q. 2013. 
[233, 234] 
Genistein decreased AST and ALT levels. It decreased levels of inflammatory mediators 
(interleukin 6, tumour necrosis factor, myeloperoxidase). Genistein administration was able 
to prevent the development of liver injury even after fibrosis was evident. 
Rats given intragastric alcohol and a subset were given 
intragastric genistein for 24 weeks. 
 
Peng JH. 2013. 
[234] 
Puerarin inhibited endotoxin gut leakage, Kupffer cell activation, and endotoxin receptors 
expression. This showed that puerarin is involved in the alleviation of chronic alcoholic liver 
injury in rats. 
Rats were administered ethanol with or without puerarin at low 
and high dose for 5 weeks.  
* Flavonoid is an alternate spelling of flavanoid 
Key:  Study results show flavonoid safety   Study results show flavonoid toxicity  Study results are not conclusive 
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8.8 Limitations 
 The herbs included in this study have some evidence for hepatotoxicity and this 
evidence is not absolute and frequently disputed among experts. The evidence for 
immune liver injury from the signal detection study is mainly limited by the quality 
of the reporting in AERS data and evidence from the literature for immune liver 
injury is mainly limited by low quality reports, which cannot be reliably used to 
conclude causal relationships between herb exposure and liver injury. It is very 
important in pharmacophore modelling to have accurate and correct labelling of 
‘active’ molecules because they determine the hypotheses generated. Therefore, in 
this study all the steps were taken to ensure that the highest quality evidence was 
used. However, this limitation remains. 
 Herbs have many constituents, most of which are unknown. Therefore, the search 
was limited only to the known constituents. Some herbs have greater number of 
identified constituents; while for others very little is known. This introduced some 
bias as herbs with greater number of constituents contributed more to the 
hypotheses. It is also possible that toxicity is due to multiple compounds within a 
plant, which this study has not accounted for.  
 The search was limited to parent compounds. However, metabolites may also be 
involved in eliciting the immune liver injury and this was not considered. This can be 
included in future studies. 
 The search was limited to the most commonly shared chemical groups. This worked 
to refine the search to obtain relevant results, however it is also possible that 
excluded taxonomic groups have molecular features shared with structurally 
different molecules. 
 The validation test involved the use of drugs. Ideally, actives and inactives would be 
derived from herbal sources. This would require a repeat of the initial signal 
detection study using herbs identified from the literature to not have liver injury and 
absence of reports with liver injury terms in the AERS data would confirm they are 
inactive.  
 There was high variability in the chemical structures of the included 
phytoconstituents and not all phytoconstituents contribute to the toxicity. They 
were included however, and the resulting poor matching rate is reduced due to that.  
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8.9 CHAPTER 7 AND 8 SUMMARY 
The key points discussed are summarised below: 
Signal detection 
 The FDA AERS data (2004 – 2011) was the most appropriate choice for this study 
because it is a large database, contained sufficient numbers of cases for this study 
and is publically available 
 Population data from pharmacovigilance systems is a very good data source for the 
study of rare idiosyncratic reactions such as drug- or herb-induced liver injury, for 
which there are no validated in vivo or in vitro models 
 The ROR was chosen over other statistical tools to analyse herb exposure and 
hepatotoxicity associations found in the database because it is more sensitive and 
most frequently used 
 This study was the first to investigate herb-hepatotoxicity associations at a 
population level using pharmacovigilance data 
 A total of 15 significant signals were observed. These signals imply association and 
further investigation is required to determine whether herb exposure was causal 
 Signals for specific herbs were interpreted with consideration of all the available 
safety or toxicity evidence using historic use information, clinical safety evidence and 
pharmacological evidence. This comprised a comprehensive and thorough safety 
assessment, which is rare in the literature for HILI. More often than not, published 
articles assess safety based on one type of evidence, for example clinical case 
reports. This is considered unsatisfactory in this study 
 Signals for hoodia, ginseng and ginkgo provide new information for their association 
with liver injury. Analysis at specific liver injury phenotypes and mechanistic 
groupings provided new information on the nature of their hepatotoxicities. These 
new signals warrant further investigation 
 Signals for kava, valerian, Herbalife®, black cohosh, senna, green tea and noni 
provide further evidence for their association with liver injury events 
 Pharmacovigilance data has several limitations, such as under reporting, uneven 
reporting, variable reporting quality and lack of control group. However, it provides 
valuable information on rare drug reactions and is the most frequently used source 
for information on such reactions 
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Pharmacophore modelling  
 In silico pharmacophore modelling was a valuable approach to find clues to immune 
HILI toxicity mechanisms. This is because HILI is a rare reaction currently with no 
reliable in vivo or in vitro models for the toxicity. In addition, studies aiming to 
identify culprit toxic phytoconstituents are narrow and specific in their approach by 
their nature because they examine a small number of constituents for a specific herb 
 This is the first study of its kind to examine immune HILI using pharmacophore 
modelling to identify clues for toxicity 
 A pharmacophore hypothesis represents the three dimensional arrangement of 
chemical features essential for binding between a ligand and its target. It is 
beneficial to use when a set of ligands is known to be active but the receptor site is 
unknown 
 Training set ligand selection is crucial for a reliable pharmacophore model. In this 
study, phytoconstituents were included if they belonged to a chemical group that 
was shared by at least four herbs. In this way, the ligands that are included would 
likely contain similar chemical features with ligands from other herb sources. 
 The number of matching ligands was frequently found to be low. This is due to the 
high structural variability among the ligands in the training set. Two steps were 
undertaken to reduce variability: training set selection was based on 
phytoconstituent chemical groupings and several pharmacophore modelling 
strategies were used to identify possible hypotheses 
 Attempts to use different strategies to improve the ligand match rate for generated 
hypotheses did not significantly improve results. However, in future studies different 
ligand selection criteria could be investigated to improve result 
 Validation of pharmacophore hypotheses is essential to determine a model’s 
reliability and predictive power. It would be beneficial to investigate the use of 
active and inactive compounds from herbal sources in future studies, which would 
form the test and decoy sets for validation 
 There are several hypotheses to explain HILI/DILI events: the danger hypothesis, the 
hapten hypothesis, formation of active metabolites which activate APCs, 
pharmacological interaction hypothesis and involvement of epigenetic factors. The 
pharmacophore hypotheses generated give clues to the essential features necessary 
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for binding to a receptor, which would cause hepatotoxicity. It is not possible to 
make further deductions about the type of mechanisms involved in HILI 
 Flavanoids frequently featured as hits for high scoring hypotheses. Although 
flavanoids are usually perceived to be beneficial and hepatoprotective, some 
research shows they may have toxic effects as well. These toxic effects are 
attributed to the flavone core structure 
 Pharmacophore modelling does have limitations such as, assumption that 
phytoconstituents act independently, they act on the same receptor and they have 
sufficient bioavailability. Other limitations, such as limiting ligands to parent 
structures and limited numbers of known phytoconstituents, are important to 
consider in interpreting results. Nevertheless, hypotheses generated from this study 
have shown relatively high predictive power and confirm the results of similar 
studies investigating possible pharmacophores in DILI 
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9 Future studies 
Suggestions for future studies include: 
 Signal detection work may be repeated using different pharmacovigilance 
databases, such as the WHO VigiBase, to compare signal results. Pharmacovigilance 
databases from Asian countries would present an invaluable source of herb-
hepatotoxicity signals for traditional herbs in the region. Poison centre databases 
may also be explored.  
 Signal detection work using FDA AERS data may be conducted again using data from 
1969 to 2014. This will be beneficial in revealing signals of association for herbs that 
are less popular currently and will provide useful information on herb reporting over 
time. 
 Conduct signal detection work using a cleaner AERS dataset. This is was not available 
at the time of the study; however, research groups are currently generating a 
‘cleaned’ version with standardised entries in the drug name field. This will produce 
results with greater accuracy. 
 Conduct signal detection work using different statistical tools for signal detection, 
such as the PRR, EBGM or IC to explore the effect of the statistical tool used on 
signal sensitivity specifically for herbal medicines. 
 Conduct signal detection work using a different ‘background’ for statistical analysis; 
for example, include only reports with any herb intake as the background in 
calculations of ROR. This may provide useful information and reveal new signals of 
association not previously detectable because herb medicine entry to the market 
differs to that of conventional drugs and therefore may affect its pharmacovigilance. 
 Investigate herb exposure-hepatotoxicity associations using data mining methods. In 
this method, there are no specific herbs that we seek to search for existing signals. 
Instead, all liver injury cases are identified and then a compilation is made of all the 
herbs or drugs consumed by these patients. Following that, ROR analysis may be 
carried out to find out if the associations are significant.  
 Investigate whether signals of herb-hepatotoxicity association are also associated 
with predisposing factors that are possible for idiosyncratic reactions such as co-
morbidities (for example, asthma or cardiovascular disease). This would require 
identification of cases with defined predisposing factors and investigating for 
bivariate relationships and analysing for patterns. This may reveal valuable 
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information on some of the predisposing factors common to patients that 
experience an idiosyncratic reaction.   
 Pharmacophore modelling may be extended to include metabolites of parent 
compounds, which may cause or contribute to toxic effects on the liver. 
 Explore pharmacophore models using modified inclusion and exclusion criteria for 
the ligand training set. For example, include molecules belonging to taxonomic 
groups shared by fewer groups. Another approach would be to search deeper into 
each plant phytochemistry to identify important compounds not previously 
included. 
 Explore pharmacophore models using modified strategies. For example, a new 
strategy would be to focus on phytochemicals that are present in relatively high 
concentration in the plant and exclude phytochemicals present in minute amounts. 
 Explore pharmacophore models using a balanced ligand training set. Stratified 
sampling can be used to obtain a sample of ligands from each herb and from each 
chemical group so that certain herbs or chemical groups do not dominate a 
pharmacophore hypothesis. This may lead to a smaller ligand training set. 
 Further investigate pharmacophore models produced by conducting a QSAR study to 
determine pharmacophore features that contribute positively or negatively to a 
ligand’s activity. This data may also be used to predict ligand activity. 
 Conduct a validation study using active and inactive compounds from plant sources 
 Investigate in silico docking of active ligands with possible target receptors, such as 
toll like receptors, which are present on APC and that are involved in immune 
mediated reactions associated with liver injury. 
 Investigate pharmacophore model correlation with in vitro study results. This would 
require selection of a pharmacophore model with good predictive power followed 
by experimental investigation of ligand toxicities, which possess the pharmacophoric 
features in the model. 
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10 Appendix A. Herb search terms 
 Herb common names and botanical names to be used in AERS search  
(Empty boxes = no information found)  
Herb name  Botanical name Herbal Medicines 
(Medicines 
Complete) 
Natural medicine comprehensive database 
Aloe Vera Aloe vera Aloe gel 
 
Aloe Capensis, Aloe Gel, Aloe Latex, Aloe Leaf Gel, Aloe Perfoliata, Aloe Vera 
Barbenoids, Aloe Vera Gel,Aloes, Aloès, Aloès de Curaçao, Aloès des Barbades, Aloès 
du Cap, Aloès Vrai, Aloès Vulgaire, Barbados Aloe, Burn Plant, Cape 
Aloe, Chritkumari, Curacao Aloe, Elephant's Gall, Gel de la Feuille d'Aloès, Ghee-
Kunwar, Ghi-Kuvar, Ghrita-Kumari, Gvar Patha, Hsiang-Dan, Indian Aloe, Jafarabad 
Aloe, Kanya, Kumari, Latex d'Aloès, Lily of the Desert, Lu-Hui, Miracle Plant, Plant of 
Immortality, Plante de l'Immortalité, Plante de la Peau,Plante de Premiers 
Secours, Plante Miracle, Plantes des Brûlures, Sábila 
Bilberry Vaccinium  
myrtillus 
 
Blueberry, Bogberr
y, Huckleberry, Myr
tilus 
niger Gilib., Whortl
eberry 
Airelle, Arándano, Bilberry Fruit, Bilberry Leaf, Black 
Whortles, Bleaberry, Brimbelle, Burren Myrtle, Dwarf Bilberry, Dyeberry, European 
Bilberry, Feuille de Myrtille, Fruit de Myrtille, Gueule 
Noire, Huckleberry,Hurtleberry, Mauret, Myrtille, Myrtille Européenne, Myrtilli 
Fructus, Raisin des Bois, Swedish Bilberry,Trackleberry, Whortleberry, Wineberry. 
Black cohosh Actaea racemosa 
Cimicifuga 
racemosa 
Actaea monogyna 
Walter, Black Snake
root, Cimicifuga, Ci
micifuga racemosa 
(L.) 
Nutt., Macrotys Act
aea  
Actaea racemosa L. 
(Ranunculaceae) 
Actée à Grappes, Actée à Grappes Noires, Actée Noire, Aristolochiaceae Noire, Baie 
d'actée, Baneberry, Black Aristolochiaceae, Black 
Snakeroot, Bugbane, Bugwort, Cimicaire à grappes, Cimicifuga, Cimicifuge, Cohosh 
Negro, Cohosh Noir, Cytise, Herbe aux 
Punaises, Macrotys, Phytoestrogen, Phytoestrogène, Racine de Serpent, Racine de 
Squaw, Racine Noire de Serpents, Rattle Root, Rattle Top, Rattlesnake 
Root, Rattleweed,Rhizoma Cimicifugae, Sheng Ma, Snakeroot, Squaw Root 
Cranberry  Vaccinium macroca
rpon 
Oxycoccus 
macrocarpus  
 Agrio, Airelle à Gros Fruits, Airelle Canneberge, Airelle Européenne, Airelle 
Rouge, American Cranberry,Arándano, Arándano Americano, Arándano 
Rojo, Arándano Trepador, Atoca, Atoka, Bearberry, Canneberge,Canneberge à 
Feuillage Persistant, Canneberge d'Amérique, Canneberge Européenne, Cocktail au 
Jus de Canneberge, Cranberry Extract, Cranberry Fruit, Cranberry Fruit 
Juice, Cranberry Juice, Cranberry Juice Cocktail, Cranberry Juice 
Concentrate, Cranberry Powder, Cranberry Powdered Extract, Craneberry, Da Guo 
Yue Jie, Da Guo Yue Ju, Da Guo Suan Guo Man Yue Ju, European Cranberry, Extrait 
de Canneberge, Große Moosbeere, Gros Atoca, Grosse Moosbeere, Jus de 
Canneberge, Jus de Canneberge à Base de Concentré,Jus de Canneberge 
Frais, Kliukva, Kliukva Obyknovennaia, Kranbeere, Large Cranberry, Man Yue Ju, Man 
Yue Mei, Moosebeere, Mossberry, Oomi No Tsuruko Kemomo, Petite 
Cannberge, Pois de Fagne, Pomme des Prés, Ronce d'Amerique, Sirop de 
Canneberge, Small Cranberry, Trailing Swamp Cranberry 
Echinacea   Echinacea 
  purpurea  
 Echinacea pallida 
 Echinacea angustifo
lia  
 Black Sampson,  
 Coneflower 
 *Echinacea angustif
olia DC. 
(Asteraceae) 
 †Echinacea pallida  
 (Nutt.) Nutt. 
 ‡Echinacea purpure
a (L.) Moench 
 
American Cone Flower, Black Sampson, Black Susans, Brauneria 
Angustifolia, Brauneria Pallida, Comb 
Flower, Coneflower, Echinaceawurzel, Échinacée, Échinacée Angustifolia, Échinacée 
Pallida, Échinacée Pourpre, Échinacée Purpurea, Equinácea, Fleur à 
Hérisson, Hedgehog, Igelkopfwurzel, Indian Head, Kansas Snakeroot, Narrow-leaved 
Purple Cone Flower, Pale Coneflower, Purple Cone 
Flower, Purpursonnenhutkraut,Purpursonnenhutwurzel, Racine d'echininacea, Red 
Sunflower, Rock-Up-Hat, Roter Sonnenhut, Rudbeckie Pourpre, Schmallblaettrige 
Kegelblumenwurzel, Schmallblaettriger Sonnenhut, Scurvy 
Root, Snakeroot,Sonnenhutwurzel 
Evening 
Primrose 
Oenothera  
biennis 
 
Common Evening P
rimrose, King's Cure
all,  
Aceite de Onagra, Acide Cis-linoléique, Cis-Linoleic Acid, EPO, Evening 
Primrose, Evening Primrose Seed Oil,Fever Plant, Herbe-aux-ânes, Huile de Graines 
d'Onagre, Huile D'Onagre, Huile de Primerose, Huile de Primevère 
Vespérale, Jambon de Jardinier, Jambon du Paysan, King's Cureall, Mâche 
Rouge, Night Willow-Herb, Œnothère, Oil of Evening Primrose, Onagraire, Onagre 
Bisannuelle, Onagre Commune, Primevère du Soir, Primrose, Primrose 
Oil, Scabish, Sun Drop 
Garlic Allium sativum 
 
Ajo, Allium Aged Garlic Extract, Ail, Ajo, Allii Sativi Bulbus, Allium, Camphor of the Poor, Clove 
Garlic, Garlic Oil, Da Suan,Lasun, Lasuna, Nectar of the Gods, Poor Man's 
Treacle, Rason, Rust Treacle, Stinking Rose 
Germander  Teucrium 
Chamaedrys, 
Polium, Capitatum, 
Viscidum 
Teucrium 
chamaedrys 
Camedrio, Chasse-Fièvre, Chêneau, Chenette, Germandrée, Germandrée 
Officinale, Germandrée Petit Chêne, Petit Chêne, Wall Germander, Wild Germander 
Ginger Zingiber officinale Gan Jiang, Zingiber African Ginger, Ardraka, Black Ginger, Cochin Ginger, Gan 
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 Jiang, Gingembre, Gingembre Africain, Gingembre Cochin, Gingembre 
Indien, Gingembre Jamaïquain, Gingembre Noir, Ginger Essential Oil, Ginger 
Root, Huile Essentielle de Gingembre, Imber, Indian Ginger, Jamaica 
Ginger, Jengibre, Jiang, Kankyo, Kanshokyo,Nagara, Race Ginger, Racine de 
Gingembre, Rhizoma Zingiberi, Rhizoma Zingiberis, Rhizoma Zingiberis Recens, Shen 
Jiang, Sheng 
Jiang, Shoga, Shokyo, Shunthi, Srungavera, Sunth, Sunthi, Vishvabheshaja,Zingiberis 
Rhizoma, Zingiberis Siccatum Rhizoma, Zinzeberis, Zinziber Officinale, Zinziber 
Officinalis 
Ginkgo  Ginkgo biloba Fossil Tree, Kew Tre
e, Maidenhair Tree, 
Yin Xing (whole 
plant), Yin Xing Ye 
(leaves), Bai Guo 
(seeds),Salisburia  
adiantifolia Sm., S. 
biloba (L.) 
Hoffmans 
Abricot Argenté Japonais, Adiantifolia, Arbe aux Écus, Arbe aux Quarante Écus, Arbe 
du Ciel, Arbre Fossile, Bai Guo Ye, Baiguo, Extrait de Feuille de Ginkgo, Extrait de 
Ginkgo, Fossil Tree, Ginkgo Biloba Leaf, Ginkgo Folium, Graine de Ginkgo, Herba 
Ginkgo Biloba, Japanese Silver Apricot, Kew Tree, Maidenhair Tree, Noyer du 
Japon, Pei Go Su Ye, Salisburia Adiantifolia, Yen Xing, Yinhsing 
Ginseng  Panax ginseng 
 
Ren 
Shen, Asian Ginsen
g, Chinese Ginseng, 
Korean Ginseng, 
Oriental Ginseng 
Eleutherococcus 
senticosus 
Siberian Ginseng, 
Touch-Me-Not, 
Wild Pepper 
American Ginseng, Anchi Ginseng, Baie Rouge, Canadian Ginseng, Ginseng, Ginseng 
à Cinq Folioles,Ginseng Américain, Ginseng Americano, Ginseng 
d'Amérique, Ginseng D'Amérique du Nord, Ginseng Canadien, Ginseng de 
l'Ontario, Ginseng du Wisconsin, Ginseng Occidental, Ginseng Root, North American 
Ginseng, Occidental Ginseng, Ontario Ginseng, Panax Quinquefolium, Racine de 
Ginseng, Red Berry, Ren Shen, Sang, Shang, Shi Yang Seng, Wisconsin Ginseng, Xi 
Yang Shen 
Grape seed Vitis vinifera   Activin, Black Grape Raisins, Calzin, Concord Grape, Draksha, Enocianina, European 
Wine Grape, Extrait de Feuille de Raisin, Extrait de Feuille de Vigne Rouge, Extrait de 
Peau de Raisin, Extrait de Pepins de Raisin,Feuille de raisin, Feuille de Vigne 
Rouge, Feuille de Vigne Rouge AS 195, Flame Grape, Flame Raisins,Flame 
Seedless, Folia Vitis Viniferae, Grape Fruit, Grape Fruit Skin, Grape Juice, Grape 
Leaf, Grape Leaf Extract, Grape Seed, Grape Seed Extract, Grape Seed Oil, Grape 
Skin, Grape Skin Extract, Grapes, Grapeseed,Huile de Pépins de Raisin, Kali 
Draksha, Leucoanthocyanin, Muscat, Muskat, Oligomères 
Procyanidoliques,Oligomeric Proanthocyanidins, Oligomeric 
Procyanidins, OPC, OPCs, PCO, PCOs, Peau de Raisin, Pépin de Raisin, Petite 
Sirah, Proanthocyanidines 
Oligomériques, Proanthodyn, Proanthodyne, Procyanidines 
Oligomériques, Procyanidolic Oligomers, Purple Grape, Raisin, Raisin Blanc, Raisin de 
Table, Raisin de Vigne, Raisins, Raisins Noirs, Red Globe, Red Grape, Red 
Malaga, Red Vine Leaf AS 195, Red Vine Leaf Extract, Sultanas, Table 
Grapes, Thompson Seedless, Uva, White Grape, Wine Grape, Wine Grapes 
Greater 
celandine  
Chelidonium  
majus 
Common celandine, 
garden celandine, 
swallow 
wort. Greater celan
dine should not be 
confused with 
Lesser celandine 
(Ranunculus 
ficaria L., 
Ranunculaceae) 
which is unrelated  
Bai Qu Cai, Celandine, Celidonia Mayor, Chelidonii Herba, Grande 
Chélidoine, Grande Éclaire, Herbe à Verrues, Herbe aux Verrues, Parties Aériennes 
de la Grande Chélidoine, Racine de Chélidoine, Racine de Grande 
Chélidoine, Rhizome de Chélidoine, Rhizome de la Grande 
Chélidoine, Schollkraut, Tetterwort,Verruguera 
Green tea Camellia sinensis,   Constituant Polyphénolique de Thé Vert, CPTV, EGCG, Epigallo Catechin 
Gallate, Épigallo-Catéchine Gallate,Epigallocatechin Gallate, Extrait de Thé 
Vert, Extrait de Camellia Sinensis, Extrait de Thé, Extrait de Thea Sinensis, Green 
Sencha Tea, Green Tea Extract, Green Tea Polyphenolic 
Fraction, GTP, GTPF, Japanese Tea,Kunecatechins, Poly E, Polyphenon E, PTV, Té 
Verde, Tea Extract, Tea Green, Tea, Thé, Thé de Camillia, Thé Japonais, Thé Vert de 
Yame, Thé Vert, Thé Vert Sensha, Yame Green Tea, Yame Tea. 
Other synonyms: Camellia thea, Camellia theifera, Thea bohea, Thea sinensis, Thea 
viridis  
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Kava  Piper methysticum 
 
Kawa, Kawa-kawa, 
Macropiper 
methysticum (G. 
Forst.) Hook. & 
Arn., M. latifolium 
Miq., Waghi, Wati, 
Bari (Irian Jaya), 
Koniak, Keu, Oyo 
(Papua New 
Guinea) 
Ava Pepper, Ava Root, Awa, Gea, Gi, Intoxicating Long Pepper, Intoxicating 
Pepper, Kao, Kavain, Kavapipar,Kawa, Kawa Kawa, Kawa 
Pepper, Kawapfeffer, Kew, Lawena, Long Pepper, Malohu, Maluk, Maori 
Kava,Meruk, Milik, Poivre des Cannibales, Poivre des 
Papous, Rauschpfeffer, Rhizome Di Kava-
Kava, Sakau,Tonga, Waka, Wurzelstock, Yagona, Yangona, Yaqona, Yaquon, Yongona 
Milk Thistle Silybum marianum, 
synonym Carduus 
marianus 
Lady's Thistle, Mari
ana 
lactea Hill, Marian  
Thistle,29 
Mediterranean Milk
 Thistle, St Mary's T
histle 
Artichaut Sauvage, Blessed Milk Thistle, Cardo Lechoso, Cardui Mariae 
Fructus, Cardui Mariae Herba,Carduus Marianum, Chardon Argenté, Chardon de 
Marie, Chardon de Notre-Dame, Chardon Marbré,Chardon-Marie, Épine 
Blanche, Holy Thistle, Lady's Thistle, Lait de Notre-Dame, Legalon, Marian 
Thistle,Mariendistel, Mary Thistle, Our Lady's Thistle, Shui Fei Ji, Silibinin, Silybe de 
Marie, Silybin, Silybum, Silymarin,Silymarine, St. Mary Thistle, St. Marys Thistle 
 
Pycnogenol Pinus pinaster  
 
Condensed Tannins, Écorce de Pin, Écorce de Pin Maritime, Extrait d'Écorce de 
Pin, French Marine Pine Bark Extract, French Maritime Pine Bark 
Extract, Leucoanthocyanidins, Maritime Bark Extract, Oligomères de 
Procyanidine, Oligomères Procyanidoliques, Oligomeric 
Proanthocyanidins, OPC, OPCs, PCO, PCOs, Pine Bark, Pine Bark 
Extract, Proanthocyanidines Oligomériques, Procyandiol Oligomers, Procyanidin 
Oligomers,Procyanodolic Oligomers, Pycnogénol, Pygenol, Tannins Condensés 
Saw Palmetto Serenoa repens 
 
Sabal, Sabal serrula
ta (Michx.) 
Schult.f., 
Serenoa, Serenoa 
serrulata (Michx.) 
Hook.f. ex B.D.Jacks 
American Dwarf Palm Tree, Baies du Chou Palmiste, Baies du Palmier Scie, Cabbage 
Palm, Chou Palmiste,Ju-Zhong, Palma Enana Americana, Palmier de Floride, Palmier 
Nain, Palmier Nain Américain, Palmier Scie,Sabal, Sabal Fructus, Saw Palmetto Berry 
 
 
  
Soy Glycine max  Cosse de Soja, Cosse de Soya, Daidzein, Daidzéine, Edamame, Estrogène 
Végétal, Fermented Soy, Fève de Soja, Fève de Soya, Fibre de Soja, Fibre de 
Soya, Frijol de Soya, Genistein, Génistéine, Haba Soya, Haricot de Soja, Haricot de 
Soya, Hydrolyzed Soy Protein, Isoflavone, Isoflavone de Soja, Isoflavone de 
Soya, Isoflavones,Isolated Soy Protein, Isolated Soybean Protein, Lait de Soja, Lait de 
Soya, Legume, Miso, Natto,Phytoestrogen, Phyto-œstrogène, Plant 
Estrogen, Protéine de Haricot de Soja Isolée, Protéine de Haricot de Soya 
Isolée, Protéine de Soja, Protéine de Soya, Protéine de Soja Isolée, Protéine de Soya 
Isolée, Protéine de Soya Isolée, Shoyu, Soja, Sojabohne, Soy Bean, Soy Fiber, Soy 
Germ, Soy Isoflavone, Soy Isoflavones, Soy Milk, Soy Protein, Soy Protein 
Isolate, Soya, Soya Bean, Soja Fermenté, Soya Fermenté, Soybean, Soybean 
Curd, Soybean Isoflavone, Soybean Isoflavones, Tempeh, Texturized Vegetable 
Protein, Tofu, Touchi 
Glycine max, synonyms Glycine soja, Dolichos soja, Glycine gracilis, Glycine 
hispida, Phaseolus max, Soja hispida, Soja max 
St john’s wort Hypericum 
 perforatum 
 
Goatweed, Hyperic
um, Hypericum ver
onense Schrank, H. 
noeanum Boiss. 
(synonyms of H. 
perforatum subsp.v
eronense (Schrank) 
H.Lindb.), Millepert
uis, Klamath weed 
Amber, Amber Touch-and-Heal, Barbe de Saint-Jean, Chasse-diable, Demon 
Chaser, Fuga Daemonum,Goatweed, Hardhay, Herbe à la Brûlure, Herbe à Mille 
Trous, Herbe Aux Fées, Herbe Aux Mille Vertus, Herbe Aux Piqûres, Herbe de Saint 
Éloi, Herbe de la Saint-Jean, Herbe du Charpentier, Herbe Percée, Hierba de San 
Juan, Hypereikon, Hyperici Herba, Hypericum, Klamath 
Weed, Millepertuis, Millepertuis Perforé, Rosin Rose, Saynt Johannes 
Wort, SJW, Tipton Weed 
 
Valerian Valeriana  
officinalis 
 
All-Heal, 
Belgian Valerian, 
Common Valerian, 
Fragrant Valerian, 
Garden Valerian 
All-Heal, Amantilla, Baldrian, Baldrianwurzel, Belgium Valerian, Common 
Valerian, Fragrant Valerian, Garden Heliotrope, Garden Valerian, Grande 
Valériane, Guérit Tout, Herbe à la Femme Meurtrie, Herbe aux Chats,Herbe aux 
Coupures, Herbe de Notre-Dame, Herbe de Saint-Georges, Herbe du Loup, Indian 
Valerian,Mexican Valerian, Pacific Valerian, Rhizome de Valériane, Tagar, Tagar-
Ganthoda, Tagara, Valeriana,Valeriana Pseudofficinalis, Valeriana 
Rhizome, Valerianae Radix, Valeriane, Valériane, Valériane à Petites 
Feuilles, Valériane Africaine, Valériane Celtique, Valériane Commune, Valériane de 
Belgique, Valériane des Collines, Valériane Dioïque, Valériane du Jardin, Valériane 
Indienne, Valériane Mexicaine, Valériane Officinale, Valériane Sauvage. 
Valeriana officinalis; Valeriana edulis; Valeriana angustifolia; Valeriana jatamansii, 
synonym Valeriana wallichii; Valeriana sitchensis 
Yohimbe Pausinystalia 
johimbe 
 
Corynanthe 
johimbe K.Schum., 
Pausinystalia 
trillesii Beille, Pausi
11-hydroxy Yohimbine, Alpha Yohimbine HCl, Coryanthe Yohimbe, Corynanthe 
Johimbe, Johimbi, Yohimbehe,Yohimbehe Cortex, Yohimbine, Yohimbine 
HCl, Yohimbinum Muriaticum. 
Pausinystalia yohimbe, synonyms Pausinystalia johimbe, Corynanthe 
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nystalia yohimbe Pi
erre ex 
Bielle,Pausinystalia 
zenkeri W.Brandt, 
Yohimbeherinde. 
johimbi, Corynanthe yohimbi 
 
Senna  Senna alexandrina Not in database Not in database 
Arrowroot Maranta 
arundinacea 
Not in database Arrow-Root, Arrurruz, Dictame, Herbe aux Flèches, Maranta, Marante, Marante 
Arundinacée  
Maranta arundinacea 
Bush tea  Aspalathus linearis Not in database Green Red Bush, Infusion Rooibos, Kaffree Tea, Red Bush, Rooibos, Rooibos 
Rouge, Rooibos Tea, Té Rojo,Té Rojo Rooibos, Thé Rooibos, Thé Rouge 
Aspalathus linearis, synonyms Aspalathus contaminatus, Borbonia pinifolia, Psoralea 
linearis 
Coltsfoot Tussilago farfara Not in database Ass's Foot, Brandlattich, British Tobacco, Bullsfoot, Chasse-
Toux, Coughwort, Farfarae Folium Leaf,Fieldhove, Filuis Ante Patrem, Flower 
Velure, Foal's Foot, Foalswort, Guflatich, Hallfoot, Herbe aux Pattes,Herbe de Saint-
Guérin, Horsefoot, Horsehoof, Kuandong Hua, Kwandong Hwa, Pas Diane, Pas 
d'Ane, Pas d'Âne, Pas-d'Âne, Pas-de-Baudet, Pferdefut, Pied-de-
Cheval, Plisson, Procheton, Taconnet, Tussilage,Tussilage Pas d'Âne, Uña de Caballo 
Distaff thistle Atractylis lanacea 
Atractylis 
gummifera  
Not in database Not in database 
Ephedra / Ma 
huang 
Ephedra distachya 
Synonym: Ephedra 
vulgaris 
Ephedra equisetina 
Ephedra 
shennungiana 
Ephedra gerardiana 
Ephedra intermedia 
Ephedra sinica 
Ephedra sinensis; 
and other Ephedra 
species. 
 *Cao Ma Huang, E. 
mahuang Liu 
 †E. 
shennungiana Tang 
 ‡Zhong Ma Huang 
 **E. 
gerardiana var. con
gesta C.Y. Cheng, 
Shan 
Ling Ma Huang 
 ††E. 
scoparia Lange, E. 
nebrodensis Tineo 
ex Guss 
Ephedra (and some 
other herbs) has 
also been referred 
to as 'herbal 
ecstasy' 
Alcaloïde d'Éphédrine, Belcho, Cao Mahuang, Chinese Ephedra, Chinese Joint-
Fir, Cao Ma-Huang, Desert Herb, Efedra, Éphédra, Éphédra Américain, Éphédra 
Chinoise, Éphédra Européen, Ephedra 
Sinisa, Éphèdre,Ephedrine, Éphédrine, Ephedrine Alkaloid, Épitonin, Herbal 
Ecstasy, Indian Jointfir, Joint Fir, Ma Huang,Mahuanggen (ma huang 
root), Mongolian Ephedra, Muzei Ma Huang, Pakistani Ephedra, Popotillo, Raisin de 
Mer, Sea Grape, Shuang Sui Ma Huang, Teamster's Tea, Thé de Désert, Yellow 
Astringent, Yellow Horse,Zhong Mahuang. 
Gotu kola Centella asiatica, 
synonym  
Hydrocotyle 
asiatica;  
Centella coriacea 
 Brahma-Buti, Brahma-Manduki, Brahmi, Centella, Centella Asiática, Centella 
Asiatique, Centellase, Divya,Hydrocotyle, Hydrocotyle Asiatique, Hydrocotyle 
Indien, Indischer Wassernabel, Idrocotyle, Indian Pennywort,Indian Water 
Navelwort, Ji Xue Cao, Khulakhudi, Luei Gong Gen, Luo De 
Da, Madecassol, Mandukaparni,Manduk Parani, Mandukig, Marsh 
Penny, TTFCA, Talepetrako, Thick-Leaved Pennywort, Tsubo-kusa,Tungchian, White 
Rot 
Groundsel  Senecio vulgaris Golden Ragwort, 
Golden Senecio, 
Heart-
leaved Groundsel, 
Squaw Weed, life 
root 
Cineraria, Common Groundsel, Flor Amarilla, Ground Glutton, Grundy 
Swallow, Hierba Cana, Petit Séneçon,Senecio Común, Séneçon Commun, Séneçon 
Vulgaire, Simson, Yuyito 
Guarana  Paullinia cupana, 
synonym Paullinia 
sorbilis 
Not in database Brazilian Cocoa, Cacao Brésilien, Guarana Seed Extract, Guaranine, Zoom 
Heliotropium  Heliotropium  Not in database Not in database 
Impila   Not in database Not in database 
Isabgol  Plantago ovata, 
synonyms Plantago 
fastigiata, Plantago 
insularis, Plantago 
ispaghula, Plantago 
decumbens 
Blond Psyllium, 
Indian Plantago, 
Ispagol, Ispaghul, 
Pale Psyllium, 
Spogel 
 
Balle de Psyllium, Blond Plantago, Blonde Psyllium, Che Qian Zi, Dietary 
Fiber, Englishman's Foot, Fibre Alimentaire, Indian 
Plantago, Ipágula, Isabgola, Isabgul, Ispaghul, Ispaghula, Ispagol, Pale 
Psyllium,Plantaginis Ovatae Semen, Plantaginis Ovatae Testa, Psilio, Psillium 
Blond, Psyllium, Psyllium Blond,Psyllium Husk, Sand Plantain, Spogel. 
Kambala   Not in database Not in database 
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Mate  Ilex paraguariensis Ilex, Jesuit's Brazil 
Tea, Paraguay Tea, 
St Bartholomew's 
Tea, Yerba Maté 
Chimarrao, Green Mate, Hervea, Ilex, Jesuit's Brazil Tea, Jesuit's Tea, Maté, Maté 
Folium, Paraguay Tea, St. Bartholemew's Tea, Thé de Saint Barthélémy, Thé des 
Jésuites, Thé du Brésil, Thé du Paraguay, Yerbamate,Yerba Mate, Yerba Maté. 
Mistletoe  (European) Viscum 
Album 
(American) 
Phoradendron 
leucarpum, 
synonyms Phoraden
dron 
flavescens, Phorade
ndron 
serontium, Viscum 
leucarpum, Viscum 
flavescens; Phorade
ndron 
macrophyllum; Pho
radendron 
tomentosum 
Viscum album  (American) Eastern Mistletoe, Gui Américain, Gui de Chêne, Mistletoe, Muérdago 
Americano 
Noni  Morinda citrifolia Canary Wood, Hog 
Apple, Indian 
mulberry, Morinda 
Ba Ji Tian, Bois Douleur, Canarywood, Cheese Fruit, Hai Ba Ji, Hawaiian Noni, Hog 
Apple, Indian Mulberry,Indian Noni, Jus de 
Noni, Luoling, Mengkudu, Menkoedoe, Mora de la India, Morinda, Mulberry, Mûre 
Indienne,Nhau, Noni Juice, Nono, Nonu, Pau-Azeitona, Rotten Cheese 
Fruit, Ruibarbo Caribe, Tahitian Noni Juice, Ura,Wild Pine, Wu Ning, Yor 
Oleander  Nerium oleander, 
synonyms Nerium 
indicum, Nerium 
odorum; Thevetia 
peruviana, 
synonyms Cascabel
a thevetia, Cerbera 
thevetia, Thevetia 
neriifolia 
Not in database Adelfa, Baladre, Common Oleander, Exile Tree, Huang Hua Jia, Jia Zhu 
Tao, Kaner, Karvir, Karvira, Laurel Rosa, Laurier-Rose, Laurier Rose, Laurose, Nérier à 
Feuilles de Laurier, Nérion, Oleanderblatter, Oléandre,Oleandri Folium, Rose 
Bay, Rose Laurel, Sweet Scented Oleander, Yellow Oleander 
Oxeye daisy Chrysanthemum 
leucanthemum 
Not in database Butter Daisy, Chrysanthème Leucanthème, Dun Daisy, Golden 
Daisy, Goldenseal, Grande Marguerite, Great Ox-Eye, Herb Margaret, Horse 
Daisy, Horse Gowan, Margarita, Marguerite, Marguerite Blanche, Marguerite des 
Champs, Marguerite Commune, Marguerite Vulgaire, Maudlin 
Daisy, Maudlinwort, Moon Daisy, Moon Flower,Moon Penny, Poverty Weed, White 
Daisy, White Weed 
Pennyroyal  Mentha pulegium, 
synonym Pulegium 
vulgare; Hedeoma 
pulegioides, 
synonym Melissa 
pulegioides 
 *Pulegium 
vulgare Mill., P. 
parviflorum (Req.) 
Samp. pro parte 
 †Melissa 
pulegioides L., 
Squaw Mint 
American Pennyroyal, Dictame de Virginie, European Pennyroyal, Feuille de Menthe 
Pouliot, Frétillet, Herbe aux Puces, Herbe de Saint-Laurent, Huile de Menthe 
Pouliot, Lurk-In-The-Ditch, Menthe Pouliot, Menthe Pouliote, Mosquito 
Plant, Piliolerial, Poleo, Pouliot, Pouliot Royal, Pudding Grass, Pulegium, Run-By-The-
Ground, Squaw Balm, Squawmint, Stinking Balm, Tickweed 
Pro-lean ®  Brand name   
Rattle box Crotalaria   
Red yeast rice  Monascus 
purpureus; 
other Monascus 
species. 
 Arroz de Levadura Roja, Cholestin, Hong Qu, Koji Rouge, Levure de Riz 
Rouge, Monascus, Monascus Purpureus Went, Red Rice, Red Rice Yeast, Red Yeast 
Rice, Red Yeast Rice Extract, Riz Rouge, XueZhiKang,Xue Zhi Kang, XZK, Zhibituo, Zhi 
Tai 
Sassafras  Sassafras albidum, 
synonyms Sassafras 
officinale, Sassafras 
variifolium, Laurus 
albida. 
 Ague Tree, Bois de Cannelle, Cinnamon Wood, Common Sassafras, Kuntze 
Saloop, Laurier des Iroquois,Saloop, Sasafras, Saxifrax 
Stonecrop Sedum acre  Bird Bread, Creeping Tom, Gazon d'Or, Gold Chain, Golden Moss, Jack-of-the-
Buttery, Mousetail, Orpin Âcre,Orpin Brûlant, Pain d'Oiseau, Pampajarito, Petite 
Joubarbe, Poivre de Muraille, Prick Madam, Trique-Madame,Uva de 
Gato, Vermiculaire, Vermiculaire Âcre, Wall Ginger, Wallpepper 
Venencapsan ® Brand name   
Venoplant ® Brand name   
Wolf’s foot Lycopodium 
clavatum 
 Licopodio, Lycopode, Lycopode en Massue, Lycopodium, Shen Jin Cao, Stags 
Horn, Vegetable Sulfur, Witch Meal, Wolfs Claw 
Cascara sagrada Frangula purshiana, Cascara Sagrada, R Aulne Noir, Bitter Bark, Bois Noir, Bois à 
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synonym Rhamnus 
purshiana 
hamni Purshianae C
ortex, Rhamnus, Rh
amnuspurshiana DC
. 
Poudre, Borzène, Bourgène, Buckthorn, California Buckthorn,Cáscara, Cascara 
Sagrada, Chittem Bark, Dogwood Bark, Écorce Sacrée, Nerprun, Pastel 
Bourd, Purshiana Bark, Rhamni Purshianae Cortex, Rhubarbe des Paysans, Sacred 
Bark, Sagrada Bark, Yellow Bark 
  
Fenugreek Trigonella foenum-
graecum; Trigonella 
foenugraecum 
Bockshorn  Alholva, Bird's Foot, Bockshornklee, Bockshornsame, Chandrika, Egypt 
Fenugreek, Fenogreco, Fenugrec,Foenugraeci Semen, Foenugreek, Greek 
Clover, Greek Hay, Greek Hay Seed, Hu Lu 
Ba, Methi, Methika,Medhika, Sénégrain, Sénégré, Trigonella, Trigonella 
Foenum, Trigonelle, Woo Lu Bar 
Hoodia Hoodia gordonii Hoodia barklyi Dyer
, Hoodia burkei N.E.
Br., Hoodia longispi
na Plowes,Scytanth
us 
gordonii (Masson) 
Hook., Stapelia 
gordonii Masson. 
Cactus, Cactus Hoodia, Cactus du Kalahari, Extrait de Hoodia, Hoodia Gordonii 
Cactus, Hoodia P57, Kalahari Cactus, Kalahari Diet, P57, Xhoba 
Hydroxycut® Brand name   
Horse chestnut Aesculus 
hippocastanum. 
Aesculus 
 
  
Aescin, Buckeye, Castaño de Indias, Châtaignier de Mer, Châtaignier des 
Chevaux, Chestnut, Escine, Faux-Châtaignier, Hippocastani Cortex, Hippocastani 
Flos, Hippocastani Folium, Hippocastani Semen,Hippocastanum Vulgare 
Gaertn, Marron Europeen, Marronnier, Marronnier Blanc, Marronnier 
Commun,Marronnier d'Inde, Marronnier des Chevaux, Pu, Spanish 
Chestnut, Venastat, Venostat, Venostasin Retard,White Chestnut.  
Hyssop  Hyssopus officinalis.  Herbe de Joseph, Herbe Sacrée, Herbe 
Sainte, Hiope, Hisopo, Hissopo, Hysope, Hysope Officinale, Jufa,Rabo De Gato, Ysop. 
Skullcap Scutellaria 
lateriflora 
 *Helmet Flower, 
Hoodwort, Quaker 
Bonnet, Scutellaria, 
Skullcap 
 †S. 
grandiflora Adams.,
 S. 
lanceolaria Miq., S. 
macrantha Fisch., 
BaicalSkullcap, 
Huang Qin  
American Skullcap, Blue Pimpernel, Blue Skullcap, Escutelaria, Grande 
Toque, Helmet Flower, Hoodwort,Mad Weed, Mad-Dog Skullcap, Quaker 
Bonnet, Scullcap, Scutellaria, Scutellaire, Scutellaire de Virginie,Scutellaire 
Latériflore, Scutelluria, Toque Bleue, Toque Casquée, Toque des Marais. 
Comfrey Symphytum 
officinale. 
Symphytum Radix 
 
  
Ass Ear, Black Root, Blackwort, Bruisewort, Common Comfrey, Consolidae 
Radix, Consoude, Consoude Officinale, Consound, Consuelda, Grande 
Consoude, Gum Plant, Healing Herb, Herbe aux Charpentiers,Herbe à la 
Coupure, Knitback, Knitbone, Langue-de-Vache, Oreille d'Âne, Salsify, Slippery 
Root, Wallwort. 
Noni  Morinda citrifolia Canary Wood, Hog 
Apple, Indian 
mulberry, Morinda. 
  
Ba Ji Tian, Bois Douleur, Canarywood, Cheese Fruit, Hai Ba Ji, Hawaiian Noni, Hog 
Apple, Indian Mulberry,Indian Noni, Jus de 
Noni, Luoling, Mengkudu, Menkoedoe, Mora de la India, Morinda, Mulberry, Mûre 
Indienne,Nhau, Noni Juice, Nono, Nonu, Pau-Azeitona, Rotten Cheese 
Fruit, Ruibarbo Caribe, Tahitian Noni Juice, Ura,Wild Pine, Wu Ning, Yor. 
Usnic acid Usnea 
barbata; Usnea 
florida; Usnea 
hirta; Usnea plicata 
 coltsAcide Usnique, Barba de Capuchino, Barbe de Jupiter, Barbe de Saint 
Antoine, Beard Moss, Mousse d'Arbre,Musgo de los Arboles, Old Man's 
Beard, Sodium Usniate, Tree Moss, Tree's Dandruff, Usnea Lichen, Usnée,Usnée 
Barbue, Usnée Fleurie, Usniate de Sodium, Usnic Acid, Woman's Long Hair 
Chaso   Not in database Not in database 
Bai Fang  Not in database Not in database 
Ba Jiao Lian  Dysosma ple Not in database 
Boh Gol Zhee  Syn. Bu Ku Zi Not in database 
Dai Saiko To  Syn. Da Chai Hu 
Tang 
Not in database 
Ho Shou Wu  Syn. He Shou Wu Not in database 
Jin Bu Huan  Not in database Not in database 
Onshido  Not in database Not in database 
Shenmin  Not in database Not in database 
Shou Wu Pian  Not in database Not in database 
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Shu Ling   Not in database Not in database 
Xiao Chai Hu 
Tang 
 Syn. Syo Xiao Hu 
Tang 
Not in database 
Chi R Yun   Not in database Not in database 
Sho Saiko To  Not in database Not in database 
Vitamins and minerals 
Vitamin A Vitamin A  3-Dehydroretinol, 3-Déhydrorétinol, Acétate de Rétinol, Antixerophthalmic 
Vitamin, Axerophtholum,Dehydroretinol, Déhydrorétinol, Fat-Soluble 
Vitamin, Oleovitamin A, Palmitate de 
Rétinol, Retinoids,Rétinoïdes, Retinol, Rétinol, Retinol Acetate, Retinol 
Palmitate, Retinyl Acetate, Rétinyl Acétate, Retinyl Palmitate, Rétinyl 
Palmitate, Vitamin A Acetate, Vitamin A Palmitate, Vitamin A1, Vitamin A2, Vitamina 
A,Vitamine A, Vitamine A1, Vitamine A2, Vitamine Liposoluble, Vitaminum A. 
Dietary Supplement 
Glucosamine 2-amino-2-
deoxyglucose 
hydrochloride. 
Not in database 2-Amino-2-Deoxy-Beta-D-Glucopyranose, 2-Amino-2-Deoxy-Beta-D-Glucopyranose 
Hydrochloride, Amino Monosaccharide, Chitosamine, Chlorhidrato de 
Glucosamina, Chlorhydrate de Glucosamine, D-Glucosamine 
HCl, Glucosamine, Glucosamine HCl, Glucosamine KCl, Glucosamine-6-Phosphate 
Melatonin  N-acetyl-5-
methoxytryptamine 
Not in database MEL, Melatonina, Mélatonine, MLT, N-Acétyl-5-Méthoxytryptamine, Pineal 
Hormone 
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11 Appendix B. Liver injury terms and their occurrences in FDA AERS 
data 
 Liver Injury Term (Preferred Term, 
MedDRA V16.0) 
Frequency Cumulative 
percent 
1 ALTincreased 18439 10.72428 
2 ASTincreased 17168 20.70933 
3 Hepaticenzymeincreased 10463 26.7947 
4 Liverfunctiontestabnormal 9799 32.49388 
5 Liverdisorder 8738 37.57597 
6 Jaundice 7838 42.13462 
7 Jaundiceacholuric 7838 46.69327 
8 Bloodbilirubinincreased 7738 51.19375 
9 Hepaticfailure 7609 55.61921 
10 GGTincreased 7368 59.9045 
11 Hepaticfunctionabnormal 7139 64.0566 
12 Hepatitis 6235 67.68293 
13 Ascites 5348 70.79337 
14 Hepaticsteatosis 4065 73.15761 
15 Transaminaseincreased 3655 75.28339 
16 Cholestasis 3647 77.40451 
17 Hepatotoxicity 3284 79.31452 
18 Hepatomegaly 2851 80.97268 
19 Hepaticcirrhosis 2763 82.57967 
20 Liverinjury 2340 83.94063 
21 Acutehepaticfailure 1862 85.02358 
22 Hepaticencephalopathy 1788 86.0635 
23 Hyperbilirubinaemia 1716 87.06154 
24 Hepaticnecrosis 1686 88.04213 
25 Hepatitischolestatic 1543 88.93955 
26 Hepatitis acute 1540 89.83523 
27 hypoalbuminaemia 1531 90.72567 
28 Ocularicterus 1011 91.31368 
29 Acutegraftvshostdisease 988 91.88831 
30 Jaundicecholestatic 934 92.43153 
31 Hepatitisfulminant 923 92.96835 
32 Hepatocellularinjury 875 93.47726 
33 Hyperammonaemia 860 93.97745 
34 Hepatitistoxic 790 94.43692 
35 Hepatosplenomegaly 781 94.89115 
36 Yellowskin 698 95.29711 
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37 Hepaticenzymeabnormal 654 95.67749 
38 Chronicgraftvshostdisease 600 96.02645 
39 Hepaticpain 598 96.37425 
40 Hypoproteinaemia 464 96.64412 
41 Hepaticcongestion 461 96.91224 
42 Jaundiceneonatal 421 97.1571 
43 Hepatorenalsyndrome 389 97.38334 
44 Ischaemichepatitis 298 97.55666 
45 Comahepatic 290 97.72533 
46 Asterixis 275 97.88527 
47 ALTabnormal 244 98.02718 
48 Bloodbilirubinuncongincreased 234 98.16328 
49 Bloodbilirubinunconjugatedincreased 234 98.29938 
50 Chronichepatitis 228 98.43198 
51 ASTabnormal 198 98.54714 
52 Hepatorenalfailure 197 98.66172 
53 Bloodbilirubinabnormal 185 98.76932 
54 Cholestaticliverinjury 165 98.86528 
55 ALTdecreased 143 98.94845 
56 Mixedliverinjury 141 99.03046 
57 Hypertransaminasaemia 138 99.11072 
58 HELLPsyndrome 115 99.17761 
59 Livertenderness 112 99.24275 
60 Chronichepaticfailure 108 99.30556 
61 GGTabnormal 105 99.36663 
62 Hyperbilirubinaemianeonatal 103 99.42653 
63 Reyessyndrome 92 99.48004 
64 Alcoholicliverdisease 91 99.53297 
65 AGTdecreased 84 99.58182 
66 Hepatitisalcoholic 81 99.62893 
67 Haemorrhagicascites 73 99.67139 
68 Hepatitischronicactive 71 99.71269 
69 Bloodbilirubindecreased 54 99.74409 
70 Transaminaseabnormal 53 99.77492 
71 Cholestasisofpregnancy 48 99.80283 
72 GGTdecreased 40 99.8261 
73 Subacutehepaticfailure 33 99.84529 
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74 Jaundicehepatocellular 28 99.86158 
75 Hepaticenzymedecreased 26 99.8767 
76 Neonatalhepatomegaly 22 99.88949 
77 Liverfunctiontest 21 99.90171 
78 Portaltriaditis 18 99.91218 
79 Hepaticinfiltrationeosinophilic 17 99.92206 
80 Graftvshostdiseaseinliver 12 99.92904 
81 Transaminasedecreased 11 99.93544 
82 Foetorhepaticus 10 99.94126 
83 Fattyliveralcoholic 10 99.94707 
84 Deficiencybilesecretion 9 99.95231 
85 Pneumobilia 8 99.95696 
86 Acutefattyliverofpregnancy 8 99.96161 
87 Hepatitisneonatal 8 99.96627 
88 hepatichydrothorax 7 99.97034 
89 Liverinduration 7 99.97441 
90 Perihepaticdiscomfort 6 99.9779 
91 Radiationhepatitis 6 99.98139 
92 Hepatitischronicpersistent 5 99.9843 
93 Bloodbilirubinunconjugated 5 99.9872 
94 Kernicterus 4 99.98953 
95 GlycogenstoragediseaseI 4 99.99186 
96 Lupushepatitis 3 99.9936 
97 Zievesyndrome 3 99.99535 
98 Allergichepatitis 2 99.99651 
99 Hepatocellularfoamycell 2 99.99767 
100 Bilirubinexretiondisorder 1 99.99826 
101 Liverprolapse 1 99.99884 
102 Bacterascites 1 99.99942 
103 Hepatocellulardamageneonatal 1 100 
104 Stauffers 0  
105 Criglernajjarsyndrome 0  
106 Drug induced liverinjury 0  
107 Cholestaticpruritis 0  
108 Kayser Fleischer ring 0  
109 Granulomatuousliverdisease 0  
110 Nonalcoholicsteatohepatisis 0  
111 Jaundice eextrahepaticobstruction 0  
 177 
 
112 Neonataljaundice 0  
113 Postcholecystectomysyndrome 0  
114 Hyperammonaemiacrisis 0  
115 Neonatalhepatosplenomegaly 0  
116 Periportaloedema 0  
117 Acuteyellowliveratrophy 0  
118 Cysticfibrosishepaticdisease 0  
119 GlycogenstoragediseaseIII 0  
120 GlycogenstoragediseaseVI 0  
121 Hepatitismumps 0  
 Total - liver injury cases 171937  
 Total - all cases in AERS 2681744  
 Percent liver cases 6.41  
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12 Appendix C. Alternative groupings for herbs that have literature 
evidence for liver injury 
Herb grouping based on HILI mechanism using literature evidence 
Idiosyncratic  Direct toxicity Unknown  
Greater celandine (metabolic) 
Black cohosh (immune) 
Kava (references differ) 
Jin Bu Huan 
Ephedra/Ma Huang (immune, 
references differ, study signal is 
immune)
 
Noni (idiosyncratic, possibly direct 
toxicity) 
 
Pyrrolizidine alkaloid containing 
herbs (comfrey, crotalaria, 
helitropium, senecio longilobus) 
Noni (idiosyncratic, possibly direct 
tox) 
Senna (unknown, no immune 
features, possible direct toxicity) 
 
 
Germander  
Attractylis gummifera 
Impila 
Dai-saiko-to 
Sho-saiko-to 
Green tea / herbalife
 
Mistletoe 
Distaff thistle 
 
Rare immune features: 
Shou Wu Pian 
Aloe vera 
 
No immune features: 
Cascara (possibly direct toxicity) 
Senna (possible direct toxicity) 
Chaparral (no immune features) 
Pennyroyal oil  
Saw palmetto  
Skull cap  
Valerian  
Horse chestnut 
Hydroxycut  
Valerian  
Skullcap  
 
Not considered hepatotoxic: 
St John’s wort 
Fenugreek  
Ginkgo  
Ginseng 
 
No information found: 
Soy  
Isabgol 
Evening primrose 
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Herb grouping based on hepatotoxicity pattern using literature evidence 
Hepatocellular  Cholestatic  Mixed  Unknown  
Aloe vera 
Cascara 
Chaparral 
Greater celandine 
Green tea / Herbalife 
Horse chestnut (also 
mixed) 
Ma Huang / ephedra 
Noni 
Senna 
Skull cap 
Shou Wu Pian (also 
mixed) 
Valerian (also mixed) 
 
 Horse chestnut (also 
hepatocellular) 
Kava 
Shou Wu Pian (also 
hepatocellular) 
Valerian (also hepatocellular) 
Black cohosh 
Dai-saiko-to / Sho-saiko-to 
Distaff thistle 
Germander 
Hoodia 
Hydroxycut 
Impila 
Jin Bu Huan 
Mistletoe 
Pennyroyal oil 
Pyrrolizidine alkaloids 
Saw palmetto 
Vitamin A 
 
Not considered hepatotoxic: 
St John’s wort 
Fenugreek 
Ginkgo  
Ginseng  
 
No information found: 
Soy  
Isabgol  
Evening primrose 
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13 Appendix D. Chemical constituents of herbs considered for  
pharmacophore analysis 
Black cohosh Alkaloids 
Guanidine-type: cimipronidine, cimipronidine methyl ester, cyclocimipronidine, and 
dopargine (probable Pictet-Spengler reaction product of dopamine and γ-
guanidinobutyraldehyde; the latter was detected by LC-MS in root extracts 
of black cohosh).
2, 3
 Quinolizidine-type: cytisine and N-methylcytisine.
4
 
Isoflavonoids 
The presence of formononetin (7-hydroxy-4'-methoxyisoflavone) is disputed. The reasons for 
these conflicting observations are unclear, although some suggest that differences in the 
provenance (e.g. geographical origin), time of harvest, or condition of plant material may be 
responsible.
8, 10
 As such, caution should be exercised in ascribing estrogenic properties 
of blackcohosh to isoflavones. 
Phenylpropanoids 
Hydroxycinnamic acids: caffeic, p-coumaric, ferulic and isoferulic acids.
12–14
Esters of 
hydroxycinnamic acids: methyl caffeate, methyl ferulate, cimiracemates A–
D;
13, 14
 hydroxycinnamoyl esters of fukiic acid: fukinolic acid, cimicifugic acids A, B and 
G;
12, 14
 hydroxycinnamoyl esters of piscidic acid: cimicifugic acids D–F;
12, 14
 other esters 
include cimiciphenol (3,4-dihydroxyphenyl-2-oxopropyl isoferulate), cimiciphenone (3,4-
dihydroxyphenacyl isoferulate), petasiphenone (3,4-dihydroxyphenacyl caffeate), E-
caffeoylglycolic acid (3,4-dihydroxy-E-cinnamoyl hydroxyacetic acid).
15
 Glycoside: 1-
isoferuloyl-β-glucopyranoside.
14
 
Terpenoids 
Complex mixture of more than fifty triterpene glycosides of the 9,19-cycloartenol-type with 
either β-xylose or α-arabinose O-linked at C-3. They include actein
16–21
 and related 
compounds cimicifugoside (cimigoside), 26-deoxycimicifugoside, cimiaceroside A, 
cimiracemosides A–H,
22–24
cimicifugosides H-3, H-4 and H-6,
25
 cimigenol, 26-deoxyactein, 23-
epi-26-deoxyactein (revised structure proposed for 27-deoxyactein),
21–23
cimiracemosides I–P 
and thirteen other cimiracemosides: 2'-O-acetylactein, 25-O-acetylcimigenol-3-O-α-L-
arabinoside, 25-O-acetylcimigenol-3-O-β-D-xyloside, 23-O-acetylshengmanol-3-O-α-L-
arabinoside, 23-O-acetylshengmanol-3-O-β-D-xyloside, 24-O-acetylshengmanol, 25-
anhydrocimigenol-3-O-α-L-arabinoside, 25-anhydrocimigenol-3-O-β-D-xyloside, cimigenol-3-
O-α-L-arabinoside, cimicifugosides H-1 and H-2, cimigenol-3-O-β-D-xyloside, 26-
deoxycimicifugoside;
26, 27
 actaeaepoxide-3-O-β-D-xylopyranoside.
28
 Recently described minor 
constituents comprise 12β-acetoxycimigenol-3-O-β-D-xyloside,
29
 2'-O-acetyl- and 3'-O-
acetylcimicifugoside H-1,
30
 neocimicigenosides A and B,
31
 and 24-O-acetylhydroshengmanol-
3-O-α-L-arabinoside.
32
 The major triterpene glycosides appear to be actein, 23-epi-26-
deoxyactein, 23-O-acetylshengmanol-3-O-β-D-xyloside, cimigenol-3-O-α-L-arabinoside, and 
cimigenol-3-O-β-D-xyloside.
33
 Sterols: daucosterol-6'-lineolate (= β-sitosterol-6-
linoleoylglucoside);
26
 several common sterols detected in root extracts using GC-MS.
6
 
Other constituents 
Fatty acids, including methyl and ethyl esters;
6
 glyceryl-1-palmitate.
26
Lignan: 
actaealactone;
14
 phenolics: protocatechuic acid and protocatechualdehyde,
14
 3-
hydroxytyrosol 3-O-glucoside.
3
 
Kava Kavalactones 
δ-Lactones (α-pyrones, 2-pyrones = 2H-pyran-2-ones) or 5,6-dihydro-δ-lactones with styryl or 
dihydrostyryl substituents; also referred to as kawalactones or kavapyrones.
1–10
 Dried 
rhizomes should contain at least 3.5% kavalactones
10
 and good-quality material 5.5–
8.3%.
11
 Ethanol–water extracts contain 30% kavalactones, whereas acetone–water extracts 
contain 70%.
10
 The kavalactones occur as a complex mixture of at least 18 
compounds,
4
 which are of three main types: styryl enolide pyrones (e.g. kawain (= kavain), 
dimethoxykawain, methysticin), styryl dienolide pyrones (e.g. yangonin, 
desmethoxyyangonin), and dihydrostyryl enolide pyrones (e.g. dihydrokawain, 
dimethoxydihydrokawain, dihydromethysticin). The four major kavalactones of the rhizome 
are kawain (1–2%), dihydrokawain (0.6–1%), methysticin (1.2–2%) and dihydromethysticin 
(0.5–0.8%).
10
 Smaller quantities (<0.1%) of dimeric kavalactones (e.g. trux-yangonins I, II, III) 
have also been isolated.
2, 3
 
Alkaloids/amides 
Cepharadione A (aporphine-type) is a minor component (4 kg yielded 1 mg).
12
 Small 
quantities of N-cinnamoylpyrrolidine and its O-methoxy analogue are also present.
5, 13, 14
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Chalcones and other flavonoids 
Chalcones: flavokawains A, B and C (di- or trimethyl ethers of 2',4',6'-trihydroxy- or 2',4',6',4-
tetrahydroxychalcone).
5, 8, 15
 Flavanones: pinostrobin, 5,7-dimethoxyflavanone.
15
 
Steroids 
Sitosterol, stigmasterol, stigmastanol.
5, 14
 
Esters 
Bornyl cinnamate
14
 and bornyl 3,4-methylenedioxycinnamate.
15
 
Aliphatic alcohols 
Docosan-1-ol, dodecan-1-ol, eicosan-1-ol, hexacosan-1-ol, hexadecan-1-ol, octadecan-1-ol, n-
tetradecanol, transphytol.
5
 
Other constituents 
Cinnamylideneacetone and 3,4-methylenedioxycinnamylideneacetone,
4, 5
long-chain fatty 
acids.
5
 
Ma Huang 
(ephedra) 
Alkaloids 
0.5–2.0%. Mainly (−)-ephedrine (30–90% in most species, except E. intermedia) and (+)-
pseudoephedrine, also (−)-norephedrine, (+)-norpseudoephedrine, (−)-methylephedrine and 
(+)-methylpseudoephedrine.
1, 2
 
Volatile oil 
Mainly terpenoids (e.g. α-terpineol, limonene, tetramethylpyrazine, terpinen-4-ol, linalol).
3
 
Other constituents 
Tannins (catechin, gallic acid), ephedrans (glycans) and acids (citric, malic, oxalic). 
Cascara sagrada Anthracene glycosides 
Pharmacopoeial standard, not less than 8% hydroxyanthracene 
glycosides.
G15, G28
 Cascarosides A and B are anthrone C- and O-glycosides being 8-O-β-D-
glucosides of 10-S-deoxyglucosyl aloe-emodin anthrone (aloin A) and of 10-R-deoxyglucosyl 
aloe-emodin anthrone (aloin B), respectively. Cascarosides C and D are the 8-O-β-D-
glucosides of 10-(R)-(S)-deoxyglucosyl chrysophanol anthrone (chrysaloin A and B, 
respectively). Cascarosides E and F are the 8-O-β-D-glucosides of 10-deoxyglucosyl emodin-9-
anthrone. The cascarosides comprise 60–70% of the total hydroxyanthracene complex. Aloins 
A and B, chrysaloins A and B account for 10–30% of the total hydroxyanthracene complex. 
The remaining 10–20% is a mixture of hydroxyanthracene O-glycosides including 
monoglucosides of aloe-emodin, chrysophanol, emodin and physcion. 
Other constituents 
Linoleic acid, myristic acid, syringic acid, lipids, resin and tannin 
 
Ginkgo Leaf 
Amino acids 
6-Hydroxykynurenic acid (2-carboxy-4-one-6-hydroxyquinoline), a metabolite of 
tryptophan.
3–5
 
Flavonoids 
Dimeric flavones (e.g. amentoflavone, bilobetin, ginkgetin, isoginkgetin, 
sciadopitysin);
6
 flavonols (e.g. quercetin, kaempferol) and their glycosides
3,7
 and coumaroyl 
esters. 
Terpenoids 
Sesquiterpenes (e.g. bilobalide), diterpenes (e.g. ginkgolides A, B, C, J, M, which are unique 
cage molecules,
8, 9, G48
 and triterpenes (e.g. sterols). 
Other constituents 
Benzoic acid, ginkgolic acids, 2-hexenal, polyprenols (e.g. di-trans-poly-cis-octadecaprenol), 
proanthocyanidins, sugars, waxes,
1
 a peptide.
10
 
Ginseng Terpenoids 
Complex mixture of compounds (ginsenosides or panaxosides) involves three aglycone 
structural types – two tetracyclic dammarane-type sapogenins (protopanaxadiol and 
protopanaxatriol) and a pentacyclic triterpene oleanolic acid-type. Different naming 
conventions have been used for these compounds. In Japan, they are known as ginsenosides 
and are represented by Rx where 'x' indicates a particular saponin. For example, Ra, Rb-1, Rc, 
Rd, Rg-1. In Russia, the saponins are referred to as panaxosides and are represented as 
panaxoside X where 'X' can be A–F. The suffixes in the two systems are not equivalent and 
thus panaxoside A does not equal Ra but Rg-1.
1
 
The saponin content varies between different Panax species. For example, in P. ginseng the 
major ginsenosides are Rb-1, Rc and Rg-1 whereas in P. quinquefolius Rb-1 is the only major 
ginsenoside.
1
 
Other constituents 
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Volatile oil (trace) mainly consisting of sesquiterpenes including panacene, limonene, 
terpineol, eucalyptol, α-phellandrene and citral,
2
 sesquiterpene alcohols including the 
panasinsanols A and B, and ginsenol,
3, 4
polyacetylenes,
5, 6
 sterols, polysaccharides (mainly 
pectins and glucans),
7
starch (8–32%), β-amylase,
8
 free sugars, vitamins (B1, B2, B12, 
panthotenic acid, biotin), choline (0.1–0.2%), fats, minerals. 
The sesquiterpene alcohols are stated to be characteristic components ofPanax ginseng in 
that they are absent from the volatile oils of other Panaxspecies.
4
 
Mistletoe  Acids 
Fatty acids (C12–C22), 80% oleic and palmitic, myrisitic;
5
 phenolic acids, e.g. caffeic, p-
coumaric, gentisic, p-hydroxybenzoic, p-hydroxyphenylacetic, protocatechuic, 
vanillic;
5, 6
 anisic, quinic and shikimic.
5, 6
 
Alkaloids 
It has been suggested that alkaloids can be passed on from hosts to parasitic plants such 
as mistletoe (e.g. nicotine alkaloids have been isolated from mistletoe growing on Solanaceae 
shrubs).
7
 
Amines 
Acetylcholine, choline, β-phenylethylamine, histamine, propionylcholine and tyramine.
8
 
Flavonoids 
Chalcones, e.g. 2′,4-dihydroxy-4′,6′-dimethoxychalcone-4-O-glucoside, 2′,4-dihydroxy-4′,6′,3-
trimethoxychalcone-4-O-glucoside, 2′,4-dihydroxy-4′,6′-dimethoxychalcone-4-O-
apiosyl(1→2)-glucoside.
2
 
Flavanones, e.g. (2R)-5,7-dimethoxy-4′-hydroxyflavanone-4′-O-glucoside, (2S)-4′-hydroxy-
5,7,3′-trimethoxyflavanone-4′-O-glucoside, sakuranetin, homoeriodictyol (3′-methoxy-5,7,4′-
trihydroxyflavanone).
2
 
Flavonols, e.g. quercetin, isorhamnetin, rhamnazin (3,5,4′-trihydroxy-7,3′-dimethoxyflavone; 
quercetin 7,3′-dimethyl ether) and its glycoside rhamnazin-3,4′-di-O-glucoside and other 
quercetin methyl ethers.
2
 
Lectins 
Lectins are heterodimeric glycoproteins (mol. wt between 55 kDa and 63 kDa),
2
 which belong 
to a group of type 2 ribosome-inactivating proteins (RIPs) and are structurally similar to ricin. 
They are composed of two distinct subunits, one B-subunit (B-chain, the galactose-binding 
site; 34 kDa) and one toxophoric A-subunit (A-chain, the cytotoxic-binding site, RNA-N-
glycosidase; 29 kDa). The structure of the B-chain of mistletoe lectins is based on 264 amino 
acids. Seven cysteine residues and three N-linked carbohydrate chains are 
included. Mistletoe lectins (V. album agglutinin-1, viscumin (mol. wt 60 000)) are galactoside-
specific plant lectins (63 kDa). Three different mistletoe lectins have been isolated: ML-1 
(main component; broad range of affinity for α β-linked galactopyranosyl residues), ML-2 
(affinity for D-galactose and N-acetyl-D-galactosamine) and ML-3 (affinity for N-acetyl-D-
galactosamine). The chitin-binding lectin (chitin-binding-agglutinin, visalb-CBA or visalb-CBL), 
which is distinct from ML-1, ML-2 and ML-3, is a homodimer lectin with two identical 
subunits (10.8 kDa). Its amino acid composition is similar to that of other chitin-binding 
hololectins.
2
 Reported yields of ML-1, ML-2 and ML-3 from leaves and stems are 3–
170 mg/100 g dry weight, 0.1–35 mg/100 g dry weight, and 0–67 mg/100 g dry weight, 
respectively.
2
 
ML-1, ML-2 and ML-3 have been isolated from Iscador Qu Special and Iscador M Special. 
Iscador P contains almost no mistletoe lectins (R Dierdorf, personal communication, 
September 2003).
9
 
Terpenoids 
An acyclic monoterpene glucoside, 2,6-dimethylocta-2,7-diene-1,6-diol-6-O-[6′-β-D-
apiofuranosyl]-β-D-glucopyranoside, has been isolated from leaves and stems.
10
 Phytosterols, 
including β-sitosterol, stigmasterol and glycosides, together with pentacyclic triterpenes β-
amyrin and its acetate, betulinic acid, oleandrin and oleanolic acid are present.
3, 11
 
Viscotoxins 
Viscotoxins (mol. wt 5 kDa) have been isolated from leaf homogenates. Viscotoxins are 
amphipathic, strongly basic polypeptides that are highly enriched with cysteine residues; they 
belong to the family of α- and β-thionins.
2
 Viscotoxins consist of 46 amino acid residues with 
three disulphide bonds, which stabilise the conformation of the molecule. Several different 
viscotoxins have been isolated, the main ones being viscotoxins A2, A3 and B. 
Other constituents: 
Lignans 
Syringaresinol 4,4′-O-diglucoside (eleutheroside E).
2
 
Phenylpropanoids 
Syringenin-4′-O-glucoside (syringin), syringenin-4′-O-apiosyl-1→2-glucoside (syringoside).
2
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Polyalcohols 
1-D-1-O-Methyl-muco-inositol (a derivative of O-methyl-inositol),
4
 mannitol, pinitol, 
quebrachitol and viscumitol.
2
 
Polysaccharides 
Mainly a methylester of 1→4α-galacturonic acid in the leaves and rhamnogalacturans in the 
berries. Pectin (mol. wt 42 kDa), arabinogalactan (mol. wt 110 kDa) are present in leaves, and 
a rhamnogalacturan (mol. wt 700 kDa) is found in the berries. The berries contain acidic (mol. 
wt 1340 kDa) and neutral (mol. wt 30 kDa) polysaccharides. The acidic polysaccharides 
interact with ML-1. Simple sugars and tannins are also present 
Evening 
Primrose  
Fixed oils 
14%. cis-Linoleic acid (LA) 72% (65–80%), cis-gammalinolenic acid (gamolenic acid, GLA) 2–
16%, oleic acid 9%, palmitic acid 7% and stearic acid (3%).
1–5
 
Senna  Hydroxyanthracenes 
Pharmacopoeial standards not less than 2.5% for leaf and 2.2% for C. 
angustifolia fruit.
G81, G84
 Dianthrone glycosides (1.5–3% leaf; 2–5% fruit), primarily sennosides 
A and B (rhein dianthrones) with sennosides C and D (rhein aloe-emodin heterodianthrones), 
aloe-emodin dianthrone. Sennosides A and B yield sennidin A and B respectively. Free 
anthraquinones including aloe-emodin, chrysophanol and rhein with their glycosides. 
Carbohydrates 
Polysaccharides (about 2.5%)
2
 including mucilage (arabinose, galactose, galacturonic acid, 
rhamnose) and a galactomannan (galactose, mannose);
3
free sugars (e.g. fructose, glucose, 
pinitol, sucrose). 
Flavonoids 
Flavonols, including isorhamnetin and kaempferol. 
Glycosides 
6-Hydroxymusizin and tinnevellin glycosides. 
Other constituents 
Chrysophanic acid, salicylic acid, saponin, resin, volatile oil (trace) 
Valerian  Alkaloids 
Dried roots contain 0.05–0.1% alkaloids, principally N-(p-hydroxyphenethyl)actinidine 
(0.03%), and a minor derivative (0.001%);
8
additional pyridine-type analogues: actinidine (also 
obtained from the latter alkaloids by pyrolysis) and valerianine.
5
 Other alkaloids: 2-
acetylpyrrole, 3-acetyl-2,7-naphthyridine.
5
 The identity of some alkaloids reported in early 
literature is uncertain (e.g. chatinine, valerine).
8
 
Iridoids (valepotriates) 
Levels of 0.1–2.0% depending on condition of material;
1, 3, 6
0.8% quoted for rhizomes 
collected and dried with care.
9
 Valepotriates (bicyclic monoterpenes of the iridoid class; also 
referred to as Valeriana epoxy triesters or Valeriana-type iridoids); main component is 
valtrate (80–90%),
9
which is acylated by acetyl and isovaleryl (3-methylbutanoyl) groups; 
minor components with the diene structure of valtrate include acevaltrate, 
deacetylisovaltrate, isovaltrate, and valechlorine.
5
 Other minor valepotriates are 5β,6-
dihydro homologues (monoenes) of the valtrate group, including didrovaltrate (also known as 
dihydrovaltrate, although it is 5β,6-dihydroisovaltrate), IVHD-valtrate (= 
isovaleroxyhydroxydidrovaltrate), and valerosidate, which is glycosylated;
5
 further examples 
described in recent literature are 1,5-dihydroxy-3,8-epoxyvalechlorine, jatamanvaltrates B 
and C, valeriotriate B, and volvaltrates A–D;
10, 11
 the structures of 1,5-dihydroxy-3,8-
epoxyvalechlorine and volvaltrate B were later revised.
12
Valepotriates readily undergo 
hydrolysis and decompose during storage or processing to give unsaturated aldehydes such 
as baldrinal, deacylbaldrinal, homobaldrinal, and valtroxal. 
Sterols 
Clionasterol 3-O-glucoside and a mixture of its 6ʹ-O-acylglucosyl derivatives; acyl moieties: 
hexadecanoyl (78%), 8E,11E-octadecadienoyl (17%), and 14-methylpentadecanoyl (5%).
13
 
Volatile oil 
Considerable variation in content (0.1–2.8%) and composition,
1–3, 5
depending on geographical 
location, whether wild or cultivated material, genotype (chemical races/varieties), 
environment (climate, soil), seasonality,
14
 and extraction method (hydrodistillation, 
supercritical CO2);
15
high quality material typically has 1.0–1.5% essential oil,
1
 which 
comprises numerous mono- and sesquiterpenes. Monoterpenes: bornyl acetate and bornyl 
isovalerate are usually among the main components; others include borneol, camphene, α- 
and β-pinene, myrcene, and small amounts of camphor and 1,8-cineole.
5, 16
 Sesquiterpenes: 3 
structural types predominate, based on kessane (e.g. kessyl alcohol), valerane (e.g. 
valeranone, cryptofaurinol), and valerenane (e.g. valerenic acid) skeletons.
3,5
 Valerenic and 
acetoxyvalerenic acids are major constituents found together with hydroxyvalerenic acid, a 
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hydrolysis product of the latter (formed when the herb is stored under high levels of 
humidity);
1, 3
 additional valerenanes isolated from root extracts: valerenal, valerenol, 
valerenyl esters, and (–)-pacifigorgiol;
17, 18
 (E)-(–)-3β,4β-epoxyvalerenal, (E)-(–)-3β,4β-
epoxyvalerenal acetate, and mononorvalerenone;
10
 volvalerenone, a new type of 
mononorsesquiterpenoid, appears to be derived from valerenic acid.
19
 Miscellaneous 
sesquiterpenes include β-bisabolene, α-curcumene, elemol, patchouli alcohol, and others.
5
 
Other constituents 
Amino acids: arginine, γ-aminobutyric acid (GABA), glutamine, tyrosine.
1, 20
Flavonoids: 
acacetin 7-rutinoside (linarin), (2S)-hesperetin 7-rutinoside (hesperidin), 6-C-
methylapigenin.
21, 22
 Lignans: berchemol 4ʹ-O-β-glucoside, (+)-8-hydroxypinoresinol, its 4-O- 
β-glucoside and 4ʹ-O-β-glucoside, massoniresinol 4ʹ-O-β-glucoside, pinoresinol 4-O-β-
glucoside and its 4,4ʹ-di-O-β-glucoside, pinorespiol, and 4ʹ-O-β-glucosyl-9-O-(6″-
deoxysaccharosyl)olivil.
23, 24
 
Aloe vera Aloe vera is reported to contain mono- and polysaccharides, tannins, sterols, organic acids, 
enzymes (including cyclooxygenase),
1
 saponins, vitamins and minerals.
2
 
Carbohydrates 
Glucomannan and other polysaccharides containing arabinose, galactose and xylose. 
Lipids 
Includes cholesterol, gamolenic acid and arachidonic acid.
1
 
Jin Bu Huan Tetrahydropalmatine  
Shou Wu Pian Chrysarobin, Emodin, 3 5-dihydroxy-4?-methoxystilbene, N – feruloyltyramine, Physcion, 
Polydatin, Quercetin-3-L-arabinoside, Rhein, 2 3 5 4'tetrahydroxystilbene-2-O-(6''-O-acetyl)-
B-D-glucopyranoside, B-sitosterol 
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14 Appendix E. List of training set ligands and summary of 
conformations generated 
Names start with herb, then chemical class and then the name of the constituent. 
Name Pharm Set Ligand 
Group 
Required 
Match 
Conformations 
 Black cohosh alkaloid cytisine active 1 0 1 
 Black cohosh alkaloid n methyl cytisine active 1 0 1 
 Black cohosh alkaloid cimipronidine methyl 
ester  
active 1 0 7 
 Black cohosh alkaloid cyclocimipronidine active 1 0 1 
 Kava amide pipermethystine  active 2 0 30 
 Kava amide 3a 4a-epoxypipermethystine active 2 0 13 
 Kava amide awaine active 2 0 22 
 Kava amide N-cinnamoylpyrrolidine  active 2 0 1 
 Kava amide Cepharadione A active 2 0 1 
 Kava lactones kawain active 2 0 3 
 Kava lactone methysticin active 2 0 5 
 Kava lactone dihydrokawain active 2 0 9 
 Kava lactone dimethoxydihydrokawain active 2 0 16 
 Kava lactone dihydromethysticin active 2 0 18 
 Kava lactone yangonin active 2 0 2 
 Kava lactone dimethoxykawain active 2 0 9 
 Kava chalcone flavokawain b active 2 0 4 
 Kava chalcone flavokawain c active 2 0 4 
 Kava chalcone flavokawain a active 2 0 4 
 Kava flavone pinostrobin active 2 0 1 
 Kava flavone 5 7-dimethoxyflavonone active 2 0 1 
 Ephedra Apigenin active 3 0 1 
 Ephedra Apigenin-5-rhamnoside active 3 0 21 
 Ephedra Chuanxiongzine active 3 0 1 
 Ephedra D-demethyl pseudoephedrine active 3 0 5 
 Ephedra 3 4-dimethyl-5-phenyloxazolidine active 3 0 1 
 Ephedra ephedrine active 3 0 3 
 Ephedra (4S 5R) Ephedroxane active 3 0 1 
 Ephedra 3-O-B-D-glucopyranosyl-5-9-4'-
trihydroxy-8-methoxy-flavone 
active 3 0 59 
 Ephedra Herbacetin active 3 0 11 
 Ephedra Kaempferol active 3 0 1 
 Ephedra kaempferol rhamnoside active 3 0 1 
 Ephedra leukoefdin active 3 0 2 
 Ephedra Maokonine active 3 0 3 
 Ephedra p-menth-2-en-7-ol active 3 0 8 
 Ephedra 3-methoxyherbacetin active 3 0 8 
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 Ephedra N-methylephedrine active 3 0 6 
 Ephedra Myrcene active 3 0 7 
 Ephedra norephedrine active 3 0 3 
 Ephedra norpseudoephedrine  active 3 0 4 
 Ephedra d-Pseudoephedrine active 3 0 4 
 Ephedra trans beta terpineol active 3 0 2 
 Ephedra cis beta terpineol active 3 0 6 
 Ephedra alpha terpineol active 3 0 10 
 Ephedra n-triacontanol active 3 0 125 
 Ephedra 1 3 4-trimethyl-3-cyclohexene-1-
carboxaldehyde 
active 3 0 2 
 Ephedra 2 3 4-trimethy-5-phenyloxazolidine active 3 0 1 
 Valerian alkaloid actinidine active 4 0 1 
 Valerian alkaloid valerianine active 4 0 1 
 Valerian alkaloid n-(p-
hydroxyphenethyl)actindine 
active 4 0 10 
 Valerian alkaloid 2-acetylpyrrole active 4 0 2 
 Valerian alkaloid 3-acetyl-2 7-naphthyridine active 4 0 1 
 Valerian monoterpene bornyl acetate active 4 0 1 
 Valerian monoterpene bornyl isovalerate active 4 0 5 
 Valerian sesquiterpene kessyl alcohol active 4 0 1 
 Valerian sesquiterpene valeranone active 4 0 1 
 Valerian sesquiterpene cryptofaurinol active 4 0 3 
 Valerian sesquiterpene valerenic acid active 4 0 2 
 Valerian sesquiterpene Acetoxyvalerenic Acid active 4 0 3 
 Valerian sesquiterpene Hydroxyvalerenic Acid active 4 0 2 
 Valerian sesquiterpene valerenal active 4 0 1 
 Valerian valepotriates/iridiod valtrate  active 4 0 94 
 Valerian valepotriates/iridoid didrovaltrate active 4 0 47 
 Valerian valepotriates baldrinal active 4 0 2 
 Valerian valepotriates homobaldrinal active 4 0 16 
 Valerian iridoid acevaltrate  active 4 0 81 
 Valerian iridoid valerosidate active 4 0 12 
 Valerian iridoid Desacylbaldrinal  active 4 0 1 
 Valerian iridoid homobaldrinal active 4 0 18 
 Valerian irirdoid Valtroxal active 4 0 21 
 Shou Wu Pian Chrysarobin active 5 0 2 
 Shou Wu Pian Emodin active 5 0 2 
 Shou Wu Pian 3 5-dihydroxy-4?-
methoxystilbene 
active 5 0 6 
 Shou Wu Pian N - feruloyltyramine active 5 0 13 
 Shou Wu Pian Physcion active 5 0 2 
 Shou Wu Pian Polydatin  active 5 0 3 
 Shou Wu Pian quercetin-3-L-arabinoside active 5 0 7 
 Shou Wu Pian Rhein  active 5 0 3 
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 Shou Wu Pian 2 3 5 4'tetrahydroxystilbene-2-
O-(6''-O-acetyl)-B-D-glucopyranoside 
active 5 0 79 
 Shou Wu Pian B-sitosterol active 5 0 5 
 Senna flavanoid Isorhamnetin active 6 0 4 
 Senna flavanoid 6-c-methylapigenin active 6 0 1 
 Mistletoe chalcone 4 2'-Dihydroxy-4' 6'-
dimethoxychalcone 4-glucoside 
active 7 0 14 
 Mistletoe chalcone 4 2'-Dihydroxy-4' 6' 3-
trimethoxychalcone 4-glucoside 
active 7 0 33 
 Mistletoe flavanone homoeriodictyol  active 7 0 2 
 Mistletoe flavanone 5 7-dimethoxy-4'-
hydroxyflavanone-4'-O-glucoside 
active 7 0 148 
 Mistletoe flavanone 4'-hydroxy-5 7 3'-
trimethoxyflavanone-4'-O-glucoside 
active 7 0 138 
 Mistletoe flavanoid quercetin active 7 0 4 
 Mistletoe flavanols rhamnazin active 7 0 4 
 Mistletoe flavanoid sakuranetin active 7 0 1 
 Black cohosh alkaloid cimipronidine (min) active 1 0 10 
 Black cohosh alkaloid dopargine active 1 0 43 
 Senna hydroxyanthracene Aloe-emodin active 6 0 1 
 Senna hydroxyanthracene sennidin A active 6 0 3 
 Senna hydroxyanthracene chrysophanol  active 6 0 1 
 Senna hydroxyanthracene rhein  active 6 0 2 
 Mistletoe amines acetylcholine  active 7 0 4 
 Mistletoe amine propionylcholine  active 7 0 3 
 Mistletoe amine tyramine active 7 0 2 
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15 Appendix F.  Number of entries in ‘DRUGNAME’ column in FDA 
AERS data 
 
The FDA AERS data contained 326 columns for ‘DRUGNAME’. Some cases contained at least 
one entry while others contained up to 326 entries. It was decided that a subset of the 
columns would be used to conduct the study because computer processing time would be 
excessively long. It was found that most data was contained in the first 20-30 columns (see 
graph below).  
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16 Appendix G. Univariate disproportionality analysis detailed results 
Table. Details of univariate disproportionality analysis for herbs and hepatotoxicity (all liver injury terms)  
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1 Aloe vera Aloe Vera 101 3 0.21 0.648 0.766 0.243 2.416          
2 Aloes  27 2 0.93 0.335 2.002 0.474 8.452          
3 Bilberry Vaccinium myrtillus 88 6 2.11 0.146 1.831 0.799 4.195          
4 Black cohosh Cimicifuga racemosa 298 26 9.23 0.000 2.392 1.6 3.577 * 1.953 1.294 2.948   E 
5 Borage Borago officinalis 48 3 0.75 0.386 1.668 0.518 5.368          
6 Caffeine several plant sources 2,505 158 41.22 0.000 1.686 1.435 1.98 *        
7 Cannabis Cannabis sativa, Cannabis indica, 
Cannabis ruderalis 
778 57 25.56 0.000 1.979 1.511 2.591 * 1.892 1.438 2.490    
8 Chinese  452 75 198.90 0.000 4.981 3.887 6.382 * 2.834 2.176 3.692    
9 Cocaine Erythroxylum coca, Erythroxylum 
novogranatense 
2,752 119 1.73 0.189 1.131 0.941 1.359          
10 Cranberry Vaccinium Oxycoccus 573 22 0.01 0.909 0.975 0.631 1.507          
11 Echinacea  E. purpurea, E. angustifolia, E. 
pallida 
275 18 5.44 0.02 1.753 1.087 2.827 *        
12 Fenugreek Trigonella foenum-graecum 16 1 0.25 0.616 1.668 0.22 12.629          
13 Garlic Allium sativum 1,080 38 0.31 0.579 0.913 0.66 1.261   0.681 0.490 0.947 P  
14 Ginger Zingiber officinale 207 7 0.12 0.730 0.876 0.412 1.861          
15 Ginkgo Ginkgo Biloba 1,512 103 36.10 0.000 1.830 1.498 2.236 * 1.400 1.141 1.716    
16 Ginseng Panax Ginseng 234 25 29.64 0.000 2.994 1.977 4.533 * 1.826 1.175 2.837    
17 Glucosamine  6,934 283 1.07 0.301 1.065 0.945 1.2   0.829 0.735 0.936 P  
18 Grapeseed  385 17 0.34 0.559 1.156 0.711 1.88          
19 Greater 
Celandine 
Chelidonium majus 7 1 2.07 0.151 4.171 0.502 34.642         E 
20 Green tea Camellia sinensis 196 17 12.38 0.000 2.377 1.445 3.909 * 1.838 1.103 3.063    
21 Guarana Paullinia cupana 17 2 2.89 0.089 3.411 0.78 14.991
5 
         
22 Herbalife  28 8 46.34 0.000 10.010 4.409 22.726 * 3.493 1.503 8.118   E 
23 Heroin Papaver somniferum (check 
herbal source) 
809 25 1.24 0.265 0.798 0.536 1.188          
24 Hoodia Hoodia go donii 19 5 25.97 0.000 8.937 3.219 24.813 * 7.195 2.538 20.396   E 
25 Horse chestnut Aesculus hippocastanum 29 2 0.73 0.392 1.854 0.441 7.795          
26 Hydroxycut®   38 5 8.92 0.003 3.876 1.513 9.928 * 3.844 1.493 9.897    
27 Isabgol Plantago ovata 929 48 4.41 0.036 1.364 1.02 1.823 * 0.225 0.098 0.517 P  
28 Kava Piper methysticum 27 7 35.64 0.000 8.759 3.7 20.71 * 6.813 2.813 16.498   E 
29 Ma Huang / 
Ephedra 
Ephedra sinica 2,879 193 63.84 0.000 1.800 1.555 2.083 * 1.396 1.202 1.622   E 
30 Mat   4 1 4.85 0.028 8.341 0.868 80.189          
31 Marijuana Cannabis sativa, Cannabis 
indica,Cannabis ruderalis 
1,090 46 0.42 0.517 1.103 0.821 1.481          
32 Melatonin  1,389 47 0.79 0.373 0.876 0.655 1.172   0.674 0.502 0.904 P  
33 Methampheta
mine 
 810 37 1.15 0.283 1.198 0.861 1.666          
34 M lk thistle Silybum marianum 339 49 103.32 0.000 4.230 3.125 5.725 * 3.537 2.589 4.831    
35 Mistletoe Viscum album 45 4 3.10 0.078 2.441 0.874 6.816         E 
36 Noni Morinda citrifolia 4,996 306 77.17 0.000 1.671 1.488 1.876 * 1.155 1.027 1.299    
37 Opium Papaver somniferum 6,947 351 27.59 0.000 1.333 1.197 1.484 *        
38 Primrose Primula vulgaris 322 22 7.79 0.005 1.835 1.19 2.83 *        
39 Red yeast rice  323 9 0.85 0.357 0.733 0.378 1.422          
40 Saw palmetto Serenoa repens 967 41 0.41 0.520 1.180 0.81 1.515         E 
41 Senna Senna alexandrina 8,103 670 430.85 0.000 2.264 2.091 2.451 * 1.503 1.386 1.631    
42 Soy   380 34 26.80 0.000 2.459 1.729 3.498 * 1.865 1.300 2.676    
43 St John's wort Hypericum perforatum 222 13 2.44 0.119 1.557 0.889 2.726          
44 Unspecified 
herb 
 3,517 404 556.93 0.000 3.256 2.935 3.613 * 2.578 2.307 2.881    
45 Usnic acid  2 1 25.02 0.000 0.038 0.038 0.038          
46 Valerian Valeriana officinalis 223 34 78.49 0.000 4.503 3.125 6.487 * 3.618 2.489 5.261   E 
47 Vitamin A  1,834 93 7.49 0.006 1.337 1.085 1.647 *?        
48 Arrow root Maranta arundinacea 0 0                
49 Atractylis 
gummifera 
Atractylis gummifera 0 0               E 
50 B sh tea Aspalathus linearis 0 0                
51 Cascara 
sagrada 
Rhamnus purshiana 15 0               E 
52 Chaparral Larrea tridentata 4 0               E 
53 Coltsfoot Tussilago farfara 0 0                
54 Germander Teucrium chamaedrys 0 0               E 
55 Gotu Kola Centella asiatica 5 0                
56 Groundsel Senecio vulgaris 0 0                
57 Hyssop Hyssopus officinalis 0 0                
58 Impila  0 0                
59 Kambala  0 0                
60 Oleander Nerium oleander 0 0                
61 Oxeye daisy Leucanthemum vulgare 1 0                
62 PA - Comfrey  Symphytum×  uplandicum 4 0               E 
63 PA - crotalaria 
(rattlebox) 
 0 0               E 
64 PA - hioheliotropium  0 0               E 
65 PA - Senecio 
longilobus 
 0 0               E 
66 Pennyroyal  Mentha pulegium 0 0                
67 Pro-Lean ®  0 0                
68 Pycnogenol  17 0                
69 Sassafras Sassafras albidum 0 0                
70 Skullcap Scutellaria baicalensis 5 0                
71 Stonecrop Sedum Acre 0 0                
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72 Venencapsan ®  0 0                
73 Venoplant ®  2 0                
74 Wolf's foot  0 0                
75 X-Ellis ®  0 0                
76 Yohimbine  11 0                
77 Ba Jiao Lian  0 0                
78 Bai Fang  0 0                
79 Boh Gol Zhee  0 0                
80 Chaso  0 0                
81 Chi R Yun  0 0               E 
82 Dai Saiko To  0 0               E 
83 Ho Shou Wu  0 0               E 
84 Jin Bu Huan  0 0               E 
85 Shenmin  0 0               E 
86 Sho Saiko To  0 0               E 
87 Shou Wu Pian  0 0               E 
88 Shu Ling  0 0               E 
89 Xiao Chai Hu 
Tang 
 0 0               E 
90 Onshido   0 0                      
 TOTAL  54,820 3,438            
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 Herb Aloe 
vera 
Aloes Bilberry Black 
cohosh 
Borage Caffeine Cannabi
s 
Chinese Cocaine Cranberr
y 
Echinace
a  
Fenugre
ek 
Garlic Ginger Ginkgo Ginseng Glucosa
mine 
Grapese
ed 
Greater 
Celandin
e 
Green 
tea 
Guarana Herbalif
e 
Heroin 
All liver 
injury 
Cases 3 2 6 26 3 158 57 75 119 22 18 1 38 7 103 25 283 17 1 17 2 8 25 
 OR 0.766 2.002 1.831 2.392 1.668 1.686 1.979 4.981 1.131 0.975 1.753 1.668 0.913 0.876 1.83 2.994 1.065 1.156 4.171 2.377 3.411 10.01 0.798 
 CI 
lower 
0.243 0.474 0.799 1.6 0.518 1.435 1.511 3.887 0.941 0.631 1.087 0.22 0.66 0.412 1.498 1.977 0.945 0.711 0.502 1.445 0.78 4.409 0.536 
 CI 
upper 
2.416 8.452 4.195 3.577 5.368 1.98 2.591 6.382 1.359 1.507 2.827 12.629 1.261 1.861 2.236 4.533 1.2 1.88 34.642 3.909 14.9915 22.726 1.188 
     *  * * *   *    * *    *  *  
Immune 
liver injury 
Cases 1  0 3 1 21 9 10 22 0 3 0 4 1 14 4 35 1 0 0 0 1 2 
 OR 2.066   2.101 4.395 1.748 2.419 4.676 1.666  2.279  0.768 1.003 1.932 3.593 1.048 0.538    7.651 0.512 
 CI 
lower 
0.288   0.674 0.606 1.137 1.253 2.498 1.095  0.73  0.288 0.141 1.141 1.337 0.752 0.076    1.04 0.128 
 CI 
upper 
14.81   6.552 31.859 2.686 4.667 8.754 2.535  7.11  2.05 7.153 3.27 9.657 1.462 3.829    56.309 2.05 
       * * * *      * *      *  
Liver 
injury, 
death 
Cases         1      2  2   1    
 OR         0.707      2.58  0.561   9.89    
 CI 
lower 
        0.1      0.644  0.14   1.399    
 CI 
upper 
        5.027      10.338  2.246   71.318    
                     *    
Steatosis Cases   1 2 1 12 7 2 14 4   3 2 4 5 19 1  3 1  1 
 OR   7.545 4.436 13.967 3.165 5.967 2.918 3.364 4.617   1.829 6.405 1.742 14.346 1.807 1.709  10.208 41.028  0.812 
 CI 
lower 
  1.051 1.104 1.927 1.794 2.833 0.727 1.988 1.726   0.589 1.591 0.652 5.911 1.151 0.24  3.262 5.44  0.114 
 CI 
upper 
  54.182 17.827 101.253 5.586 12.567 11.707 5.693 12.35   5.681 25.794 4.648 34.814 2.838 12.168  31.943 309.442  5.774 
    * * * * *  * *    *  * *   * *   
Necrosis Cases  1  2  9 2 1 4      3 2 10 1  3   1 
 OR  32.705  5.747  3.071 2.192 1.885 1.238      1.691 7.332 1.228 2.214  13.225   1.052 
 CI 
lower 
 4.437  1.43  1.595 0.547 0.265 0.464      0.544 1.822 0.66 0.311  4.226   0.148 
 CI 
upper 
 241.084  23.096  5.915 8.783 13.416 3.302      5.251 29.506 2.286 15.763  41.389   7.48 
   *  *  *          *    *    
Cholestasis Cases  1    11 2 2 3  1  2  30  11  1 3  2 1 
 OR  16.611    1.906 1.113 1.919 0.471  1.576  0.801  8.779  0.686  71.981 6.715  33.227 0.534 
 CI 
lower 
 2.254    1.054 0.278 0.478 0.152  0.221  0.2  6.111  0.379  8.665 2.0146  7.885 0.075 
 CI 
upper 
 122.427    3.448 4.459 7.7 1.462  11.23  3.208  12.612  1.239  597.979 21.009  140.023 3.799 
   *    *         *    * *  *  
hepatic 
failure 
Cases      9 3 5 22 1 2  2  6 1 16 2  3  1 1 
 OR      0.987 1.06 3.064 2.21 0.479 2.006  0.508  1.091 1.175 0.633 1.43  4.258  10.144 0.339 
 CI 
lower 
     0.513 0.341 1.269 1.452 0.067 0.499  0.127  0.489 0.0165 0.387 0.356  1.361  1.378 0.048 
 CI 
upper 
     1.901 3.295 7.4 3.363 3.405 8.065  2.034  2.433 8.38 1.034 5.74  13.32  74.655 2.409 
         * *           *  *  
Jaundice  Cases  1  1  15 1 4 4  4 1 5 1 14 3 27 1  2  2 2 
 OR  11.205  0.981  1.756 0.375 2.601 0.424  4.301 19.421 1.355 1.414 2.725 3.784 1.139 0.759  3.003  22.411 0.722 
 CI 
lower 
 1.52  0.138  1.057 0.053 0.972 0.159  1.602 2.565 0.563 0.198 1.609 1.211 0.78 0.107  0.746  5.319 0.18 
 CI 
upper 
 82.576  6.986  2.918 2.665 6.963 1.13  11.545 147.041 3.263 10.087 4.614 11.821 1.663 5.399  12.097  94.438 2.892 
   *    *     * *   * *      *  
Liver 
vascular 
Cases    1  2 1  2        1       
 OR    5.212  1.237 1.992  1.125        0.223       
 CI 
lower 
   0.731  0.309 0.28  0.281        0.031       
 CI 
upper 
   37.146  4.951 14.167  4.506        1.582       
                         
hepatic 
cirrhosis 
Cases    1  9 1 4 4    2  6 2 3   1   1 
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 OR    3.28  3.52 1.253 8.706 1.418    1.807  3.886 8.4 0.421   4.995   1.205 
 CI 
lower 
   0.46  1.827 0.176 3.251 0.531    0.451  1.742 2.087 0.136   0.7   0.17 
 CI 
upper 
   23.368  6.78 8.912 23.315 3.784    7.239  8.671 33.806 1.306   35.654   8.57 
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 Herb Hoodia Horse 
chestnut 
Hydroxy
cut®  
Isabgol Kava Ma 
Huang / 
Ephedra 
Mate Marijua
na 
Melaton
in 
Metham
phetami
ne 
Milk 
thistle 
Mistleto
e 
Noni Opium Primros
e 
Red 
yeast 
rice 
Saw 
palmett
o 
Senna Soy  St John's 
wort 
Unspecif
ied herb 
Usnic 
acid 
Valerian Vitamin 
A 
All liver 
injury 
Cases 5 2 5 48 7 193 1 46 47 37 49 4 306 351 22 9 41 670 34 13 404 1 34 93 
 OR 8.937 1.854 3.876 1.364 8.759 1.8 8.341 1.103 0.876 1.198 4.23 2.441 1.671 1.333 1.835 0.733 1.18 2.264 2.459 1.557 3.256 0.038 4.503 1.337 
 CI 
lower 
3.219 0.441 1.513 1.02 3.7 1.555 0.868 0.821 0.655 0.861 3.125 0.874 1.488 1.197 1.19 0.378 0.81 2.091 1.729 0.889 2.935 0.038 3.125 1.085 
 CI 
upper 
24.813 7.795 9.928 1.823 20.71 2.083 80.189 1.481 1.172 1.666 5.725 6.816 1.876 1.484 2.83 1.422 1.515 2.451 3.498 2.726 3.613 0.038 6.487 1.647 
  *  * * * *     *  * * *   * *  *  * *? 
Immune 
liver injury 
Cases 0 0 0 4 1 26  12 5 9 5 1 27 43 7 0 0 119 3 3 53 0 4 13 
 OR    0.893 7.945 1.884  2.301 0.746 2.322 3.093 4.695 1.123 1.288 4.592   3.098 1.644 2.83 3.169  3.774 1.475 
 CI 
lower 
   0.334 1.078 1.28  1.302 0.31 1.203 1.279 0.647 0.769 0.953 2.171   2.583 0.528 0.906 2.415  1.404 0.855 
 CI 
upper 
   2.385 58.55 2.773  4.065 1.796 4.48 7.481 34.079 1.639 1.739 9.714   3.716 5.121 8.844 4.159  10.146 2.546 
      * *  *  * * *   *   *   *  *  
Liver 
injury, 
death 
Cases    1         3     14   3   1 
 OR    2.098         1.17     3.393   1.667   1.062 
 CI 
lower 
   0.295         0.377     2.003   0.536   0.149 
 CI 
upper 
   14.923         3.633     5.747   5.166   7.548 
                   *       
Steatosis Cases 2 1 1 7  11 1 2 4 6 10  11  1  2 25 1 1 19  2  
 OR 77.248 23.444 17.742 4.991  2.521 218.817 1.207 1.896 4.903 19.995  1.449  2.045  1.36 2.037 1.732 2.97 3.577  5.942  
 CI 
lower 
17.842 3.189 2.434 2.371  1.394 22.757 0.301 0.71 2.195 10.65  0.802  0.287  0.34 1.374 0.243 0.416 2.276  1.476  
 CI 
upper 
334.456 172.35 129.338 10.502  4.561 2104.04 4.832 5.062 10.953 37.538  2.621  14.564  5.449 3.021 13.329 21.184 5.62  23.915  
  * * * *  * *   * *       *   *  *  
Necrosis Cases    1  12  1  2 1  9    3 17 1  13  2 3 
 OR    0.916  3.568  0.781  2.105 2.516  1.536    2.647 1.791 2.243  3.163  7.697 1.393 
 CI 
lower 
   0.129  2.022  0.11  0.525 0.353  0.798    0.852 1.112 0.315  1.833  1.912 0.449 
 CI 
upper 
   6.512  6.297  5.548  8.434 17.915  2.956    5.226 2.887 15.972  5.458  30.984 4.326 
       *            *   *  *  
Cholestasi
s 
Cases   1 2  3  1 1  2 1 34  3  4 15 3 1 22  7 12 
 OR   11.672 0.932  0.45  0.396 0.311  2.563 9.815 2.97  4.062  1.794 0.8 3.437 1.954 2.724  14.009 2.848 
 CI 
lower 
  1.601 0.233  0.145  0.056 0.044  0.638 1.352 2.118  1.303  0.672 0.482 1.103 0.274 1.79  6.597 1.613 
 CI 
upper 
  85.086 3.731  1.397  2.817 2.21  10.293 71.252 4.165  12.666  4.792 1.329 10.709 13.936 4.146  29.749 5.026 
    *         * *  *    *  *  * * 
hepatic 
failure 
Cases    5  29  7 2 10 3  35    3 48 3  35  2 3 
 OR    1.482  2.792  1.771 0.395 3.426 2.446  1.935    0.852 1.635 2.18  2.759  2.479 0.449 
 CI 
lower 
   0.615  1.936  0.842 0.099 1.836 0.785  1.387    0.274 1.23 0.7  1.976  0.616 0.144 
 CI 
upper 
   3.57  4.027  3.724 1.58 6.393 7.622  2.7    2.647 2.173 6.79  3.851  9.974 1.392 
       *    *   *     *   *    
Jaundice  Cases 1   2 1 8   2 2 2  44  10  9 43 5 1 43 1 2 15 
 OR 16.184   0.628 11.205 0.812   0.42 0.721 1.729  2.596  9.345  2.738 1.557 3.885 1.318 3.618 1 2.636 2.404 
 CI 
lower 
2.16   0.157 1.52 0.405   0.105 0.18 0.431  1.928  4.977  1.42 1.153 1.607 0.185 2.676 1 0.655 1.446 
 CI 
upper 
121.246   2.517 82.576 1.625   1.681 2.888 6.942  3.495  17.546  5.28 2.102 9.392 9.4 4.89 1 10.609 3.998 
  *    *        *  *  * * *  * *  * 
Liver 
vascular 
Cases    1     2    4     16 2  9    
 OR    1.668     2.233    1.24     3.081 8.195  3.985    
 CI 
lower 
   0.235     0.557    0.465     1.882 2.041  2.068    
 CI 
upper 
   11.859     8.943    3.31     5.042 32.915  7.679    
                   * *  *    
hepatic 
cirrhosis 
Cases    2  6   1 3 5   4 11    13   11   2 
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 OR    2.102  2.036   0.701 3.623 14.603  0.78 1.547    1.568   3.064   1.063 
 CI 
lower 
   0.525  0.913   0.099 1.165 6.034  0.292 0.855    0.909   1.693   0.266 
 CI 
upper 
   8.421  4.54   4.985 11.264 35.342  2.081 2.797    2.704   5.544   4.256 
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17 Appendix H. Confounders in logistic regression model 
 Confounders for herb-induced liver injury 
Confounder  ROR 95% CI Confounder  ROR 95% CI 
Lower  Upper  Lower  Upper  
Amoxicillin 2.059 1.910 2.220 Paroxetine .799 .756 .846 
Amoxiclav 1.831 1.622 2.066 Erythromy 1.687 1.478 1.925 
Nitrofuran 2.067 1.791 2.386 Flutamide 3.524 2.672 4.648 
Isoniazid 3.542 3.184 3.940 Azathioprin 1.898 1.767 2.038 
Duloxetin 2.515 2.413 2.622 Ticlopidin 1.026 .999 1.053 
Valproate 2.147 2.025 2.277 Phenytoin 1.775 1.663 1.893 
Interferon beta .560 .527 .596 Allopurinol 1.863 1.774 1.957 
Ciprofloxacin 2.161 2.035 2.294 Nevirapine 5.321 4.949 5.721 
Lamotrigine 1.073 1.014 1.136 Propylthiouracil 3.566 2.707 4.697 
Methyldopa 1.494 1.122 1.991 Rifampicin 3.184 2.883 3.517 
Telithromycin 7.198 6.578 7.877 Posaconazole 3.145 2.545 3.885 
Diclofenac 2.118 2.008 2.233 Celecoxib .643 .602 .686 
Terbinafine 2.487 2.050 3.017 Sulindac 2.030 1.612 2.557 
Sulfamethoxaz 2.157 1.791 2.599 Sulfasalazin 1.992 1.810 2.192 
Trimethoprim 2.286 1.855 2.817 Cyproheptadine 1.622 1.124 2.340 
Trimethoprim+ 
sulphamethoxazole 
1.198 .974 1.472 Deferasirox 2.414 2.241 2.601 
Atomoxetine 1.522 1.401 1.654 Roxithromycin 2.536 1.704 3.775 
Azithromycin 1.556 1.440 1.683 Levofloxacin 2.360 2.163 2.575 
Oxacillin 2.397 2.064 2.785 Nimesulid 3.162 2.441 4.096 
Atorvastatin 1.456 1.411 1.503 Age 1.005 1.005 1.005 
Etanercept .453 .432 .475 Tobacco .099 .032 .307 
Mercaptopurine 2.581 2.288 2.913 Alcohol 2.327 2.133 2.539 
Minocycline 3.083 2.760 3.444 Caffeine 1.279 1.084 1.510 
Acetaminophen 1.255 1.214 1.296 Drug abuse .791 .675 .927 
Carbamezapin 2.131 1.982 2.291 Malnutrition 3.994 3.558 4.485 
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18 Appendix I. Ligands possessing structural features matching 
pharmacophore hypothesis 
Ligands are listed from high alignment score to lowest starting with the reference 
ligand.Names start with herb, then chemical class and then the name of the constituent. 
AAR.532 AAR.66 
Mistletoe flavanoid quercetin 
 Ephedra Herbacetin 
 Mistletoe flavanols rhamnazin 
 Senna flavanoid Isorhamnetin 
 Ephedra 3-methoxyherbacetin 
 Shou Wu Pian quercetin-3-L-arabinoside 
 Ephedra Apigenin 
 Ephedra 3-O-B-D-glucopyranosyl-5-9-4'-trihydroxy-8-
methoxy-flavone 
 Senna flavanoid 6-c-methylapigenin 
 Ephedra kaempferol rhamnoside 
 Kava chalcone flavokawain c 
 Kava chalcone flavokawain a 
 Ephedra Kaempferol 
 Kava lactone dimethoxykawain 
 Mistletoe flavanone 4'-hydroxy-5 7 3'-
trimethoxyflavanone-4'-O-glucoside 
 Mistletoe flavanone homoeriodictyol  
 Ephedra Apigenin-5-rhamnoside 
 Mistletoe flavanoid sakuranetin 
 Shou Wu Pian N - feruloyltyramine 
 Mistletoe chalcone 4 2'-Dihydroxy-4' 6' 3-
trimethoxychalcone 4-glucoside 
 Kava lactone dimethoxydihydrokawain 
 Kava lactone dihydromethysticin 
 Kava lactone yangonin 
 Black cohosh alkaloid dopargine 
 Shou Wu Pian 2 3 5 4'tetrahydroxystilbene-2-O-(6''-
O-acetyl)-B-D-glucopyranoside 
 Mistletoe chalcone 4 2'-Dihydroxy-4' 6'-
dimethoxychalcone 4-glucoside 
 Ephedra leukoefdin 
 Shou Wu Pian Rhein  
 Senna hydroxyanthracene rhein  
 Kava lactone methysticin 
 Valerian iridoid homobaldrinal 
 Shou Wu Pian Physcion 
 Valerian valepotriates homobaldrinal 
 Senna hydroxyanthracene sennidin A 
 Mistletoe flavanone 5 7-dimethoxy-4'-
hydroxyflavanone-4'-O-glucoside 
 Valerian valepotriates baldrinal 
 Senna hydroxyanthracene Aloe-emodin 
 Kava amide Cepharadione A 
 Shou Wu Pian Polydatin  
 Valerian iridoid Desacylbaldrinal  
 Shou Wu Pian Emodin 
 
 Kava flavone 5 7-dimethoxyflavonone 
 Kava flavone pinostrobin 
 Mistletoe flavanoid sakuranetin 
 Mistletoe flavanone homoeriodictyol  
 Ephedra Herbacetin 
 Mistletoe flavanoid quercetin 
 Mistletoe flavanols rhamnazin 
 Senna flavanoid Isorhamnetin 
 Ephedra 3-methoxyherbacetin 
 Ephedra Apigenin 
 Ephedra Kaempferol 
 Senna flavanoid 6-c-methylapigenin 
 Mistletoe flavanone 5 7-dimethoxy-4'-
hydroxyflavanone-4'-O-glucoside 
 Mistletoe flavanone 4'-hydroxy-5 7 3'-
trimethoxyflavanone-4'-O-glucoside 
 Shou Wu Pian quercetin-3-L-arabinoside 
 Ephedra Apigenin-5-rhamnoside 
 Ephedra 3-O-B-D-glucopyranosyl-5-9-4'-trihydroxy-8-
methoxy-flavone 
 Ephedra kaempferol rhamnoside 
 Kava chalcone flavokawain b 
 Kava chalcone flavokawain c 
 Kava chalcone flavokawain a 
 Ephedra leukoefdin 
 Mistletoe chalcone 4 2'-Dihydroxy-4' 6'-
dimethoxychalcone 4-glucoside 
 Mistletoe chalcone 4 2'-Dihydroxy-4' 6' 3-
trimethoxychalcone 4-glucoside 
 Kava amide Cepharadione A 
 Valerian valepotriates homobaldrinal 
 Valerian iridoid homobaldrinal 
 Shou Wu Pian Rhein  
 Senna hydroxyanthracene rhein  
 Shou Wu Pian Emodin 
 Valerian iridoid Desacylbaldrinal  
 Shou Wu Pian Physcion 
 Shou Wu Pian 2 3 5 4'tetrahydroxystilbene-2-O-(6''-
O-acetyl)-B-D-glucopyranoside 
 Valerian valepotriates baldrinal 
 Kava lactone dihydromethysticin 
 Shou Wu Pian Polydatin  
 Senna hydroxyanthracene sennidin A 
 Shou Wu Pian N - feruloyltyramine 
 Kava lactone yangonin 
 Kava lactone dimethoxydihydrokawain 
 Senna hydroxyanthracene Aloe-emodin 
 Shou Wu Pian 3 5-dihydroxy-4?-methoxystilbene 
 Kava amide pipermethystine  
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